▁there ▁is ▁limited ▁experience ▁with ▁hydro ch lor o thi az ides ▁during ▁pre gna ncy ▁ , ▁especially ▁during ▁the ▁first ▁tri mester ▁ .
▁patients ▁in ▁the ▁la tter ▁treatment ▁arm ▁received ▁place bo ▁( ▁for ▁le di pas vir ▁/ ▁sof os bu vir ▁and ▁riba vir in ▁) ▁during ▁the ▁first ▁12 ▁weeks ▁ , ▁followed ▁by ▁active ▁blind ed ▁ therapy ▁during ▁the ▁subsequent
▁log - rank ▁test ▁two ▁side d ▁p - valu ed
▁in ▁patients ▁with ▁compensa ted ▁ liver ▁disease ▁ , ▁these ▁increase s ▁in ▁se rum ▁alt ▁were ▁generally ▁not ▁ac com pani ed ▁by ▁an ▁increase ▁in ▁se rum ▁bilir u bin ▁concentration s ▁or ▁sign s ▁of ▁he pati c ▁de com pensa tion ▁ .
▁the ▁reco mbin ant ▁human ▁hy alu ron idas e ▁facilita tes ▁the ▁dispersi on ▁and ▁ab sor p tion ▁of ▁ ig ▁10 ▁% ▁ .
▁your ▁health care ▁professional ▁will ▁throw ▁away ▁any ▁medicine s ▁that ▁are ▁no ▁longer ▁being ▁used ▁ .
▁sil den a fil ▁act avis ▁is ▁indicate d ▁in ▁adult ▁men ▁with ▁er ect ile ▁dys function ▁ , ▁which ▁is ▁the ▁in ability ▁to ▁achieve ▁or ▁maintain ▁a ▁pen ile ▁er ection ▁ sufficient ▁for ▁satisfac tory ▁sexual ▁performance ▁ .
▁temo zo lom ide ▁accord ▁140 ▁mg ▁hard ▁capsule s ▁ .
▁see ▁a ▁doctor ▁straight ▁away ▁if ▁you ▁notice ▁any ▁of ▁the ▁following ▁- ▁you ▁may ▁need ▁urgent ▁medical ▁treatment ▁:
▁in ▁the ▁larger ▁study ▁a ▁re duction ▁of ▁21 ▁% ▁( ▁90 ▁% ▁ci ▁14 ▁% ▁ -27 ▁% ▁) ▁in ▁au c ▁of ▁sva ▁was ▁observe d ▁after ▁repeat ed ▁co - administration ▁of ▁sim vasta tin ▁40 ▁mg ▁and ▁feno fi bra te ▁145 ▁mg ▁in ▁the ▁evening ▁ .
▁it ▁is ▁ad vis able ▁to ▁ad minister ▁qu t enza ▁in ▁a ▁well ▁ventila ted ▁treatment ▁area ▁ .
▁one ▁non - fa tal ▁post ▁marketing ▁case ▁of ▁ana phy la ctic ▁shock ▁has ▁been ▁reported ▁with ▁ac li dini um ▁brom ide ▁/ ▁form ote rol ▁fumar ate ▁di hydrat e ▁during ▁the ▁current ▁report ing ▁interval ▁ .
▁eu ▁/ ▁1 ▁/ ▁01 ▁/ ▁185 ▁/ ▁ 004 ▁4 ▁pack ▁bli ster ▁eu ▁/ ▁1 ▁/ ▁01 ▁/ ▁185 ▁/ ▁03 4 ▁1 ▁pack ▁un bli ster ed
▁the ▁risk ▁of ▁la ctic ▁acid osis ▁must ▁be ▁considered ▁in ▁the ▁event ▁of ▁non - specific ▁sign s ▁such ▁as ▁muscle ▁cr amp s ▁ , ▁digestiv e ▁disorder s ▁as ▁abdominal ▁pain ▁and ▁severe ▁as th enia ▁ .
▁powder ▁vi al ▁2000 ▁iu
▁if ▁the ▁vi als ▁are ▁store d ▁under ▁refrigera tion ▁ , ▁allow ▁the ▁required ▁number ▁of ▁doce ta xel ▁teva ▁ pharma ▁box es ▁to ▁stand ▁at ▁room ▁temperature ▁( ▁below ▁25 ▁° ▁c ▁) ▁for ▁5 ▁minutes ▁ .
▁marketing ▁author isation ▁holder ▁ale x ion ▁ europe ▁sa s
▁when ▁plate let s ▁recommended ▁course
▁since ▁dos ing ▁is ▁individual ly ▁adjust ed ▁according ▁to ▁response ▁this ▁is ▁not ▁expected ▁to ▁have ▁clinic al ▁consequences ▁ .
▁eu ▁/ ▁1 ▁/ ▁97 ▁/ ▁04 6 ▁/ ▁ 016 ▁- ▁14 ▁tablets
▁for ▁intra mus cular ▁inject ion ▁only ▁ .
▁this ▁was ▁demonstrat ed ▁in ▁both ▁the ▁primary ▁analysis ▁at ▁one ▁year ▁and ▁in ▁the ▁confirma tory ▁analysis ▁at ▁two ▁years ▁end point ▁( ▁table ▁2 ▁) ▁ .
▁ pharma co therapeut ic ▁group ▁: ▁direct ▁ac ting ▁anti vir als ▁ , ▁at c ▁code ▁: ▁j 05 a e 04
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁out er ▁box ▁and ▁vi al ▁label ▁ .
▁very ▁rare ▁reports ▁of ▁ste ven s - joh n son ▁syndrome ▁have ▁occur red ▁in ▁the ▁post ▁marketing ▁setting ▁ .
▁overall ▁ , ▁107 ▁of ▁113 ▁subject s ▁without ▁cir r ho sis ▁and ▁147 ▁of ▁155 ▁subject s ▁with ▁cir r ho sis ▁achieve d ▁sv r 12 ▁after ▁12 -24 ▁weeks ▁of ▁treatment ▁ .
▁she lf - life ▁after ▁recon stitu tion ▁according ▁to ▁direction s ▁: ▁6 ▁hours ▁ .
▁what ▁should ▁i ▁do ▁before ▁i ▁give ▁myself ▁a ▁sub cuta ne ous ▁inject ion ▁of ▁teva gra s tim ▁?
▁bottle s ▁: ▁this ▁medicine ▁does ▁not ▁require ▁any ▁special ▁temperature ▁storage ▁conditions ▁ .
▁pulmonar y ▁disease s ▁induc ed ▁by ▁met ho tre xa te ▁ , ▁like ▁pneu moni tis ▁ , ▁can ▁occur ▁acu tely ▁at ▁any ▁time ▁of ▁ therapy ▁ , ▁they ▁were ▁not ▁always ▁completely ▁rever sible ▁and ▁have ▁been ▁reported ▁already ▁at ▁all ▁dos es ▁( ▁inclusive ▁low ▁dos es ▁of ▁7.5 ▁mg ▁/ ▁week ▁) ▁ .
▁other ▁medicine s ▁and ▁bude son ide ▁/ ▁form ote rol ▁teva
▁w hi ▁studies ▁combine d ▁- ▁additional ▁risk ▁of ▁is cha e mic ▁stroke ▁* ▁over ▁5 ▁years ▁use
▁administration ▁of ▁pe metre x ed ▁to ▁male ▁mi ce ▁result ed ▁in ▁reproduc tive ▁ toxic ity ▁character ised ▁by ▁reduce d ▁fertil ity ▁rates ▁and ▁testi cular ▁a trop hy ▁ .
▁patients ▁with ▁m cd ▁produce ▁too ▁much ▁il -6 ▁and ▁this ▁is ▁thought ▁to ▁contribute ▁to ▁the ▁ab normal ▁growth ▁of ▁certain ▁cell s ▁in ▁lymph ▁no des ▁ .
▁it ▁is ▁suppli ed ▁as ▁a ▁powder ▁which ▁will ▁be ▁mix ed ▁with ▁steril e ▁water ▁before ▁it ▁is ▁given ▁ .
▁alternative ly ▁ , ▁any ▁other ▁suitable - vali da ted ▁method ▁may ▁be ▁used ▁ , ▁carried ▁out ▁by ▁any ▁objective ly ▁qualified ▁laborator y ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁if ▁you ▁notice ▁that ▁the ▁vi al ▁is ▁damage d ▁or ▁the ▁solution ▁contain s ▁parti cula te ▁matter ▁or ▁appears ▁disco lou red ▁ .
▁for ▁each ▁inject ion ▁you ▁will ▁need ▁:
▁common ▁( ▁more ▁than ▁1 ▁in ▁a ▁100 ▁patients ▁) ▁side ▁effects ▁of ▁in ove lon ▁are ▁:
▁in vira se ▁/ ▁rito na vir ▁should ▁be ▁ad minister ed ▁with ▁or ▁after ▁food ▁ .
▁all ▁dos ing ▁will ▁be ▁taken ▁once ▁daily ▁oral ly ▁( ▁by ▁mouth ▁) ▁ .
▁in ▁two - year ▁car cino geni city ▁studies ▁conduct ed ▁in ▁rat s ▁( ▁ ≥ ▁1 ▁mg ▁/ ▁kg ▁/ ▁day ▁; ▁7 ▁times ▁system ic ▁exposure ▁following ▁a ▁human ▁dose ▁of ▁0.5 ▁mg ▁/ ▁day ▁based ▁on ▁plasma ▁au c ▁) ▁an ▁increased ▁incide nce ▁of ▁renal ▁tub ular ▁ade noma ▁and ▁car cino ma ▁in ▁male s ▁and ▁granul osa ▁cell ▁tu mo urs ▁of ▁the ▁ova ry ▁in ▁female s ▁was ▁not ed ▁ .
▁modi graf ▁1 ▁mg ▁granul es ▁for ▁oral ▁suspens ion ▁tac rol imus
▁this ▁medicinal ▁product ▁contain s ▁50 ▁vol ▁% ▁et han ol ▁an hydro us ▁( ▁alcohol ▁) ▁ , ▁i . e . ▁up ▁to ▁27 65 ▁mg ▁et han ol ▁an hydro us ▁per ▁7 ▁ml ▁vi al ▁ .
▁these ▁instructions ▁can ▁be ▁found ▁at ▁the ▁end ▁of ▁the ▁package ▁le a flet ▁ .
▁if ▁a ▁dose ▁is ▁missed ▁during ▁the ▁first ▁two ▁weeks ▁of ▁treatment ▁ , ▁patients ▁should ▁not ▁make ▁up ▁the ▁missed ▁dose ▁ , ▁but ▁should ▁continue ▁the ▁usual ▁dos ing ▁schedule ▁ .
▁component ▁of ▁a ▁multi pack ▁ , ▁can ▁' t ▁be ▁sold ▁separate ly ▁ .
▁no ▁dose ▁adjust ment ▁is ▁necessary ▁in ▁patients ▁with ▁he pati c ▁im pair ment ▁ .
▁la ctos e ▁( ▁120 ▁mg ▁/ ▁film - co ated ▁tablet ▁) ▁and ▁so ya ▁le ci thin ▁( ▁0.1 95 ▁mg ▁/ ▁film - co ated ▁tablet ▁) ▁ .
▁the ▁other ▁ingredients ▁are ▁la ctos e ▁mono hydrat e ▁ , ▁micro c ry stal line ▁cell ul ose ▁ , ▁collo i dal ▁an hydro us ▁si lica ▁ , ▁cro spo vido ne ▁ , ▁magnesium ▁stea rate ▁ , ▁all ▁in ▁the ▁tablet ▁core ▁; ▁hy pro mel lose ▁ , ▁poly sor bate ▁80 ▁ , ▁macro gol ▁400 ▁ , ▁titan ium ▁ dioxid e ▁( ▁e ▁171 ▁) ▁ , ▁and ▁additional ▁for ▁me man tine ▁accord ▁15 ▁mg ▁and ▁me man tine ▁accord ▁20 ▁mg ▁film - co ated ▁tablets ▁ir on ▁oxid e ▁yellow ▁and ▁red ▁( ▁e ▁172 ▁) ▁ , ▁all ▁in ▁the ▁tablet ▁coa ting
▁pre medic ation ▁with ▁de x mede tomi dine ▁will ▁significantly ▁reduce ▁the ▁dos age ▁of ▁the ▁in duction ▁agent ▁required ▁and ▁will ▁reduce ▁volatil e ▁ana e sthetic ▁requirements ▁for ▁maintenance ▁ana es the sia ▁ .
▁that ▁he ▁should ▁return ▁the ▁capsule s ▁to ▁the ▁ pharma ci st ▁at ▁the ▁end ▁of ▁treatment
▁gast riti s ▁ , ▁dy spe psi a ▁ , ▁di ar r ho e a ▁ , ▁abdominal ▁pain ▁ , ▁na use a ▁ , ▁con s tip ation
▁vot rien t ▁can ▁cause ▁severe ▁ble ed ing ▁in ▁the ▁digestiv e ▁system ▁( ▁such ▁as ▁stomach ▁ , ▁gull et ▁ , ▁re ctum ▁or ▁inte s tine ▁) ▁ , ▁or ▁the ▁lung s ▁ , ▁ki dne ys ▁ , ▁mouth ▁ , ▁vagina ▁and ▁brain ▁ , ▁although ▁this ▁is ▁un com mon ▁ .
▁now ▁press ▁the ▁am po ule ▁firm ly ▁over ▁the ▁ne ck ▁ , ▁and ▁break ▁the ▁am po ule ▁away ▁from ▁the ▁colour ed ▁dot ▁ .
▁this ▁might ▁just ▁be ▁for ▁the ▁first ▁inject ion ▁or ▁it ▁may ▁be ▁a ▁gradual ▁change ▁over ▁several ▁weeks ▁or ▁months ▁ .
▁there ▁is ▁an ▁increased ▁risk ▁of ▁ble ed ing ▁if ▁rom ip losti m ▁treatment ▁is ▁dis continu ed ▁in ▁the ▁presence ▁of ▁antico a gul ants ▁or ▁anti - plate let ▁agents ▁ .
▁ac m pag ▁is ▁ pharma c ological ly ▁active ▁and ▁is ▁suspect ed ▁to ▁be ▁responsible ▁for ▁some ▁of ▁mm f ▁' s ▁side ▁effects ▁( ▁di ar r ho e a ▁ , ▁le uc op enia ▁) ▁ .
▁2 ▁pre - fill ed ▁pens ▁of ▁0.5 ▁ml ▁solution ▁4 ▁pre - fill ed ▁pens ▁of ▁0.5 ▁ml ▁solution
▁to pote can ▁ea gle ▁3 ▁mg ▁/ ▁1 ▁ml ▁concentrat e ▁for ▁solution ▁for ▁in fusion
▁blood ▁creati ne ▁ phos pho kina se ▁increased
▁media n ▁- ▁months ▁( ▁95 ▁% ▁ci ▁)
▁if ▁an ▁individual ▁is ▁expected ▁to ▁be ▁at ▁particular ▁risk ▁of ▁exposure ▁to ▁men ▁a ▁and ▁received ▁a ▁dose ▁of ▁men ve o ▁more ▁than ▁approximately ▁one ▁year ▁previously ▁ , ▁consideration ▁may ▁be ▁given ▁to ▁ad minister ing ▁a ▁boost er ▁dose ▁ .
▁in ▁p vc ▁/ ▁p vd c ▁/ ▁aluminium ▁bli sters ▁ , ▁store ▁below ▁30 ▁° ▁c ▁ .
▁side ▁effects ▁with ▁pe metre x ed ▁may ▁include ▁:
▁14 x 1 ▁tablets ▁( ▁unit ▁dose ▁)
▁the ▁studies ▁either ▁recruit ed ▁patients ▁who ▁were ▁being ▁treated ▁with ▁che mo therapy ▁( ▁two ▁studies ▁) ▁or ▁used ▁patient ▁population s ▁in ▁which ▁er y thro po ies is ▁stimula ting ▁agents ▁are ▁not ▁indicate d ▁: ▁ana emia ▁in ▁patients ▁with ▁cancer ▁not ▁receiving ▁che mo therapy ▁ , ▁and ▁head ▁and ▁ne ck ▁cancer ▁patients ▁receiving ▁radio therapy ▁ .
▁there ▁was ▁no ▁difference ▁in ▁ef fica cy ▁between ▁e ribu lin ▁and ▁da car bazi ne ▁in ▁patients ▁with ▁advanced ▁or ▁meta static ▁lei om yo sar com a ▁ .
▁na dir ▁plate let s ▁< ▁ 50,000 ▁/ ▁mm 3 ▁with ▁ble e dinga ▁ , ▁regardless ▁of ▁na dir ▁an c
▁influenza ▁can ▁be ▁associated ▁with ▁a ▁variety ▁of ▁neurologi c ▁and ▁behaviour al ▁symptoms ▁which ▁can ▁include ▁events ▁such ▁as ▁hal lucina tions ▁ , ▁de li rium ▁ , ▁and ▁ab normal ▁behaviour ▁ , ▁in ▁some ▁cases ▁result ing ▁in ▁fatal ▁outcome s ▁ .
▁privi gen ▁is ▁made ▁from ▁human ▁plasma ▁ .
▁tra cle er ▁with ▁food ▁and ▁drink
▁do ▁not ▁use ▁zo le dro nic ▁acid ▁act avis ▁after ▁the ▁exp i ry ▁date ▁state d ▁on ▁the ▁vi al ▁and ▁carton ▁after ▁exp ▁ .
▁in ▁vi tro ▁ , ▁this ▁metabol ite ▁shows ▁minimal ▁inhibi tion ▁of ▁a ce tyl cho line ster ase ▁( ▁< ▁10 ▁% ▁) ▁ .
▁a ▁bottle ▁with ▁child ▁resist ant ▁ closure ▁contain ing ▁30 ▁film - co ated ▁tablets ▁ .
▁use ▁in ▁el der ly ▁( ▁> ▁75 ▁years ▁)
▁a ▁large ▁amount ▁of ▁data ▁on ▁pregnant ▁women ▁( ▁more ▁than ▁1000 ▁pre gna ncy ▁outcome s ▁) ▁indicate s ▁no ▁mal forma tive ▁nor ▁fo eto ▁/ ▁ne ona tal ▁ toxic ity ▁of ▁garda sil ▁9 ▁( ▁see ▁section ▁5.1 ▁) ▁ .
▁what ▁xil iar x ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁treatment - ▁experienced ▁( ▁n ▁= ▁69 ▁)
▁the ▁con com i tant ▁use ▁of ▁other ▁central ▁ner vous ▁system ▁de press ants ▁ , ▁including ▁other ▁op io ids ▁ , ▁seda tives ▁or ▁hypno tics ▁ , ▁general ▁ana e sthetic s ▁ , ▁ph eno thi az ines ▁ , ▁tranquil lis ers ▁ , ▁skelet al ▁muscle ▁relax ants ▁ , ▁se dating ▁anti hi stamine s ▁and ▁alcohol ▁may ▁produce ▁addit ive ▁de press ant ▁effects ▁ .
▁for ▁dos ing ▁recommendations ▁with ▁calci ne uri n ▁inhibi tors ▁refer ▁to ▁section ▁4.5 ▁ .
▁at ▁a ▁media n ▁follow - up ▁time ▁of ▁77 ▁months ▁ , ▁a cute ▁leuk a emia ▁occur red ▁in ▁1 ▁of ▁5 32 ▁( ▁0.2 ▁% ▁) ▁patients ▁who ▁received ▁doce ta xel ▁ , ▁do xor ubi cin ▁ , ▁and ▁ cyclo phos pha mi de ▁in ▁the ▁ge ica m ▁9 805 ▁study ▁ .
▁4- hydro xy ▁ ator vasta tin ▁: ▁au c ▁: ▁ ↓ ▁4 ▁% ▁( ▁ ↓ ▁0 ▁to ▁ ↓ ▁31 ▁)
▁please ▁check ▁the ▁rever se ▁( ▁insulin ▁) ▁side ▁of ▁this ▁le a flet ▁for ▁instructions ▁on ▁how ▁to ▁store ▁solo star ▁ .
▁pain ▁in ▁leg ▁( ▁s ▁) ▁( ▁pain ▁in ▁extrem ity ▁)
▁the ▁recon stitu ted ▁solution ▁may ▁exhibi t ▁a ▁s light ▁op al esc ence ▁ .
▁carton s ▁contain ing ▁10 ▁x ▁1 ▁ , ▁30 ▁x ▁1 ▁or ▁60 ▁x ▁1 ▁hard ▁capsule s ▁in ▁perfor ated ▁aluminium ▁unit ▁dose ▁bli sters ▁ .
▁patients ▁remain ed ▁on ▁stable ▁dos es ▁of ▁ nsa ids ▁and ▁or ▁pred nis one ▁( ▁0.2 ▁mg ▁/ ▁kg ▁/ ▁day ▁or ▁10 ▁mg ▁/ ▁day ▁maximum ▁) ▁ .
▁use ▁intr insa ▁only ▁as ▁long ▁as ▁you ▁experience ▁a ▁positive ▁effect ▁of ▁the ▁treatment ▁ .
▁lock ed ▁with ▁safety ▁guard ▁out
▁care ful ▁consideration ▁of ▁the ▁activity ▁to ▁be ▁ad minister ed ▁is ▁required ▁since ▁an ▁increased ▁radi ation ▁exposure ▁is ▁possible ▁in ▁these ▁patients ▁ .
▁insulin ▁human ▁win thro p ▁in fus at ▁must ▁only ▁be ▁used ▁if ▁the ▁solution ▁is ▁clear ▁ , ▁colour less ▁ , ▁with ▁no ▁solid ▁parti cles ▁visible ▁ , ▁and ▁has ▁a ▁water - like ▁consiste ncy ▁ .
▁dis continu ation ▁should ▁also ▁be ▁considered ▁when ▁evidence ▁of ▁a ▁ therapeut ic ▁effect ▁is ▁no ▁longer ▁present ▁ .
▁in ▁pre clin ical ▁studies ▁ , ▁olan za pine ▁exhibi ted ▁a ▁range ▁of ▁receptor ▁a ffin ities ▁( ▁ki ▁< ▁100 ▁n m ▁) ▁for ▁serotonin ▁5 ht 2 a ▁/ ▁2 c ▁ , ▁5 ht 3 ▁ , ▁5 ht 6 ▁; ▁dop amine ▁d 1 ▁ , ▁d 2 ▁ , ▁d 3 ▁ , ▁d 4 ▁ , ▁d 5 ▁; ▁cho liner gi c ▁mus cari nic ▁receptor s ▁m 1- m 5 ▁; ▁α ▁1 ▁ad r energi c ▁; ▁and ▁his tamine ▁h 1 ▁receptor s ▁ .
▁whenever ▁the ▁risk ▁management ▁system ▁is ▁modifi ed ▁ , ▁especially ▁as ▁the ▁result ▁of ▁new ▁information ▁being ▁received ▁that ▁may ▁lead ▁to ▁a ▁significant ▁change ▁to ▁the ▁benefit ▁/ ▁risk ▁profile ▁or ▁as ▁the ▁result ▁of ▁an ▁important ▁( ▁ pharma co vigil ance ▁or ▁risk ▁minim isation ▁) ▁miles tone ▁being ▁reached ▁ .
▁new ▁primary ▁melan om as ▁have ▁been ▁reported ▁in ▁clinic al ▁trial s ▁ .
▁the ▁number ▁of ▁ul cer ative ▁col itis - related ▁sur g ical ▁procedure s ▁was ▁also ▁lower ▁in ▁the ▁5 ▁and ▁10 ▁mg ▁/ ▁kg ▁in flix ima b ▁treatment ▁groups ▁than ▁in ▁the ▁place bo ▁group ▁( ▁mean ▁number ▁of ▁sur g ical ▁procedure s ▁per ▁100 ▁subject - year s ▁: ▁22 ▁and ▁19 ▁vs ▁ .
▁the ▁system ic ▁exposure ▁to ▁ rani biz um ab ▁is ▁low ▁after ▁o cular ▁administration ▁ , ▁but ▁due ▁to ▁its ▁mechanism ▁of ▁action ▁ , ▁ rani biz um ab ▁must ▁be ▁regard ed ▁as ▁potential ly ▁ter ato ge nic ▁and ▁em bry o - ▁/ ▁fo eto toxic ▁ .
▁if ▁the ▁liquid ▁is ▁below ▁the ▁fill ▁line ▁ , ▁return ▁the ▁entire ▁pack ▁to ▁the ▁pharmacy ▁ .
▁fund us co pic ▁examina tion ▁is ▁recommended ▁at ▁the ▁initiat ion ▁and ▁period ically ▁during ▁the ▁course ▁of ▁treatment ▁ .
▁kuvan ▁has ▁no ▁or ▁negli gi ble ▁influence ▁on ▁the ▁ability ▁to ▁drive ▁and ▁use ▁machines ▁ .
▁feed ▁your ▁child ▁regularly ▁to ▁avoid ▁prolong ed ▁fast ▁ .
▁patients ▁with ▁a ▁low ▁body ▁weight ▁( ▁< ▁60 ▁kg ▁) ▁are ▁more ▁likely ▁to ▁experience ▁higher ▁plasma ▁concentration s ▁of ▁posa con a zole ▁and ▁should ▁be ▁close ly ▁monitor ed ▁for ▁advers e ▁events ▁ .
▁in ▁dog s ▁ , ▁pru ca lo pri de ▁alter s ▁colon ic ▁mot ility ▁pattern s ▁via ▁serotonin ▁5- ht 4 ▁receptor ▁stimul ation ▁: ▁it ▁stimula tes ▁proxima l ▁colon ic ▁mot ility ▁ , ▁enhance s ▁gastro duo den al ▁mot ility ▁and ▁accelerat es ▁de lay ed ▁gas tric ▁empty ing ▁ .
▁keep ▁the ▁vi al ▁in ▁the ▁original ▁carton ▁in ▁order ▁to ▁protect ▁from ▁light ▁ .
▁the ▁dose ▁for ▁el der ly ▁patients ▁should ▁be ▁lower ed ▁due ▁to ▁age - related ▁reduce d ▁ liver ▁and ▁ki dne y ▁function ▁ .
▁the ▁terminal ▁half - life ▁range d ▁from ▁ 2.8 ▁to
▁len vati ni b ▁has ▁not ▁been ▁studie d ▁in ▁patients ▁who ▁have ▁had ▁an ▁arterial ▁ thro mbo e mbol ism ▁within ▁the ▁previous ▁6 ▁months ▁ , ▁and ▁therefore ▁should ▁be ▁used ▁with ▁cau tion ▁in ▁such ▁patients ▁ .
▁appropriate ▁monitoring ▁and ▁medical ▁support ▁measure s ▁should ▁be ▁available ▁for ▁immediate ▁use ▁when ▁ad minister ing ▁ved oli zum ab ▁ .
▁you ▁must ▁not ▁breast - feed ▁while ▁you ▁are ▁treated ▁with ▁doce ta xel ▁win thro p ▁ .
▁the ▁dose ▁recommend ation ▁in ▁mg ▁/ ▁kg ▁body ▁weight ▁is ▁the ▁same ▁in ▁children ▁and ▁adults ▁ .
▁patients ▁should ▁not ▁be ▁initiat ed ▁on ▁a eri vio ▁spir o max ▁during ▁an ▁ex ace rb ation ▁ , ▁or ▁if ▁they ▁have ▁significantly ▁worse ning ▁or ▁acu tely ▁deteriora ting ▁as th ma ▁ .
▁nu loj ix ▁ , ▁in ▁combination ▁with ▁corti co steroid s ▁and ▁a ▁my co phen o lic ▁acid ▁( ▁ mpa ▁) ▁ , ▁is ▁indicate d ▁for ▁pro phy la xis ▁of ▁graf t ▁ reje ction ▁in ▁adults ▁receiving ▁a ▁renal ▁transplant ▁( ▁see ▁section ▁5.1 ▁for ▁data ▁on ▁renal ▁function ▁) ▁ .
▁aluminium ▁bli sters ▁in ▁carton s ▁of ▁2 ▁ , ▁4 ▁ , ▁8 ▁or ▁12 ▁tablets ▁ .
▁disc ard ▁four ▁weeks ▁after ▁first ▁opening ▁ .
▁sc r ▁% ▁( ▁95 ▁% ▁ci ▁) ▁)
▁only ▁inject ▁one ▁dose ▁per ▁day ▁ .
▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 001 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 002 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 003 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 004 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 005 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 006 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 007 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 008 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 009 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 010 ▁eu ▁/ ▁1 ▁/ ▁10 ▁/ ▁ 634 ▁/ ▁ 011
▁du ores p ▁spir o max ▁160 ▁micro gram s ▁/ ▁4.5 ▁micro gram s ▁ , ▁in hal ation ▁powder
▁survival ▁estima tes ▁were ▁lower ▁in ▁the ▁sub group ▁of ▁patients ▁with ▁pah ▁seconda ry ▁to ▁system ic ▁sc ler osis ▁ .
▁uns table ▁ang ina ▁pec toris ▁ , ▁vent ri cular ▁ar rhythm ia ▁ , ▁my o card ial ▁in far ction 2
▁when ▁using ▁ cia mbra ▁in ▁combination ▁with ▁ci s plat in ▁:
▁e distri de ▁5 ▁mg ▁film - co ated ▁tablets ▁e distri de ▁10 ▁mg ▁film - co ated ▁tablets ▁da pag lif lozi n
▁1 ▁pre - fill ed ▁sy ringe ▁with ▁0.3 ▁ml ▁solution ▁for ▁inject ion ▁contain s ▁1 ▁000 ▁international ▁unit s ▁( ▁iu ▁) ▁e po etin ▁ze ta ▁( ▁reco mbin ant ▁human ▁er y thro po i etin ▁) ▁ .
▁the ▁majority ▁of ▁patients ▁( ▁88 ▁% ▁) ▁achieve d ▁target ▁fonda par in ux ▁concentration s ▁at ▁4 ▁hours ▁after ▁the ▁first ▁dose ▁of ▁fonda par in ux ▁ .
▁cases ▁of ▁pan creati tis ▁were ▁observe d ▁with ▁ex ta via ▁use ▁ , ▁often ▁associated ▁with ▁hyper tri gly ceri da emia ▁ .
▁substance s ▁that ▁may ▁enhance ▁the ▁blood - glu co se - lo wering ▁activity ▁and ▁increase ▁sus cept i bility ▁to ▁hypo gly ca emia ▁include ▁oral ▁anti dia be tic ▁medicinal ▁products ▁ , ▁ang io ten sin ▁convert ing ▁enzym e ▁( ▁a ce ▁) ▁inhibi tors ▁ , ▁di so pyr ami de ▁ , ▁fibra tes ▁ , ▁flu o xe tine ▁ , ▁mono amine ▁oxid ase ▁inhibi tors ▁( ▁m aois ▁) ▁ , ▁pen to xi fyll ine ▁ , ▁prop oxy phen e ▁ , ▁sa lic yla tes ▁and ▁sul fon ami de ▁antibiotic s ▁ .
▁tablet ▁film ▁coa t ▁: ▁hy pro mel lose ▁ , ▁titan ium ▁ dioxid e ▁( ▁e 171 ▁) ▁ , ▁macro gol ▁ , ▁poly sor bate ▁80 ▁ , ▁ir on ▁oxid e ▁yellow ▁( ▁e 172 ▁) ▁ , ▁ir on ▁oxid e ▁red ▁( ▁e 172 ▁) ▁ .
▁if ▁you ▁drop ▁it ▁or ▁suspect ▁a ▁problem ▁ , ▁att ach ▁a ▁new ▁need le ▁and ▁check ▁the ▁insulin ▁flow ▁before ▁you ▁inject ▁ .
▁no ▁clinic ally ▁relevant ▁effect ▁of ▁food ▁was ▁observe d ▁on ▁the ▁bio ava il ability ▁of ▁nome ges trol ▁ac etate ▁ .
▁what ▁pri tor plus ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁use ▁in ▁women ▁of ▁child be aring ▁potential
▁au c ▁4. 76 ▁( ▁4. 07 ▁ , ▁5. 56 ▁)
▁di so dium ▁hydro gen ▁ phos pha te ▁( ▁na 2 h po 4 ▁) ▁po tas s ium ▁di hydro gen ▁ phos pha te ▁( ▁kh 2 po 4 ▁) ▁po tas s ium ▁chlor ide ▁( ▁k cl ▁)
▁ pharma co therapeut ic ▁group ▁: ▁anti neo plast ic ▁agent ▁ , ▁other ▁anti neo plast ic ▁agents ▁ , ▁protein ▁kina se ▁inhibi tor ▁ , ▁at c ▁code ▁: ▁l 01 xe 07
▁lo xi com ▁1 ▁mg ▁che w able ▁tablets ▁for ▁dog s ▁lo xi com ▁2.5 ▁mg ▁che w able ▁tablets ▁for ▁dog s ▁melo xi cam
▁how ▁to ▁use ▁org alu tran
▁28 ▁x ▁1 ▁tablet ▁( ▁unit
▁if ▁you ▁get ▁side ▁effects ▁your ▁doctor ▁may ▁decide ▁that ▁you ▁should ▁take ▁lower ▁dos es ▁of ▁me kin ist ▁and ▁da bra fen ib ▁ .
▁2 ▁end oto xin ▁administration ▁in ▁cal ves ▁and ▁pig s ▁ .
▁ab se a med ▁is ▁given ▁by ▁inject ion ▁under ▁the ▁skin ▁each ▁week ▁for ▁three ▁weeks ▁before ▁surgery ▁and ▁on ▁the ▁day ▁of ▁surgery ▁ .
▁go nal - f ▁75 ▁iu ▁( ▁5.5 ▁μ g ▁) ▁powder ▁for ▁solution ▁for ▁inject ion ▁fol li trop in ▁alfa
▁1 ▁cart ridge ▁contain s ▁3 ▁ml ▁equivalent ▁to ▁300 ▁unit s
▁a ▁ ≥ ▁50 ▁% ▁re duction ▁from ▁base line ▁in ▁the ▁number ▁of ▁dra ining ▁fi stu las ▁over ▁a ▁period ▁of ▁ ≥ ▁4 ▁weeks ▁ .
▁if ▁you ▁need ▁smaller ▁dos es ▁ , ▁making ▁liquid ▁tam i flu ▁from ▁capsule s ▁involve s ▁extra ▁steps ▁ .
▁pack s ▁of ▁3 ▁ , ▁4 ▁ , ▁5 ▁ , ▁6 ▁ , ▁9 ▁and ▁10 ▁pens ▁of ▁3 ▁ml ▁are ▁available ▁ .
▁if ▁you ▁have ▁ble ed ing ▁problems ▁( ▁e . g . ▁ha emo phil ia ▁) ▁or ▁have ▁had ▁them ▁in ▁the ▁past ▁ , ▁or ▁you ▁are ▁taking ▁other ▁medicine s ▁which ▁may ▁prolong ▁ble ed ing ▁time ▁( ▁e . g . ▁war far in ▁ , ▁clo pido gre l ▁ , ▁a ce tyl sali cy lic ▁acid ▁) ▁ .
▁press ▁the ▁pen ▁firm ly ▁against ▁the ▁skin ▁to ▁start ▁the ▁inject ion ▁ .
▁it ▁should ▁be ▁ad minister ed ▁once ▁monthly ▁as ▁a ▁single ▁inject ion ▁( ▁no ▁soon er ▁than ▁26 ▁days ▁after ▁the ▁previous ▁inject ion ▁) ▁ .
▁if ▁you ▁inject ▁your ▁insulin ▁too ▁often ▁at ▁the ▁same ▁skin ▁site ▁ , ▁fa tty ▁tissu e ▁under ▁the ▁skin ▁at ▁this ▁site ▁may ▁either ▁sh rink ▁( ▁lipo a trop hy ▁ , ▁may ▁affect ▁up ▁to ▁1 ▁in ▁100 ▁people ▁) ▁or ▁thi cken ▁( ▁lipo hy per trop hy ▁) ▁ .
▁st . ▁joh n ▁' s ▁ wort ▁( ▁hyper icum ▁perfor atum ▁) ▁( ▁a ▁herbal ▁reme dy ▁used ▁for ▁depression ▁and ▁anxiety ▁)
▁table ▁16 ▁: ▁changes ▁in ▁c pt ▁score ▁parameter s ▁from ▁base line ▁to ▁week ▁12 ▁and ▁24 ▁post - tre at ment ▁in ▁patients ▁a chie ving ▁sv r 12 ▁ , ▁as tral -4
▁alan ine ▁amino transfer ase ▁eleva tions ▁occur ▁common ly ▁in ▁patients ▁treated ▁with ▁vand etan ib ▁ .
▁the ▁media n ▁number ▁of ▁treatment ▁cycle s ▁was ▁19 ▁for ▁the ▁emp licit i ▁arm ▁and ▁14 ▁for ▁the ▁compara tor ▁arm ▁ .
▁on ▁treatment ▁2 ▁( ▁22. 1 ▁% ▁) ▁patients ▁experienced ▁mild ▁related ▁advers e ▁events ▁( ▁gastro o es op hage al ▁ref lux ▁/ ▁abdominal ▁pain ▁; ▁abdominal ▁disco m fort ▁) ▁and ▁1 ▁( ▁11. 1 ▁% ▁) ▁patient ▁experienced ▁a ▁not ▁related ▁serious ▁advers e ▁event ▁( ▁re current ▁v te ▁of ▁the ▁leg ▁) ▁in ▁the ▁post ▁treatment ▁period ▁> ▁3 ▁days ▁after ▁stop ▁of ▁da biga tran ▁et ex ila te ▁ .
▁pe ak ▁plasma ▁concentration s ▁are ▁att ained ▁at ▁1.5 -2 ▁hours ▁after ▁oral ▁administration ▁ .
▁le a flet s ▁giving ▁detailed ▁instructions ▁for ▁use ▁of ▁e vice l ▁in ▁con jun ction ▁with ▁the ▁application ▁device ▁and ▁option al ▁accesso ry ▁tips ▁are ▁provided ▁with ▁the ▁package ▁of ▁the ▁application ▁device ▁and ▁of ▁the ▁accesso ry ▁tips ▁ .
▁because ▁of ▁how ▁q tern ▁works ▁ , ▁your ▁urin e ▁will ▁test ▁positive ▁for ▁sugar ▁while ▁you ▁are ▁on ▁this ▁medicine ▁ .
▁novom ix ▁30 ▁may ▁be ▁used ▁in ▁combination ▁with ▁tablets ▁for ▁diabetes ▁ .
▁what ▁rasi lez ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁not ▁known ▁: ▁gastro inte stin al ▁ul cer ▁perfor ation ▁ , ▁retro peri tone al ▁ha e mor r hage ▁ , ▁ha e mate mesi s ▁ , ▁gas tric ▁ul cer ▁ , ▁oes op hagi tis ▁ul cer ative ▁ , ▁su bile us ▁ , ▁en tero coli tis ▁ , ▁ha e mor r ho ids ▁ , ▁hi atus ▁her nia ▁ , ▁recta l ▁ha e mor r hage ▁ , ▁ging ivit is ▁ .
▁direct ▁the ▁dilu ent ▁against ▁the ▁side ▁of ▁the ▁vi al ▁to ▁avoid ▁excessive ▁fo am ing ▁ .
▁70 ▁ , ▁a venue ▁du ▁général ▁de ▁gau lle ▁f - 92 800 ▁putea ux
▁how ▁to ▁store ▁heli xa te ▁ne x gen ▁500 ▁iu
▁reta crit ▁8 ▁000 ▁iu ▁/ ▁ 0.8 ▁ml ▁solution ▁for ▁inject ion ▁in ▁pre - fill ed ▁sy ringe ▁eu ▁/ ▁1 ▁/ ▁07 ▁/ ▁ 431 ▁/ ▁01 3 ▁1 ▁pre - fill ed ▁sy ringe
▁e mend ▁works ▁by ▁block ing ▁signal s ▁to ▁that ▁area ▁and ▁is ▁used ▁to ▁prevent ▁na use a ▁and ▁vom i ting ▁after ▁surgery ▁in ▁adults ▁ .
▁co - administration ▁of ▁such ▁medicinal ▁products ▁is ▁not ▁recommended ▁with ▁sov aldi ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁to ▁ensure ▁proper ▁inject ion ▁ , ▁allow ▁the ▁pre - fill ed ▁pen ▁to ▁sit ▁at ▁room ▁temperature ▁outside ▁the ▁box ▁for ▁30 ▁minutes ▁out ▁of ▁the ▁reach ▁of ▁children ▁ .
▁however ▁ , ▁the ▁maximum ▁observe d ▁plasma ▁concentration s ▁as ▁well ▁as ▁volume s ▁of ▁distribution ▁estima tes ▁were ▁similar ▁across ▁the ▁groups ▁ .
▁sil den a fil ▁used ▁to ▁treat ▁er ect ile ▁dys function ▁may ▁be ▁taken ▁under ▁doctor ▁' s ▁super vision ▁( ▁see ▁war nings ▁and ▁precau tions ▁section ▁) ▁; ▁products ▁that ▁contain ▁st ▁joh n ▁' s ▁ wort ▁( ▁hyper icum ▁perfor atum ▁) ▁ .
▁a ▁study ▁in ▁rabbi ts ▁demonstrat ed ▁no ▁effect ▁on ▁fertil ity ▁indice s ▁in ▁male s ▁or ▁female s ▁although ▁testi cular ▁de genera tion ▁was ▁observe d ▁in ▁male s ▁ .
▁a ▁second ▁inject ion ▁ , ▁5-10 ▁mg ▁ , ▁may ▁be ▁ad minister ed ▁2 ▁hours ▁after ▁the ▁first ▁inject ion ▁on ▁the ▁basis ▁of ▁individual ▁clinic al ▁status ▁ .
▁non e ▁of ▁the ▁ingredients ▁in ▁the ▁vaccin e ▁can ▁cause ▁flu ▁ .
▁ben ly sta ▁should ▁not ▁be ▁inf used ▁con com i tant ly ▁in ▁the ▁same ▁intra ven ous ▁line ▁with ▁other ▁agents ▁ .
▁monitoring ▁of ▁blood ▁gluco se ▁is ▁necessary ▁during ▁insulin ▁in fusion ▁ .
▁there ▁is ▁no ▁relevant ▁use ▁of ▁alim ta ▁in ▁the ▁pa e dia tric ▁population ▁in ▁malign ant ▁ple ural ▁mes oth elio ma ▁and ▁non - s mall ▁cell ▁lung ▁cancer ▁ .
▁you ▁will ▁need ▁to ▁take ▁ni vesti m ▁until ▁your ▁white ▁blood ▁cell ▁count ▁is ▁normal ▁ .
▁trans amin ase ▁eleva tions ▁were ▁generally ▁trans ient ▁ .
▁hepatitis ▁a ▁virus ▁( ▁in activa ted ▁) ▁1,2 ▁720 ▁el isa ▁unit s ▁hepatitis ▁b ▁surface ▁anti gen 3,4 ▁20 ▁micro gram s
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁bli ster ▁and ▁the ▁carton ▁after ▁exp ▁ .
▁please ▁refer ▁to ▁the ▁sm pc ▁ .
▁do ▁not ▁keep ▁or ▁store ▁the ▁trans der mal ▁patch ▁outside ▁the ▁seal ed ▁sa chet ▁ .
▁quadra met ▁should ▁only ▁be ▁ad minister ed ▁by ▁physician s ▁experienced ▁in ▁the ▁use ▁of ▁radio pharma ce u tical s ▁and ▁after ▁full ▁on c ological ▁evaluation ▁of ▁the ▁patient ▁by ▁qualified ▁physician s ▁ .
▁by ▁stop ping ▁blood ▁ves sels ▁growing ▁in ▁the ▁cancer ▁by ▁stimula ting ▁part ▁of ▁the ▁immun e ▁system ▁to ▁attack ▁the ▁cancer ▁cell s ▁ .
▁nivo lum ab ▁or ▁nivo lum ab ▁in ▁combination ▁with ▁i pili mum ab ▁must ▁be ▁permanent ly ▁dis continu ed ▁for ▁any ▁severe ▁immun e - related ▁advers e ▁reaction ▁that ▁recurs ▁and ▁for ▁any ▁life - th rea te ning ▁immun e - related ▁advers e ▁reaction ▁ .
▁red ▁spot s ▁under ▁the ▁skin
▁no ▁specific ▁advice ▁can ▁be ▁given ▁on ▁whether ▁to ▁use ▁or ▁not ▁in ▁breast feed ing ▁mother s ▁ .
▁however ▁ , ▁the ▁temperature ▁ rise ▁may ▁be ▁0.5 ▁° ▁c ▁higher ▁and ▁the ▁swe lling s ▁may ▁be ▁more ▁prono un ced ▁and ▁palp able ▁for ▁a ▁longer ▁period ▁ .
▁this ▁28 ▁day ▁period ▁is ▁one ▁treatment ▁cycle ▁ .
▁immun ological ▁properties ▁of ▁the ▁product ▁: ▁to ▁stimula te ▁active ▁immun ity ▁in ▁order ▁to ▁provide ▁passiv e ▁immun ity ▁to ▁the ▁pro gen y ▁against ▁en tero toxic osis ▁caused ▁by ▁e . ▁ coli ▁express ing ▁fi mbria l ▁a dhe sins ▁f 4 ab ▁( ▁k 88 ab ▁) ▁ , ▁f 4 ac ▁( ▁k 88 ac ▁) ▁ , ▁f 5 ▁( ▁k 99 ▁) ▁ , ▁f 6 ▁( ▁ 987 p ▁) ▁and ▁against ▁( ▁ne cro tic ▁) ▁enter itis ▁caused ▁by ▁c . ▁per f ringen s ▁type ▁c ▁ .
▁tar ce va ▁with ▁food ▁and ▁drink
▁in ▁100 ▁% ▁human ▁se rum ▁ , ▁the ▁mean ▁protein ▁ fold ▁shift ▁was ▁75 ▁ fold ▁ , ▁result ing ▁in ▁protein ▁adjust ed ▁ ic 90 ▁of ▁0.0 64 ▁ug ▁/ ▁ml ▁ .
▁use ▁1 ▁ml ▁oral ▁dispens er ▁if ▁dose ▁is ▁1 ▁ml ▁or ▁less ▁ .
▁are ▁allergi c ▁to ▁tega fur ▁ , ▁gim era cil ▁ , ▁o tera cil ▁or ▁any ▁of ▁the ▁other ▁ingredients ▁of ▁this ▁medicine ▁( ▁listed ▁in ▁section ▁6 ▁) ▁ .
▁me at ▁and ▁of fal ▁: ▁5 ▁days ▁( ▁pig s ▁)
▁if ▁you ▁are ▁pregnant ▁ , ▁or ▁thinking ▁about ▁becoming ▁pregnant ▁ , ▁tell ▁your ▁doctor ▁ .
▁advers e ▁event ▁data ▁collect ed ▁in ▁clinic al ▁trial s ▁suggest ▁that ▁eur arte sim ▁has ▁no ▁influence ▁on ▁the ▁ability ▁to ▁drive ▁and ▁operate ▁machines ▁once ▁the ▁patient ▁has ▁recover ed ▁from ▁the ▁a cute ▁infection ▁ .
▁white ▁adjust able ▁multi dos e ▁pre - fill ed ▁sy ringe ▁consist ing ▁of ▁high ▁den s ity ▁poly e thy lene ▁( ▁hd pe ▁ , ▁barre l ▁ , ▁plu nger ▁and ▁ring ▁) ▁and ▁low ▁den s ity ▁poly e thy lene ▁( ▁l d pe ▁ , ▁cap ▁and ▁seal ▁) ▁ .
▁men ▁wish ing ▁to ▁father ▁a ▁child ▁should ▁contact ▁their ▁doctor ▁who ▁may ▁advise ▁them ▁to ▁stop ▁taking ▁a rava ▁and ▁take ▁certain ▁medicine s ▁to ▁remove ▁a rava ▁rapid ly ▁and ▁ sufficient ly ▁from ▁their ▁body ▁ .
▁this ▁medicine ▁is ▁intended ▁to ▁treat ▁one ▁area ▁of ▁25 ▁cm 2 ▁for ▁three ▁days ▁ .
▁data ▁collect ed ▁in ▁the ▁post - marketing ▁phase ▁will ▁also ▁be ▁examine d ▁to ▁determine ▁if ▁a ▁suitable ▁na gla zy me ▁maintenance ▁dose ▁can ▁be ▁recommended ▁relative ▁to ▁the ▁ef fica cy ▁end point s ▁used ▁in ▁the ▁clinic al ▁studies ▁ .
▁people ▁with ▁meta static ▁breast ▁cancer ▁who ▁received ▁a bra xan e ▁where ▁another ▁ therapy ▁had ▁failed ▁ , ▁were ▁more ▁likely ▁to ▁experience ▁a ▁re duction ▁in ▁tum our ▁size ▁ , ▁and ▁lived ▁longer ▁than ▁people ▁who ▁took ▁an ▁alternative ▁ therapy ▁ .
▁the ▁percentage ▁of ▁patients ▁report ing ▁ad rs ▁upon ▁re - tre at ment ▁with ▁further ▁courses ▁of ▁mab ther a ▁was ▁similar ▁to ▁the ▁percentage ▁of ▁patients ▁report ing ▁ad rs ▁upon ▁initial ▁exposure ▁( ▁any ▁grade ▁and ▁grade ▁3 ▁/ ▁4 ▁ad rs ▁) ▁ .
▁bring ▁the ▁powder ▁and ▁solve nt ▁vi als ▁to ▁a ▁temperature ▁not ▁above ▁25 ▁° ▁c ▁by ▁holding ▁them ▁in ▁the ▁hands ▁ .
▁each ▁carton ▁contain s ▁one ▁high - dens ity ▁poly e thy lene ▁( ▁hd pe ▁) ▁bottle ▁or ▁three ▁high - dens ity ▁poly e thy lene ▁( ▁hd pe ▁) ▁bottle s ▁closed ▁with ▁child - re si stant ▁poly propyl ene ▁ closure ▁ .
▁fe ndri x ▁should ▁not ▁be ▁given ▁to ▁subject s ▁with ▁hyper sensitiv ity ▁after ▁previous ▁administration ▁of ▁other ▁hepatitis ▁b ▁vaccin es ▁ .
▁clinic ally ▁important ▁disrupt ions ▁of ▁the ▁blood - bra in ▁barrier
▁the ▁key ▁cardiovascular ▁safety ▁analysis ▁included ▁occur r ence ▁and ▁tim ing ▁of ▁a ▁com posit e ▁end point ▁of ▁major ▁advers e ▁cardiovascular ▁events ▁( ▁ma ce ▁) ▁ , ▁define d ▁as ▁cardiovascular ▁death ▁ , ▁non fa tal ▁mi ▁ , ▁and ▁non fa tal ▁stroke ▁ .
▁powder ▁for ▁solution ▁for ▁in fusion ▁5 ▁vi als
▁name ▁of ▁the ▁medicinal ▁product ▁and ▁route ▁( ▁s ▁) ▁of ▁administration
▁the ▁maximum ▁recommended ▁daily ▁dose ▁is ▁16 ▁mg ▁ .
▁di ar r ho e a ▁with ▁mix ed ▁cell ▁ inflammation ▁of ▁the ▁ca e cum ▁or ▁colon ▁was ▁observe d ▁in ▁mon key s ▁and ▁was ▁associated ▁with ▁an ▁infla mma tory ▁response ▁ , ▁and ▁may ▁have ▁been ▁due ▁to ▁a ▁disrupt ion ▁of ▁the ▁normal ▁intestinal ▁flora ▁ .
▁pel zon t ▁: ▁use ▁in ▁patients ▁with ▁he pati c ▁insu ffi cie ncy ▁has ▁not ▁been ▁studie d ▁ .
▁pre - emp tive ▁treatment ▁for ▁skin ▁reaction ▁was ▁not ▁permit ted ▁prior ▁to ▁the ▁beginning ▁of ▁the ▁second ▁treatment ▁cycle ▁ .
▁rito na vir ▁does ▁not ▁inhibi t ▁o at 1 ▁and ▁is ▁not ▁expected ▁to ▁inhibi t ▁o ct 2 ▁ , ▁o at 3 ▁ , ▁mate 1 ▁and ▁mate 2 k ▁at ▁clinic ally ▁relevant ▁concentration s ▁ .
▁talk ▁to ▁your ▁doctor ▁if ▁you ▁or ▁the ▁child ▁you ▁are ▁car ing ▁for ▁: ▁are ▁a ▁woman ▁of ▁child be aring ▁age ▁( ▁see ▁section ▁" ▁pre gna ncy ▁and ▁breast - feed ing ▁" ▁) ▁ . ▁are ▁a ▁male ▁and ▁your ▁female ▁partner ▁is ▁of ▁child be aring ▁age ▁( ▁see ▁section ▁" ▁pre gna ncy ▁and ▁breast - ▁feed ing ▁" ▁)
▁the ▁relevan ce ▁of ▁this ▁response ▁for ▁humans ▁is ▁currently ▁un know n ▁ .
▁on ▁the ▁basis ▁of ▁the ▁high ▁oral ▁bio ava il ability ▁( ▁98 ▁% ▁ , ▁see ▁section ▁5.2 ▁) ▁ , ▁switch ing ▁between ▁intra ven ous ▁and ▁oral ▁administration ▁is ▁appropriate ▁when ▁clinic ally ▁indicate d ▁ .
▁each ▁capsule ▁contain s ▁8 ▁mg ▁of ▁si lo dos in ▁ .
▁if ▁you ▁forget ▁to ▁use ▁heli xa te ▁ne x gen ▁2000 ▁iu
▁as ▁to cer an ib ▁likely ▁is ▁elimina ted ▁to ▁a ▁large ▁extent ▁by ▁metabolism ▁in ▁the ▁ liver ▁ , ▁the ▁combination ▁with ▁other ▁drugs ▁capable ▁of ▁induc ing ▁or ▁inhibi ting ▁ liver ▁enzym es ▁should ▁be ▁used ▁with ▁cau tion ▁ .
▁the ▁t max ▁of ▁digo xin ▁was ▁de lay ed ▁by ▁1.5 ▁hour ▁and ▁the ▁c max ▁was ▁reduce d ▁by ▁26 ▁% ▁ .
▁there ▁is ▁evidence ▁that ▁ca ffe ine ▁causes ▁ta chy ar rhythm ias ▁in ▁susceptible ▁individuals ▁ .
▁media n ▁time ▁to ▁disease ▁fl are
▁electro card i ogram ▁q t ▁prolong ed ▁con duction ▁disorder ▁ , ▁sinus ▁ta chy car dia
▁progression s ▁were ▁observe d ▁in ▁ 3.8 ▁% ▁of ▁patients ▁in ▁the ▁ever ol imus ▁arm ▁compared ▁with ▁20. 5 ▁% ▁in ▁the ▁place bo ▁arm ▁ .
▁before ▁any ▁surgery ▁ , ▁the ▁health care ▁professional ▁should ▁ensure ▁that ▁the ▁patient ▁has ▁been ▁properly ▁informe d ▁on ▁how ▁to ▁use ▁ion sys ▁post - operativ ely ▁ .
▁container ▁: ▁store ▁liquid ▁nit rogen ▁container ▁secure ly ▁in ▁up right ▁position ▁in ▁a ▁clean ▁ , ▁dry ▁and ▁well - ventil ated ▁room ▁separate d ▁from ▁the ▁hat ching ▁/ ▁chicken ▁room ▁in ▁the ▁hat cher y ▁ .
▁90 ▁hard ▁capsule s ▁: ▁bottle
▁in cuba tion ▁with ▁rat ▁ , ▁dog ▁ , ▁and ▁human ▁ liver ▁micro some s ▁as ▁well ▁as ▁human ▁he pato cy tes ▁produced ▁no ▁detect able ▁metabol ites ▁of ▁re gade no son ▁ .
▁the ▁green ▁light ▁will ▁switch ▁off ▁and ▁the ▁number ▁of ▁dos es ▁deliver ed ▁will ▁flash ▁on ▁and ▁off ▁ .
▁the ▁final ▁concentration ▁of ▁the ▁solution ▁is ▁6 ▁mg ▁/ ▁ml ▁my co phen ola te ▁mo fe til ▁ .
▁war far in ▁and ▁tip rana vir ▁are
▁your ▁doctor ▁will ▁decide ▁ , ▁if ▁you ▁should ▁be ▁treated ▁with ▁xa rel to ▁and ▁if ▁you ▁should ▁be ▁kept ▁under ▁close r ▁observation ▁ .
▁if ▁patients ▁develop ▁sustain ed ▁ , ▁un exp lain ed ▁ , ▁clinic ally ▁significant ▁alt ▁and ▁/ ▁or ▁a st ▁eleva tion ▁ , ▁or ▁if ▁alt ▁and ▁/ ▁or ▁a st ▁eleva tion ▁is ▁ac com pani ed ▁by ▁sign s ▁or ▁symptoms ▁of ▁he pati c ▁injury ▁( ▁e . g . ▁ja undi ce ▁) ▁ , ▁amb ris en tan ▁ therapy ▁should ▁be ▁dis continu ed ▁ .
▁the ▁patient ▁may ▁store ▁re bi f ▁at ▁or ▁below ▁25 ▁° ▁c ▁for ▁a ▁single ▁period ▁up ▁to ▁14 ▁days ▁ .
▁serious ▁un liste d ▁advers e ▁reaction s ▁( ▁soc ▁ , ▁hl t ▁ , ▁pt s ▁) ▁strat ified ▁according ▁to ▁type ▁of ▁report ▁( ▁med ically ▁confirm ed ▁or ▁non - med ically ▁confirm ed ▁) ▁ , ▁for ▁the ▁period ▁covered ▁by ▁the ▁report ▁and ▁cum ul ative ly ▁ .
▁up tra vi ▁200 ▁micro gram ▁tablets ▁up tra vi ▁400 ▁micro gram ▁tablets ▁up tra vi ▁600 ▁micro gram ▁tablets ▁up tra vi ▁800 ▁micro gram ▁tablets ▁up tra vi ▁1,000 ▁micro gram ▁tablets ▁up tra vi ▁1 , 200 ▁micro gram ▁tablets ▁up tra vi ▁1 , 400 ▁micro gram ▁tablets ▁up tra vi ▁1 , 600 ▁micro gram ▁tablets
▁met h oxy ▁poly e thy lene ▁gly col - e po etin ▁beta ▁ , ▁the ▁active ▁substance ▁of ▁mir cera ▁ , ▁is ▁a ▁continuo us ▁er y thro po i etin ▁receptor ▁activa tor ▁that ▁shows ▁a ▁different ▁activity ▁at ▁the ▁receptor ▁level ▁character ized ▁by ▁a ▁slow er ▁association ▁to ▁and ▁fast er ▁disso ci ation ▁from ▁the ▁receptor ▁ , ▁a ▁reduce d ▁specific ▁activity ▁in ▁vi tro ▁with ▁an ▁increased ▁activity ▁in ▁vivo ▁ , ▁as ▁well ▁as ▁an ▁increased ▁half - life ▁ , ▁in ▁contrast ▁to ▁er y thro po i etin ▁ .
▁the ▁safety ▁and ▁ef fica cy ▁of ▁this ▁medicinal ▁product ▁in ▁children ▁and ▁adolescents ▁from ▁birth ▁to ▁< ▁18 ▁years ▁of ▁age ▁have ▁not ▁been ▁established ▁ .
▁the ▁powder ▁in ▁the ▁vi al ▁must ▁then ▁be ▁disso l ved ▁by ▁adding ▁all ▁the ▁solve nt ▁from ▁the ▁pre - fill ed ▁sy ringe ▁ .
▁individuals ▁with ▁hyper sensitiv ity ▁after ▁previous ▁administration ▁of ▁garda sil ▁9 ▁or ▁garda sil ▁/ ▁sil gard ▁should ▁not ▁receive ▁garda sil ▁9 ▁ .
▁the ▁plasma ▁protein ▁ binding ▁of ▁pali peri done ▁is ▁74 ▁% ▁ .
▁in ▁these ▁circumstances ▁ , ▁vaccin ation ▁with ▁the ▁combine d ▁vaccin e ▁should ▁start ▁at ▁6 ▁weeks ▁of ▁age ▁ .
▁ liver ▁function ▁tests ▁should ▁be ▁perform ed ▁prior ▁to ▁treatment ▁initiat ion ▁and ▁monitor ed ▁period ically ▁ , ▁as ▁clinic ally ▁indicate d ▁ .
▁0 . 95 ▁ml ▁en s uring ▁delivery ▁of ▁2 ▁full ▁spray s ▁or
▁low ▁white ▁blood ▁cell ▁count ▁ , ▁which ▁may ▁decrease ▁your ▁ability ▁to ▁fight ▁infection ▁and ▁may ▁be ▁associated ▁with ▁fe ver
▁the ▁relevan ce ▁of ▁these ▁finding s ▁for ▁the ▁clinic al ▁use ▁of ▁el on va ▁is ▁limited ▁ .
▁in ▁order ▁to ▁obtain ▁adequat e ▁ef fica cy ▁ , ▁a ▁dose ▁of ▁250 ▁micro gram ▁( ▁1.0 ▁ml ▁) ▁every ▁other ▁day ▁should ▁be ▁reached ▁ .
▁moz o bil ▁ therapy ▁should ▁be ▁initiat ed ▁and ▁super vis ed ▁by ▁a ▁physician ▁experienced ▁in ▁on c ology ▁and ▁/ ▁or ▁ha e mat ology ▁ .
▁the ▁sequenti al ▁administration ▁of ▁ni men rix ▁one ▁month ▁after ▁a ▁d tap - hb v - ip v ▁/ ▁ hib ▁vaccin e ▁result ed ▁in ▁lower ▁g m ts ▁for ▁anti body ▁against ▁groups ▁a ▁ , ▁c ▁and ▁w - 135 ▁ .
▁one ▁10 ▁mg ▁capsule ▁plus ▁two ▁4 ▁mg ▁capsule s
▁what ▁if ▁your ▁patch ▁become s ▁loo se ▁ , ▁lift s ▁at ▁the ▁edge s ▁or ▁falls ▁off ▁?
▁your ▁doctor ▁or ▁nurse ▁will ▁in struct ▁you ▁how ▁to ▁give ▁the ▁inject ion ▁of ▁glu ca gon ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁carton ▁after ▁exp ▁ .
▁unit ▁dose ▁bli sters ▁contain ing ▁56 ▁x ▁1 ▁ , ▁84 ▁x ▁1 ▁or ▁100 ▁x ▁1 ▁hard ▁capsule s ▁ .
▁further ▁analysis ▁showed ▁tre vac lyn ▁( ▁2000 ▁mg ▁/ ▁40 ▁mg ▁) ▁co - ad minister ed ▁with ▁sim vasta tin ▁when ▁compared ▁with ▁sim vasta tin ▁alone ▁significantly ▁increased ▁apo ▁a - i ▁( ▁ 8.6 ▁% ▁ , ▁2.3 ▁% ▁respective ly ▁) ▁and ▁significantly ▁decrease d ▁l p ▁( ▁a ▁) ▁( ▁ -19 . 8 ▁% ▁ , ▁0.0 ▁% ▁respective ly ▁) ▁ .
▁if ▁you ▁have ▁taken ▁od ef sey ▁during ▁your ▁pre gna ncy ▁ , ▁your ▁doctor ▁may ▁request ▁regular ▁blood ▁tests ▁and ▁other ▁diagnostic ▁tests ▁to ▁monitor ▁the ▁development ▁of ▁your ▁child ▁ .
▁however ▁ , ▁mineral ▁oil ▁must ▁not ▁be ▁applied ▁for ▁at ▁least ▁two ▁hours ▁before ▁or ▁after ▁the ▁application ▁of ▁pan ret in ▁ .
▁c max ▁: ▁ ↓ ▁45 ▁% ▁( ▁ud p - g ▁in duction ▁)
▁in ▁the ▁female ▁and ▁black ▁sub group s ▁which ▁represent ed ▁32 ▁% ▁and ▁26 ▁% ▁of ▁the ▁overall ▁study ▁population ▁respective ly ▁ , ▁a ▁renal ▁benefit ▁was ▁not ▁evident ▁ , ▁although ▁the ▁confidence ▁interval s ▁do ▁not ▁exclu de ▁it ▁ .
▁ liver ▁function ▁ab normal ▁and ▁im pair ed ▁ki dne y ▁function ▁ ,
▁as ▁the ▁du ration ▁of ▁immun ity ▁is ▁not ▁yet ▁fully ▁established ▁ , ▁any ▁re vac cin ation ▁scheme ▁should ▁be ▁agreed ▁by ▁the ▁ competent ▁authority ▁or ▁by ▁the ▁responsible ▁veterinar ian ▁ , ▁taking ▁into ▁account ▁the ▁local ▁epidemi ological ▁situation
▁solve nt ▁: ▁clear ▁ , ▁colour less ▁to ▁slightly ▁yellow ▁or ▁slightly ▁brown ▁solution ▁ .
▁hyper sensitiv ity ▁to ▁titan ium ▁allo y ▁ , ▁poly sul fone ▁or ▁silicone ▁materials ▁used ▁in ▁the ▁implant ed ▁component s ▁of ▁the ▁pump ▁ .
▁how ▁to ▁store ▁olan za pine ▁my lan
▁for ▁possible ▁sign s ▁to ▁look ▁out ▁for ▁and ▁what ▁to ▁do ▁if ▁this ▁happens ▁see ▁section ▁4 ▁' ▁possible ▁side ▁effects ▁' ▁ .
▁se rum ▁calci um ▁concentration s ▁reach ▁a ▁maximum ▁between ▁6 ▁and ▁8 ▁hours ▁post ▁dose ▁and ▁normal ly ▁return ▁to ▁base line ▁by ▁20 ▁to ▁24 ▁hours ▁after ▁each ▁administration ▁of ▁para thy roid ▁hormone ▁ .
▁choose ▁a ▁site ▁on ▁your ▁th igh ▁or ▁tum my ▁ .
▁granul es ▁for ▁use ▁in ▁drink ing ▁water ▁for ▁pig s ▁- ▁400 ▁g ▁sa chet
▁package ▁size s ▁: ▁30 ▁and ▁100 ▁tablets ▁ .
▁there ▁is ▁ , ▁however ▁ , ▁only ▁a ▁modest ▁increase ▁in ▁biologi c ▁activity ▁as ▁measure d ▁by ▁a ▁bio assa y ▁ .
▁xal up rine ▁should ▁not ▁be ▁given ▁to ▁patients ▁who ▁are ▁pregnant ▁or ▁likely ▁to ▁become ▁pregnant ▁without ▁care ful ▁assessment ▁of ▁risk ▁versus ▁benefit ▁ .
▁was h ▁your ▁hands ▁before ▁you ▁inject ▁your ▁medicine ▁ .
▁the ▁dose ▁steps ▁di alle d ▁equal ▁the ▁number ▁shown ▁in ▁the ▁dose ▁counter ▁ .
▁name ▁and ▁address ▁of ▁the ▁manufacture r ▁( ▁s ▁) ▁of ▁the ▁bi ological ▁active ▁substance
▁un change d ▁ri lu zole ▁is ▁the ▁main ▁component ▁in ▁plasma ▁and ▁is ▁ex tensi ve ly ▁metabol ised ▁by ▁cy to ch rom e ▁p 450 ▁and ▁subsequent ▁glu cu ron id ation ▁ .
▁when ▁an ▁administration ▁of ▁radio pharma ce u tical s ▁to ▁a ▁woman ▁of ▁child be aring ▁potential ▁is ▁intended ▁ , ▁it ▁is ▁important ▁to ▁determine ▁whether ▁or ▁not ▁she ▁is ▁pregnant ▁ .
▁after ▁each ▁dose ▁ , ▁the ▁number ▁is ▁count ing ▁down ward s ▁on ▁the ▁display ▁ .
▁mean ▁( ▁s d ▁) ▁mineral isation ▁lag - time ▁was ▁93 ▁( ▁70 ▁) ▁days ▁at ▁base line ▁and ▁119 ▁( ▁225 ▁) ▁days ▁at ▁week ▁24
▁ac ti nic ▁kera tos is ▁is ▁a ▁condition ▁not ▁generally ▁seen ▁within ▁the ▁pa e dia tric ▁population ▁and ▁was ▁not ▁studie d ▁ .
▁repeat ed ▁dose ▁ toxic ity ▁testing ▁and ▁em bry o - fo e tal ▁ toxic ity ▁studies ▁are ▁im prac tica ble ▁due ▁to ▁in duction ▁of ▁ , ▁and ▁interfere nce ▁with ▁anti bo dies ▁ .
▁1 ▁x ▁0.5 ▁ml ▁inject ion
▁it ▁should ▁be ▁not ed ▁that ▁patients ▁using ▁beta - block ers ▁do ▁not ▁necessarily ▁respond ▁to ▁the ▁beta - ago nist s ▁usually ▁used ▁for ▁the ▁treatment ▁of ▁hyper sensitiv ity ▁reaction s ▁ .
▁if ▁you ▁notice ▁any ▁serious ▁effects ▁or ▁other ▁effects ▁not ▁mentioned ▁in ▁this ▁package ▁le a flet ▁ , ▁please ▁inform ▁your ▁veterinar y ▁surge on ▁ .
▁the ▁tablets ▁are ▁available ▁in ▁bli sters ▁contain ing ▁10 ▁film - co ated ▁tablets ▁ .
▁im lyg ic ▁108 ▁plaque ▁form ing ▁unit s ▁( ▁p fu ▁) ▁/ ▁ml ▁solution ▁for ▁inject ion
▁the ▁european ▁medicine s ▁agency ▁has ▁wa i ved ▁the ▁obliga tion ▁to ▁submit ▁the ▁results ▁of ▁studies ▁with ▁signifo r ▁in ▁all ▁sub set s ▁of ▁the ▁pa e dia tric ▁population ▁in ▁pit uit ary - depend ant ▁cu shing ▁' s ▁disease ▁ , ▁over product ion ▁of ▁pit uit ary ▁ac th ▁and ▁pit uit ary ▁depend ant ▁hyper ad re no cor tic ism ▁( ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁) ▁ .
▁after ▁taking ▁one ▁of ▁them ▁ , ▁wait ▁at ▁least ▁2 ▁to ▁3 ▁hours ▁before ▁taking ▁the ▁other ▁ .
▁figure ▁b ▁: ▁check ▁for ▁un sus pende d ▁powder ▁and ▁repeat ▁ta pping ▁if ▁needed ▁ .
▁the ▁recommended ▁dose ▁is ▁one ▁in hal ation ▁of ▁ano ro ▁55 ▁/ ▁22 ▁micro gram s ▁once ▁daily ▁ .
▁disease ▁activity ▁was ▁also ▁assess ed ▁using ▁the ▁disease ▁activity ▁score ▁28 ▁ .
▁co - administration ▁of ▁tem si rol imus ▁5 ▁mg ▁with ▁keto con a zole ▁ , ▁a ▁ potent ▁cy p 3 a 4 ▁inhibi tor ▁ , ▁had ▁no ▁significant ▁effect ▁on ▁tem si rol imus ▁c max ▁or ▁au c ▁; ▁however ▁ , ▁si rol imus ▁au c ▁increased ▁3.1 - fold ▁ , ▁and ▁au cs um ▁( ▁tem si rol imus ▁+ ▁si rol imus ▁) ▁increased ▁2.3 - fold ▁compared ▁to ▁tem si rol imus ▁alone ▁ .
▁final ▁study ▁report ▁expected ▁end ▁of ▁jul y ▁2030 ▁ .
▁these ▁symptoms ▁may ▁reveal ▁complica tions ▁for ▁which ▁specific ▁medication ▁could ▁be ▁appropriate ▁ .
▁my ca mine ▁is ▁suppli ed ▁in ▁a ▁box ▁contain ing ▁1 ▁vi al ▁ .
▁you ▁will ▁usually ▁carry ▁on ▁taking ▁this ▁medicine ▁as ▁long ▁as ▁you ▁are ▁getting ▁benefit ▁ .
▁ir on ▁de fici en cy ▁ana emia ▁ , ▁lymph ▁no de ▁pain ▁ , ▁lymph ade no pathy ▁ , ▁neutro p enia ▁and ▁ana emia ▁( ▁both ▁occasion ally ▁severe ▁) ▁ , ▁ thro mbo cy top enia
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁ne xi um ▁control
▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁5 93 ▁/ ▁ 001 ▁10 ▁capsule s ▁+ ▁1 ▁in hal er
▁patients ▁with ▁eco g ▁performance ▁status ▁at ▁base line ▁of ▁2 ▁experienced ▁a ▁higher ▁incide nce ▁of ▁serious ▁infection s ▁compared ▁to ▁patients ▁with ▁eco g ▁performance ▁status ▁of ▁< ▁2 ▁ .
▁how ▁to ▁use ▁insulin ▁human ▁win thro p ▁com b ▁15 ▁dose
▁rasi lez ▁h ct ▁contain s ▁w heat ▁star ch ▁ .
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁use ▁ huma log ▁mix 50
▁push ▁the ▁air ▁into ▁the ▁vi al ▁ .
▁contra cep tive ▁ef fica cy ▁may ▁be ▁reduce d ▁in ▁women ▁we igh ing ▁equal ▁or ▁greater ▁than ▁90 ▁kg ▁( ▁see ▁section s ▁4.2 ▁and ▁5.1 ▁) ▁ .
▁anti - t etan us ▁( ▁0.1 ▁iu ▁/ ▁ml ▁)
▁clinic ally ▁relevant ▁ct c ▁ toxic ities ▁that ▁were ▁reported ▁in ▁ ≥ ▁1 ▁% ▁and ▁< ▁5 ▁% ▁of ▁the ▁patients ▁that ▁were ▁random ly ▁assign ed ▁to ▁receive ▁ci s plat in ▁and ▁pe metre x ed ▁include ▁: ▁renal ▁failure ▁ , ▁infection ▁ , ▁py re xia ▁ , ▁febr ile ▁neutro p enia ▁ , ▁increased ▁a st ▁ , ▁alt ▁ , ▁and ▁g gt ▁ , ▁ur tica ria ▁and ▁che st ▁pain ▁ .
▁sil den a fil ▁is ▁a ▁ potent ▁and ▁select ive ▁inhibi tor ▁of ▁c g mp ▁specific ▁ phos pho dies tera se ▁type ▁5 ▁( ▁p de 5 ▁) ▁in ▁the ▁corpus ▁cave rnos um ▁ , ▁where ▁p de 5 ▁is ▁responsible ▁for ▁degrada tion ▁of ▁c g mp ▁ .
▁the ▁ fraction ▁of ▁si tag lip tin ▁rever si bly ▁ bound ▁to ▁plasma ▁protein s ▁is ▁low ▁( ▁38 ▁% ▁) ▁ .
▁this ▁medicinal ▁product ▁must ▁not ▁be ▁mix ed ▁with ▁other ▁medicinal ▁products ▁ .
▁final ▁study ▁report ▁by ▁31 ▁december ▁2020
▁it ▁works ▁by ▁putting ▁a ▁new ▁gene ▁into ▁stem ▁cell s ▁in ▁the ▁bone ▁mar row ▁so ▁they ▁can ▁make ▁ada ▁ .
▁las o fox ife ne ▁exhibi ts ▁linear ▁ pharma cok ine tics ▁over ▁a ▁wide ▁dose ▁range ▁following ▁single - dos e ▁( ▁up ▁to ▁100 ▁mg ▁) ▁and ▁multiple - dos e ▁( ▁up ▁to ▁20 ▁mg ▁once ▁daily ▁) ▁administration ▁ .
▁cases ▁of ▁tum our ▁lys is ▁syndrome ▁( ▁tl s ▁) ▁ , ▁including ▁with ▁fatal ▁outcome ▁ , ▁have ▁been ▁reported ▁in ▁patients ▁who ▁received ▁ky pro lis ▁ .
▁from ▁the ▁four th ▁week ▁the ▁recommended ▁dose ▁is ▁four ▁pump ▁actua tions ▁once ▁daily ▁( ▁1 x ▁20 ▁mg ▁) ▁ .
▁women ▁of ▁child be aring ▁potential ▁/ ▁contra ception ▁in ▁male s ▁and ▁female s
▁the ▁con com i tant ▁use ▁of ▁to lu com bi ▁with ▁ali ski ren - conta ining ▁products ▁is ▁contra indica ted ▁in ▁patients ▁with ▁diabetes ▁mell itus ▁or ▁renal ▁im pair ment ▁( ▁g fr ▁< ▁60 ▁ml ▁/ ▁min ▁/ ▁1. 73 ▁m 2 ▁) ▁( ▁see ▁section s ▁4.5 ▁and ▁5.1 ▁) ▁ .
▁very ▁limited ▁data ▁are ▁available ▁about ▁ret rea t ment ▁after ▁interrupt ion ▁of ▁ therapy ▁for ▁more ▁than ▁4 ▁weeks ▁ .
▁if ▁you ▁accident ally ▁take ▁too ▁much ▁cyst ada ne ▁ , ▁talk ▁to ▁a ▁doctor ▁or ▁ pharma ci st ▁immediately ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁carton ▁after ▁" ▁exp ▁ . ▁"
▁the ▁volume ▁status ▁of ▁patients ▁taking ▁to lv ap tan ▁must ▁be ▁monitor ed ▁to ▁prevent ▁de hydrat ion ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁reduce d ▁number ▁of ▁white ▁blood ▁cell s ▁in ▁the ▁blood
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁carton ▁ , ▁bli ster ▁and ▁wrap per ▁after ▁' ▁exp ▁' ▁ .
▁en do the lin -1 ▁( ▁et -1 ▁) ▁is ▁a ▁ potent ▁vas cular ▁para cri ne ▁and ▁auto cri ne ▁pe pti de ▁in ▁the ▁lung ▁ , ▁and ▁can ▁also ▁promote ▁fibro sis ▁ , ▁cell ▁prolifera tion ▁ , ▁cardiac ▁hyper trop hy ▁ , ▁and ▁remodel ling ▁and ▁is ▁pro - in flam ma tory ▁ .
▁at c ▁vet ▁code ▁: ▁qi 06 a e 02
▁tip rana vir ▁/ ▁rito na vir ▁( ▁500 ▁/ ▁100 ▁mg ▁bid ▁)
▁this ▁is ▁due ▁to ▁the ▁al pha - mi me tic ▁activity ▁of ▁pseudo ep hed rine ▁sul pha te ▁in ▁combination ▁with ▁other ▁vaso con strict ors ▁such ▁as ▁bro moc ri pit ine ▁ , ▁per gol ide ▁ , ▁li sur ide ▁ , ▁ca berg o line ▁ , ▁ergo tamine ▁ , ▁di hydro er go tamine ▁or ▁any ▁other ▁de con ge stant ▁medicinal ▁product ▁used ▁as ▁a ▁na sal ▁de con ge stant ▁ , ▁either ▁by ▁oral ▁route ▁or ▁by ▁na sal ▁route ▁( ▁ phen yl prop an ola mine ▁ , ▁ phen yle ph rine ▁ , ▁e phe drin e ▁ , ▁ oxy meta zo line ▁ , ▁na pha zo line ▁... ▁) ▁ .
▁this ▁stick y ▁label ▁should ▁be ▁stuck ▁on ▁patient ▁records ▁ .
▁however ▁ , ▁severe ▁ex ace rb ations ▁ , ▁including ▁fatal ities ▁ , ▁have ▁been ▁reported ▁ .
▁18. 0 ▁mm ▁length ▁and ▁8. 0 ▁mm ▁ width ▁- ▁en grave d ▁with ▁" ▁l ▁300 ▁" ▁on ▁one ▁side ▁and ▁plain ▁on ▁the ▁other
▁in ▁study ▁g s - us -18 3 -01 45 ▁ , ▁the ▁mean ▁increase ▁from ▁base line ▁in ▁cd 4 ▁+ ▁cell ▁count ▁at ▁week ▁96 ▁was
▁ liver ▁function ▁should ▁be ▁carefully ▁monitor ed ▁during ▁mica fung in ▁treatment ▁ .
▁s light ▁ble ed ing ▁may ▁occur ▁ .
▁si mpon i ▁treatment ▁is ▁to ▁be ▁initiat ed ▁and ▁super vis ed ▁by ▁qualified ▁physician s ▁experienced ▁in ▁the ▁ diagnos is ▁and ▁treatment ▁of ▁rhe um ato id ▁ar thri tis ▁ , ▁poly arti cular ▁juvenil e ▁ idio pathi c ▁ar thri tis ▁ , ▁ps oria tic ▁ar thri tis ▁ , ▁an ky los ing ▁ spon dy liti s ▁ , ▁non - radio graphic ▁a xi al ▁ spon dy lo ar thri tis ▁ , ▁or ▁ul cer ative ▁col itis ▁ .
▁please ▁read ▁the ▁package ▁le a flet ▁for ▁disposa l ▁of ▁medicine s ▁no ▁longer ▁required
▁anti - eme tic ▁ therapy ▁may ▁be ▁ad minister ed ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁bir es p ▁spir o max ▁320 ▁m c g ▁/ ▁9 ▁m c g
▁ask ▁your ▁ pharma ci st ▁how ▁to ▁throw ▁away ▁medicine s ▁that ▁you ▁no ▁longer ▁use ▁ .
▁nem da tine ▁should ▁be ▁ad minister ed ▁once ▁a ▁day ▁and ▁should ▁be ▁taken ▁at ▁the ▁same ▁time ▁every ▁day ▁ .
▁how ▁to ▁take ▁ne xi um ▁control
▁if ▁you ▁have ▁thy roid ▁g lands ▁problems ▁ .
▁once ▁bro ach ed ▁ , ▁use ▁within ▁28 ▁days ▁by ▁...
▁in ▁pre term ▁new born s ▁ibu profe n ▁significantly ▁reduce d ▁plasma ▁concentration s ▁of ▁pro stag land ins ▁and ▁their ▁metabol ites ▁ , ▁particularly ▁p ge 2 ▁and ▁6- ke to - p g f -1 - al pha ▁ .
▁age ▁has ▁no ▁effect ▁on ▁the ▁ pharma cok ine tics ▁of ▁ne lara bine ▁or ▁ara - g ▁ .
▁the ▁vaccin e ▁should ▁be ▁ad minister ed ▁sub cuta ne ously ▁in ▁patients ▁with ▁ thro mbo cy top enia ▁or ▁any ▁coa g ulation ▁disorder ▁ .
▁once ▁bro ach ed ▁ , ▁use ▁by ▁...
▁the ▁insulin ▁solution ▁( ▁insu man ▁rapid ▁) ▁must ▁be ▁clear ▁ , ▁colour less ▁ , ▁with ▁no ▁solid ▁parti cles ▁visible ▁ , ▁and ▁must ▁have ▁a ▁water - like ▁consiste ncy ▁ .
▁safety ▁assessment ▁was ▁made ▁based ▁on ▁ 491 ▁a cro mega ly ▁patients ▁who ▁received ▁pas ireo ti de ▁( ▁4 19 ▁patients ▁received ▁pas ireo ti de ▁intra mus cular ▁use ▁and ▁72 ▁received ▁pas ireo ti de ▁sub cuta ne ous ▁use ▁) ▁in ▁phase ▁i ▁ , ▁i i ▁and ▁i ii ▁studies ▁ .
▁there ▁are ▁no ▁data ▁to ▁guide ▁co - administration ▁of ▁is en tress ▁with ▁rif ampi cin ▁in ▁patients ▁below ▁18 ▁years ▁of ▁age ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁cm in ▁: ▁ ↓ ▁12 ▁% ▁( ▁ ↓ ▁24 ▁to ▁↑ ▁1 ▁)
▁therefore ▁ , ▁ lon surf ▁should ▁be ▁treated ▁as ▁a ▁potential ▁car cino gen ▁ .
▁corti co steroid ▁tap ering ▁was ▁permit ted ▁after ▁week ▁6 ▁ .
▁table ▁2 ▁: ▁riba vir in ▁dose ▁modification ▁guide line ▁for ▁co - administration ▁with ▁har vo ni
▁4 ▁see ▁section ▁4. 8 ▁ , ▁description ▁of ▁selected ▁advers e ▁reaction s ▁for ▁more ▁details ▁ .
▁ ≥ ▁2 ▁re lapse s ▁in ▁the ▁prior ▁year ▁and ▁30 ▁% ▁had ▁previously ▁received ▁other ▁approved ▁ms ▁treatment s ▁ .
▁increase s ▁in ▁mira beg ron ▁exposure ▁due ▁to ▁drug - drug ▁interaction s ▁may ▁be ▁associated ▁with ▁increase s ▁in ▁puls e ▁rate ▁ .
▁a ▁s light ▁back ▁pressure ▁may ▁be ▁experienced ▁during ▁administration ▁of ▁the ▁water ▁for ▁inject ions ▁ , ▁which ▁is ▁considered ▁normal ▁ .
▁im pair ed ▁hea ling ▁ , ▁implant ▁site ▁hyper sensitiv ity ▁ , ▁per i pher al ▁ed ema ▁ , ▁py re xia
▁since ▁le flu nom ide ▁teva ▁can ▁cause ▁an ▁increase ▁in ▁your ▁blood ▁pressure ▁ , ▁your ▁doctor ▁will ▁also ▁check ▁your ▁blood ▁pressure ▁regularly ▁ .
▁the ▁inject ion ▁is ▁given ▁into ▁the ▁vi tre ous ▁of ▁the ▁eye ▁ , ▁which ▁is ▁the ▁je lly - like ▁substance ▁inside ▁the ▁eye ▁ .
▁the ▁ pharma cok ine tics ▁of ▁ata zana vir ▁and ▁co bici stat ▁ , ▁alone ▁or ▁in ▁combination ▁ , ▁have ▁not ▁been ▁evaluat ed ▁in ▁an ▁el der ly ▁population ▁( ▁65 ▁years ▁of ▁age ▁and ▁older ▁) ▁ .
▁ann ex ▁i i ▁for ▁salmon ida e 1
▁in ▁man ▁ , ▁an ▁activity ▁in ▁both ▁parti al ▁and ▁general ised ▁epi le psy ▁conditions ▁( ▁epi lep ti form ▁dis charge ▁/ ▁photo par oxy s mal ▁response ▁) ▁has ▁confirm ed ▁the ▁broad ▁spectrum ▁ pharma c ological ▁profile ▁of ▁leve ti race tam ▁ .
▁the ▁powder ▁may ▁take ▁up ▁to ▁45 ▁minutes ▁to ▁dis solve ▁into ▁solution ▁ .
▁it ▁reduce s ▁the ▁risk ▁of ▁spin e ▁and ▁hip ▁fra c tures ▁in ▁women ▁after ▁meno pause ▁ .
▁treatment ▁of ▁adult ▁patients ▁with ▁hypo na tra emia ▁seconda ry ▁to ▁syndrome ▁of ▁in appropria te ▁anti di ure tic ▁hormone ▁secret ion ▁( ▁si adh ▁) ▁ .
▁a ▁statistic al ▁analysis ▁of ▁non - in feri or ity ▁was ▁perform ed ▁at ▁month ▁7 ▁compar ing ▁cli a ▁anti - h pv ▁6 ▁ , ▁anti - h pv ▁11 ▁ , ▁anti - h pv ▁16 ▁ , ▁and ▁anti - h pv ▁18 ▁g m ts ▁between ▁individuals ▁ad minister ed ▁garda sil ▁9 ▁and ▁individuals ▁ad minister ed ▁garda sil ▁ .
▁when ▁matern al ▁exposure ▁to ▁the ▁anti body ▁occur red ▁during ▁organ ogen es is ▁ , ▁two ▁cases ▁of ▁retin al ▁dys plas ia ▁and ▁one ▁case ▁of ▁um bili cal ▁her nia ▁were ▁observe d ▁among ▁230 ▁off spring ▁born ▁to ▁mother s ▁expose d ▁to ▁the ▁higher ▁anti body ▁dose ▁( ▁approximately ▁4 ▁times ▁the ▁maximum ▁recommended ▁human ▁soli ris ▁dose ▁ , ▁based ▁on ▁a ▁body ▁weight ▁comparison ▁) ▁; ▁however ▁ , ▁the ▁exposure ▁did ▁not ▁increase ▁fo e tal ▁loss ▁or ▁ne ona tal ▁death ▁ .
▁0.3 7 ▁ ± ▁0.1 5 ▁( ▁n ▁= ▁12 ▁)
▁the ▁daily ▁dose ▁of ▁rif abu tin ▁should ▁be ▁increased ▁by ▁50 ▁% ▁when ▁given ▁with ▁a trip la ▁ .
▁the ▁purpose ▁of ▁the ▁third ▁multi centre ▁ , ▁double - blind ▁ , ▁random ised ▁study ▁was ▁the ▁assessment ▁of ▁ef fica cy ▁and ▁safety ▁of ▁0.0 3 ▁% ▁tac rol imus ▁o int ment ▁applied ▁once ▁or ▁twice ▁a ▁day ▁relative ▁to ▁twice ▁daily ▁administration ▁of ▁1 ▁% ▁hydro cor tis one ▁ac etate ▁o int ment ▁in ▁children ▁with ▁moderat e ▁to ▁severe ▁a topic ▁dermatit is ▁ .
▁plate let ▁count s ▁below ▁100 ▁x ▁109 ▁/ ▁l ▁were ▁observe d ▁in ▁7 ▁% ▁of ▁patients ▁treated ▁with ▁mir cera ▁and ▁4 ▁% ▁of ▁patients ▁treated ▁with ▁other ▁esas ▁ .
▁some ▁people ▁may ▁feel ▁di zzy ▁ , ▁confu sed ▁or ▁light head ed ▁after ▁receiving ▁treatment ▁ .
▁out er ▁carton ▁text ▁( ▁5 ▁x ▁3 ml ▁cart ridge s ▁)
▁raised ▁blood ▁levels ▁of ▁immun os up press ants ▁( ▁decrease d ▁he pati c ▁metabolism ▁) ▁ .
▁insu man ▁implant able ▁must ▁not ▁be ▁used ▁with ▁any ▁other ▁pump s ▁( ▁external ▁or ▁implant able ▁) ▁than ▁the ▁med tronic ▁minim ed ▁implant able ▁pump ▁or ▁with ▁any ▁other ▁medical ▁devices ▁including ▁sy ring es ▁( ▁see ▁section ▁4.2 ▁) ▁ .
▁medicinal ▁product ▁/ ▁pos s ▁ ible ▁mechanism ▁of ▁interaction
▁if ▁these ▁symptoms ▁occur ▁after ▁administration ▁ , ▁they ▁should ▁alert ▁their ▁physician ▁ .
▁each ▁li pro log ▁bas al ▁kwi k pen ▁contain s ▁300 ▁unit s ▁( ▁3 ▁milli li tres ▁) ▁ .
▁they ▁may ▁consist ▁of ▁hyper sa liv ation ▁ , ▁vom i ting ▁ , ▁le thar gy ▁ , ▁hyper gly ca emia ▁ , ▁bra dy car dia ▁or ▁bra dy pne a ▁ .
▁what ▁jina rc ▁looks ▁like ▁and ▁content s ▁of ▁the ▁pack
▁do ▁not ▁massage ▁the ▁inject ion ▁site ▁ .
▁pre - spec ified ▁events ▁that ▁occur red ▁with ▁the ▁highest ▁incide nce ▁in ▁all ▁three ▁treatment ▁groups ▁involved ▁the ▁category ▁of ▁sur g ical ▁wo und ▁complica tions ▁ , ▁including ▁deep ▁sur g ical ▁infection s ▁and ▁ster nal ▁wo und ▁hea ling ▁events ▁ .
▁firm ly ▁press ▁down ▁on ▁the ▁finger ▁grip s ▁until ▁a ▁' ▁click ▁' ▁is ▁heard ▁and ▁then ▁let ▁go ▁of ▁the ▁grip s ▁( ▁figure ▁2 ▁) ▁ .
▁like ▁all ▁medicine s ▁ , ▁vi ba tiv ▁can ▁cause ▁side ▁effects ▁ , ▁although ▁not ▁everybody ▁gets ▁them ▁ .
▁this ▁includes ▁any ▁possible ▁side ▁effects ▁not ▁listed ▁in ▁this ▁le a flet ▁ .
▁it ▁is ▁not ▁known ▁whether ▁gly bera ▁is ▁ex cre ted ▁in ▁human ▁milk ▁ .
▁da klin za ▁is ▁indicate d ▁in ▁combination ▁with ▁other ▁medicinal ▁products ▁for ▁the ▁treatment ▁of ▁chronic ▁hepatitis ▁c ▁virus ▁( ▁h c v ▁) ▁infection ▁in ▁adults ▁( ▁see ▁section s ▁4.2 ▁ , ▁4.4 ▁and ▁5.1 ▁) ▁ .
▁study ▁2 ▁spl en ecto mised ▁patients
▁vi al ▁ , ▁cart ridge ▁ , ▁cart ridge ▁for ▁op tic lik
▁the ▁total ▁body ▁and ▁renal ▁clear ance ▁are ▁157 ▁- ▁176 ▁and ▁3 ▁- ▁3.5 ▁ml ▁/ ▁min ▁ , ▁respective ly ▁ .
▁clear ▁ , ▁colour less ▁to ▁light ▁yellow ▁solution ▁ .
▁bio transform ation ▁: ▁am lo di pine ▁is ▁ex tensi ve ly ▁( ▁approximately ▁90 ▁% ▁) ▁metabol ised ▁in ▁the ▁ liver ▁to ▁in active ▁metabol ites ▁ .
▁no xa fil ▁oral ▁suspens ion ▁and ▁tablets ▁are ▁not ▁inter change able ▁ .
▁prior ▁pe gi fn ▁/ ▁ rb v ▁null ▁responder
▁if ▁you ▁wish ▁ , ▁you ▁may ▁take ▁it ▁with ▁water ▁or ▁another ▁be ver age ▁of ▁choice ▁ .
▁the ▁choice ▁of ▁the ▁in fusion ▁du ration ▁should ▁be ▁made ▁by ▁the ▁treat ing ▁physician ▁considering ▁the ▁fre que ncy ▁of ▁the ▁in fusion ▁bag ▁changes ▁ .
▁fre que ncies ▁are ▁define d ▁as ▁very ▁common ▁( ▁ ≥ ▁1 ▁/ ▁10 ▁) ▁ , ▁common ▁( ▁ ≥ ▁1 ▁/ ▁100 ▁to ▁< ▁1 ▁/ ▁10 ▁) ▁ , ▁un com mon ▁( ▁ ≥ ▁1 ▁/ ▁1,000 ▁to ▁< ▁1 ▁/ ▁100 ▁) ▁ , ▁rare ▁( ▁ ≥ ▁1 ▁/ ▁10,000 ▁to ▁< ▁1 ▁/ ▁1,000 ▁) ▁and ▁very ▁rare ▁( ▁< ▁1 ▁/ ▁10,000 ▁) ▁ .
▁te no fo vir ▁di so prox il ▁fumar ate ▁should ▁not ▁be ▁initiat ed ▁in ▁pa e dia tric ▁patients ▁with ▁renal ▁im pair ment ▁and ▁should ▁be ▁dis continu ed ▁in ▁pa e dia tric ▁patients ▁who ▁develop ▁renal ▁im pair ment ▁during ▁te no fo vir ▁di so prox il ▁fumar ate ▁ therapy ▁ .
▁each ▁tablet ▁contain s ▁145 ▁mg ▁of ▁feno fi bra te ▁and ▁40 ▁mg ▁of ▁sim vasta tin ▁ .
▁due ▁cau tion ▁should ▁be ▁ employed ▁in ▁the ▁administration ▁of ▁pro quad ▁to ▁person s ▁with ▁individual ▁or ▁family ▁history ▁of ▁convuls ions ▁ , ▁or ▁a ▁history ▁of ▁cerebral ▁injury ▁ .
▁e p clu sa ▁should ▁not ▁affect ▁your ▁ability ▁to ▁drive ▁or ▁use ▁any ▁tools ▁or ▁machine ry ▁ .
▁the ▁dose ▁can ▁be ▁set ▁in ▁steps ▁of ▁2 ▁unit s ▁ , ▁from ▁a ▁minimum ▁of ▁2 ▁unit s ▁to ▁a ▁maximum ▁of ▁40 ▁unit s ▁ .
▁in ▁a ▁clinic al ▁trial ▁with ▁healthy ▁volunteer s ▁ , ▁where ▁pra mi pe xo le ▁prolong ed - release ▁tablets ▁were ▁ti tra ted ▁fast er ▁( ▁every ▁3 ▁days ▁) ▁than ▁recommended ▁up ▁to ▁3. 15 ▁mg ▁pra mi pe xo le ▁base ▁( ▁4.5 ▁mg ▁of ▁salt ▁) ▁per ▁day ▁ , ▁an ▁increase ▁in ▁blood ▁pressure ▁and ▁heart ▁rate ▁was ▁observe d ▁ .
▁date ▁of ▁first ▁author isation ▁: ▁16 ▁december ▁2015
▁each ▁90 ▁mg ▁tablet ▁contain s ▁90 ▁mg ▁to lv ap tan ▁ .
▁hum ira ▁showed ▁statistic ally ▁significantly ▁greater ▁improvement ▁in ▁the ▁haq - s ▁total ▁score ▁and ▁the ▁sf -36 ▁physical ▁component ▁score ▁( ▁pc s ▁) ▁from ▁base line ▁to ▁week ▁12 ▁compared ▁to ▁place bo ▁ .
▁di ar r ho e a ▁is ▁a ▁very ▁common ▁advers e ▁reaction ▁leading ▁to ▁col itis ▁ , ▁ile us ▁ , ▁gastro enter itis ▁ , ▁fatigue ▁ , ▁de hydrat ion ▁ , ▁weight ▁loss ▁ , ▁renal ▁ toxic ities ▁ , ▁hypo na tra emia ▁ , ▁and ▁hypo kala emia ▁ .
▁each ▁film - co ated ▁tablet ▁contain s ▁400 ▁mg ▁of ▁imati ni b ▁( ▁as ▁mesi late ▁) ▁ .
▁contact ▁your ▁doctor ▁or ▁ pharma ci st ▁before ▁stop ping ▁ .
▁how ▁to ▁store ▁ja nu via
▁chemical ▁and ▁physical ▁in ▁use ▁stabilit y ▁has ▁been ▁demonstrat ed ▁for ▁24 ▁hours ▁at ▁25 ▁° ▁c ▁ .
▁medicine s ▁used ▁to ▁treat ▁certain ▁psychiatr ic ▁disorder s ▁such ▁as ▁depression ▁and ▁schi zo ph r enia ▁( ▁e . g . ▁clo za pine ▁ , ▁olan za pine ▁ , ▁ris peri done ▁ , ▁zip rasi done ▁ , ▁bu propi on ▁ , ▁li thi um ▁ , ▁chlor pro maz ine ▁ , ▁me sori da zi ne ▁ , ▁thi ori da zi ne ▁ , ▁ami trip ty line ▁ , ▁de si pra mine ▁ , ▁do xe pin ▁ , ▁imi pra mine ▁ , ▁ma proti line ▁ , ▁mir ta za pine ▁)
▁use ▁the ▁dos ing ▁pipe tte ▁suppli ed ▁with ▁the ▁pack ▁to ▁measure ▁your ▁dose ▁accurate ly ▁:
▁always ▁carry ▁an ▁extra ▁pen ▁and ▁new ▁need les ▁with ▁you ▁ , ▁in ▁case ▁of ▁loss ▁or ▁damage d ▁ .
▁eight y ▁percent ▁( ▁28 ▁/ ▁35 ▁) ▁ , ▁90 ▁% ▁( ▁18 ▁/ ▁20 ▁) ▁ , ▁40 ▁% ▁( ▁4 ▁/ ▁10 ▁) ▁and ▁49 ▁% ▁( ▁19 ▁/ ▁39 ▁) ▁of ▁ sime pre vir - tre ated ▁treatment - na ï ve ▁patients ▁ , ▁prior ▁re laps ers ▁ , ▁prior ▁parti al ▁responder s ▁and ▁prior ▁null ▁responder s ▁ , ▁respective ly ▁ , ▁had ▁unde tec table ▁h c v ▁ rna ▁at ▁week ▁4 ▁ .
▁12 ▁to ▁< ▁24 ▁months
▁in ▁patients ▁we igh ing ▁80 ▁kg ▁or ▁more ▁ , ▁100 ▁mg ▁( ▁the ▁content s ▁of ▁2 ▁pre - fill ed ▁sy ring es ▁) ▁4 ▁weeks ▁after ▁your ▁last ▁treatment ▁ , ▁then ▁every ▁4 ▁weeks ▁there a fter ▁ .
▁this ▁is ▁because ▁you ▁may ▁have ▁a ▁condition ▁known ▁as ▁col itis ▁( ▁an ▁ inflammation ▁of ▁the ▁bo wel ▁) ▁ .
▁since ▁a ce tyl sali cy lic ▁acid ▁ , ▁non steroid al ▁anti - in flam ma tory ▁medicinal ▁products ▁( ▁ nsa ids ▁) ▁and ▁bis phos phon ates ▁are ▁associated ▁with ▁gastro inte stin al ▁irrita tion ▁ , ▁cau tion ▁should ▁be ▁taken ▁during ▁con com i tant ▁administration ▁ .
▁there ▁is ▁no ▁specific ▁anti do te ▁to ▁sy cre st ▁ .
▁they ▁should ▁be ▁swa llow ed ▁whole ▁and ▁taken ▁with ▁a ▁meal ▁ .
▁saber vel ▁150 ▁mg ▁film - co ated ▁tablets ▁are ▁white ▁ , ▁con ca ve ▁ , ▁round ▁ , ▁film - co ated ▁tablets ▁with ▁9 ▁mm ▁diameter ▁ .
▁eu ▁/ ▁1 ▁/ ▁14 ▁/ ▁9 13 ▁/ ▁0 14 ▁98 ▁x ▁1 ▁film - co ated ▁tablets
▁however ▁ , ▁this ▁finding ▁is ▁not ▁clinic ally ▁relevant ▁as ▁system ic ▁exposure ▁for ▁both ▁el der ly ▁and ▁young ▁subject s ▁remain ed ▁very ▁low ▁from ▁o cular ▁dos ing ▁ .
▁blood ▁urin e ▁present ▁bio psy ▁skin
▁subject s ▁achieve d ▁a ▁mean ▁predict ed ▁ca v ▁at ▁stea dy ▁state ▁of ▁1,9 70 ▁ng ▁/ ▁ml ▁ .
▁animal ▁studies ▁have ▁shown ▁ex cre tion ▁of ▁i dur sul fase ▁in ▁breast ▁milk ▁ .
▁the ▁difference ▁continued ▁to ▁be ▁statistic ally ▁significant ▁through ▁month ▁6 ▁in ▁each ▁study ▁( ▁p ▁ ≤ ▁0.0 24 ▁) ▁ .
▁there ▁is ▁limited ▁information ▁available ▁with ▁regard ▁to ▁over dos e ▁in ▁humans ▁ .
▁this ▁may ▁result ▁in ▁lower ed ▁plasma ▁concentration s ▁and ▁potential ▁decrease ▁of ▁ef fica cy ▁of ▁co - ad minister ed ▁medicinal ▁products ▁ .
▁if ▁you ▁experience ▁sud den ▁decrease ▁or ▁loss ▁of ▁vision ▁ , ▁stop ▁taking ▁cialis ▁and ▁contact ▁your ▁doctor ▁immediately ▁ .
▁se iz ures ▁or ▁fit s ▁- ▁this ▁occur s ▁rare ly ▁other ▁side ▁effects ▁:
▁the ▁data ▁are ▁display ed ▁in ▁the ▁table ▁below ▁:
▁these ▁advers e ▁reaction s ▁are ▁similar ▁in ▁character ▁to ▁those ▁after ▁the ▁initial ▁five ▁dos es ▁ .
▁name ▁and ▁address ▁of ▁the ▁manufacture r ▁( ▁s ▁) ▁of ▁the ▁bi ological ▁active ▁substance
▁ pharma cok ine tics ▁determine d ▁with ▁a ▁population ▁approach ▁in ▁patients ▁with ▁er ect ile ▁dys function ▁are ▁similar ▁to ▁ pharma cok ine tics ▁in ▁subject s ▁without ▁er ect ile ▁dys function ▁ .
▁one ▁vi al ▁of ▁4 ▁ml ▁concentration ▁contain s ▁80 ▁mg ▁doce ta xel ▁ .
▁rasi lam lo ▁is ▁for ▁use ▁in ▁adults ▁ .
▁finally ▁the ▁' ▁n - deal kyl ated ▁acid ▁' ▁( ▁n w -16 89 ▁) ▁is ▁for med ▁by ▁oxid ative ▁cle ava ge ▁of ▁the ▁amin e ▁bond ▁of ▁either ▁saf inami de ▁( ▁minor ▁) ▁or ▁the ▁primary ▁saf inami de ▁acid ▁metabol ite ▁( ▁n w -11 53 ▁) ▁( ▁major ▁) ▁ .
▁the ▁effect ▁of ▁ec alta ▁in ▁pregnant ▁women ▁is ▁not ▁known ▁ .
▁continue ▁to ▁develop ▁a ▁test ▁to ▁quanti fy ▁sa ponin ▁in ▁the ▁finished ▁product ▁and ▁provide ▁regular ▁updates ▁on ▁results
▁multiple ▁mye loma ▁is ▁a ▁cancer ▁of ▁plasma ▁cell s ▁( ▁a ▁type ▁of ▁white ▁blood ▁cell ▁) ▁ .
▁before ▁each ▁in fusion ▁you ▁will ▁have ▁sample s ▁of ▁your ▁blood ▁taken ▁to ▁evaluat e ▁if ▁you ▁have ▁ sufficient ▁ki dne y ▁and ▁ liver ▁function ▁and ▁to ▁check ▁that ▁you ▁have ▁enough ▁blood ▁cell s ▁to ▁receive ▁alim ta ▁ .
▁if ▁you ▁have ▁been ▁treated ▁with ▁kry ste xx a ▁before
▁if ▁necessary ▁ , ▁the ▁dose ▁of ▁gluco se - lo wering ▁medicinal ▁products ▁should ▁be ▁adjust ed ▁during ▁ therapy ▁with ▁the ▁other ▁medicinal ▁product ▁and ▁on ▁its ▁dis continu ation ▁ .
▁car riga line ▁count y ▁cor k ▁i re land ▁ .
▁the ▁primary ▁target s ▁of ▁ toxic ity ▁included ▁the ▁bone ▁mar row ▁ , ▁lymph ore ti cular ▁system ▁ , ▁teste s ▁ , ▁the ▁gastro inte stin al ▁tract ▁and ▁ , ▁at ▁higher ▁dos es ▁ , ▁which ▁were ▁le thal ▁to ▁60 ▁% ▁to ▁100 ▁% ▁of ▁rat s ▁and ▁dog s ▁test ed ▁ , ▁de genera tion ▁of ▁the ▁retin a ▁occur red ▁ .
▁the ▁remain ing ▁single - dos e ▁container s ▁should ▁be ▁kept ▁in ▁the ▁aluminium ▁po uch ▁ .
▁um ec li dini um ▁brom ide ▁is ▁a ▁long ▁ac ting ▁mus cari nic ▁receptor ▁anta gon ist ▁( ▁also ▁refer red ▁to ▁as ▁an ▁anti cho liner gi c ▁) ▁ .
▁many ▁events ▁were ▁reported ▁to ▁occur ▁during ▁or ▁short ly ▁after ▁sexual ▁inter cours e ▁and ▁a ▁few ▁were ▁reported ▁to ▁occur ▁short ly ▁after ▁the ▁use ▁of ▁sil den a fil ▁without ▁sexual ▁activity ▁ .
▁du lo xe tine ▁my lan ▁60 ▁mg ▁is ▁available ▁in ▁bli ster ▁pack s ▁of ▁14 ▁ , ▁28 ▁ , ▁84 ▁ , ▁98 ▁and ▁in ▁a ▁multi pack ▁of ▁98 ▁compris ing ▁2 ▁carton s ▁ , ▁each ▁contain ing ▁49 ▁capsule s ▁ , ▁in ▁perfor ated ▁bli ster ▁pack s ▁contain ing ▁28 ▁x ▁1 ▁ , ▁30 ▁x ▁1 ▁ , ▁and ▁100 ▁x ▁1 cap s ules ▁and ▁bottle s ▁contain ing ▁30 ▁ , ▁100 ▁ , ▁250 ▁and ▁500 ▁capsule s ▁and ▁a ▁de sic cant ▁ .
▁advers e ▁reaction s ▁reported ▁in ▁double - blind ▁studies ▁and ▁post ▁marketing ▁experience ▁are ▁listed ▁below ▁as ▁med dra ▁prefer red ▁term ▁by ▁system ▁organ ▁class ▁and ▁absolute ▁fre que ncy ▁ .
▁the ▁ad rs ▁reported ▁in ▁four tri als ▁are ▁summa ris ed ▁and ▁categori sed ▁according ▁to ▁the ▁med dra ▁system ▁organ ▁class ▁and ▁fre que ncy ▁below ▁ .
▁doce ta xel ▁teva ▁80 ▁mg ▁/ ▁2. 88 ▁ml ▁vi al
▁hyper sensitiv ity ▁to ▁other ▁sul phon ami de - der i ved ▁substance s ▁( ▁since ▁hydro ch lor o thi azi de ▁is ▁a ▁sul phon ami de - der i ved ▁medicinal ▁product ▁) ▁ .
▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁6 10 ▁/ ▁ 008 ▁carton s ▁of ▁90 x 1 ▁tablets ▁in ▁pe el able ▁perfor ated ▁unit - dos e ▁aluminium - alum ini um ▁bli sters
▁20- 115 ▁mg ▁/ ▁m 2 ▁in ▁phase ▁i ▁studies ▁ .
▁serious ▁bacteria l ▁ , ▁fun gal ▁ , ▁and ▁new ▁or ▁re activa ted ▁viral ▁infection s ▁can ▁occur ▁during ▁and ▁following ▁the ▁complet ion ▁of ▁gaz y varo ▁ therapy ▁ .
▁pra mi pe xo le ▁accord ▁has ▁been ▁associated ▁with ▁sleep ines s ▁and ▁episode s ▁of ▁suddenly ▁fall ing ▁a sleep ▁ , ▁particularly ▁in ▁patients ▁with ▁par kin son ▁' s ▁disease ▁ .
▁if ▁you ▁have ▁ki dne y ▁or ▁ liver ▁problems
▁periodic ▁determina tions ▁of ▁se rum ▁po tas s ium ▁to ▁detect ▁possible ▁electro ly te ▁im balance ▁should ▁be ▁perform ed ▁in ▁patients ▁at ▁risk ▁at ▁appropriate ▁interval s ▁( ▁see ▁section s ▁4.4 ▁and ▁4.5 ▁) ▁ .
▁administration ▁of ▁thi azi de ▁di ure tics ▁ , ▁including ▁hydro ch lor o thi azi de ▁ , ▁with ▁vitamin ▁d ▁or ▁with ▁calci um ▁salt s ▁may ▁potentia te ▁the ▁ rise ▁in ▁se rum ▁calci um ▁ .
▁do ▁not ▁attempt ▁to ▁inject ▁yourself ▁unless ▁you ▁have ▁been ▁train ed ▁to ▁do ▁so ▁by ▁your ▁doctor ▁or ▁nurse ▁ .
▁out er ▁wrap per ▁label ▁on ▁multi pack s ▁( ▁2 x 56 ▁hard ▁capsule s ▁) ▁wrap ped ▁in ▁foi l ▁( ▁including ▁the ▁blue ▁box ▁)
▁ riste mpa ▁is ▁not ▁recommended ▁during ▁pre gna ncy ▁and ▁in ▁women ▁of ▁child be aring ▁potential ▁not ▁using ▁contra ception ▁ .
▁the ▁effective ▁dose ▁range ▁of ▁abil ify ▁solution ▁for ▁inject ion ▁is ▁5. 25 - ▁15 ▁mg ▁as ▁a ▁single ▁inject ion ▁ .
▁ir besar tan ▁teva ▁is ▁indicate d ▁in ▁adults ▁for ▁the ▁treatment ▁of ▁essential ▁hyper tension ▁ .
▁in ▁the ▁event ▁of ▁grade ▁2-4 ▁a cute ▁ toxic ity ▁ , ▁treatment ▁must ▁be ▁dis continu ed ▁immediately ▁until ▁observe d ▁ toxic ity ▁resolve s ▁ .
▁higher ▁dos es ▁should ▁not ▁be ▁used ▁in ▁children ▁ .
▁at ▁600 ▁micro gram ▁once - daily ▁ , ▁the ▁safety ▁profile ▁of ▁os lif ▁bre ezh a ler ▁was ▁overall ▁similar ▁to ▁that ▁of ▁recommended ▁dos es ▁ .
▁fira zy r ▁is ▁intended ▁for ▁sub cuta ne ous ▁inject ion ▁( ▁under ▁the ▁skin ▁) ▁ .
▁in ▁patients ▁taking ▁rasa gi line ▁ratio ph arm ▁and ▁/ ▁or ▁other ▁medication s ▁used ▁to ▁treat ▁par kin son ▁' s ▁disease ▁ , ▁the ▁following ▁have ▁been ▁observe d ▁:
▁of ▁the ▁54 ▁patients ▁withdraw n ▁from ▁or encia ▁during ▁the ▁double - blind ▁period ▁for ▁up ▁to ▁6 ▁months ▁ , ▁non e ▁had ▁an ▁in fusion ▁reaction ▁upon ▁re - ini ti ation ▁of ▁or encia ▁ .
▁serial ▁fe v 1 ▁measure ments ▁were ▁compared ▁with ▁pre - aller gen ▁challenge ▁values ▁taken ▁after ▁sa line ▁in hal ation ▁( ▁base line ▁) ▁ .
▁six ty - fi ve ▁percent ▁of ▁the ▁patients ▁studie d ▁in ▁the ▁sc n ▁trial ▁programme ▁were ▁under ▁18 ▁years ▁of ▁age ▁ .
▁bio chem ical ▁and ▁metabol ic ▁laborator y ▁test ▁ab normal ities
▁the ▁effect ▁of ▁third - space ▁fluid ▁ , ▁such ▁as ▁ple ural ▁ef fusion ▁or ▁as cite s ▁ , ▁on ▁pe metre x ed ▁is ▁not ▁fully ▁define d ▁ .
▁pain s ▁or ▁difficult ies ▁in ▁pas sing ▁urin e ▁( ▁very ▁rare ▁) ▁ , ▁blood ▁in ▁the ▁urin e ▁ , ▁protein ▁in ▁the ▁urin e
▁patients ▁should ▁be ▁advise d ▁not ▁to ▁drive ▁or ▁operate ▁machine ry ▁if ▁they ▁experience ▁som nol ence ▁ , ▁di zzi ness ▁ , ▁or ▁visual ▁disturb ance ▁while ▁taking ▁e ffen tora ▁and ▁not ▁to ▁drive ▁or ▁operate ▁machine ry ▁until ▁they ▁know ▁how ▁they ▁react ▁ .
▁for ▁por cine ▁and ▁po ul try ▁species ▁the ▁fat ▁mr l ▁relat es ▁to ▁' ▁skin ▁and ▁fat ▁in ▁natural ▁proportion s ▁' ▁ .
▁examina tion ▁of ▁anti body - posi tive ▁speci mens ▁reveal ed ▁no ▁significant ▁cross - re activ ity ▁with ▁similar ▁end ogen ous ▁pe pti des ▁( ▁glu ca gon ▁or ▁gl p -1 ▁) ▁ .
▁lan tus ▁100 ▁unit s ▁/ ▁ml ▁solution ▁for ▁inject ion ▁in ▁a ▁cart ridge ▁is ▁a ▁clear ▁and ▁colour less ▁solution ▁ .
▁your ▁doctor ▁will ▁decide ▁the ▁dose ▁of ▁ri xu bis ▁you ▁will ▁receive ▁ .
▁some ▁unde sir able ▁effects ▁mentioned ▁under ▁section ▁4. 8 ▁such ▁as ▁di zzi ness ▁and ▁verti go ▁may ▁affect ▁the ▁ability ▁to ▁drive ▁or ▁use ▁machines ▁ .
▁use ▁the ▁' ▁reli ever ▁in hal er ▁' ▁when ▁you ▁get ▁as th ma ▁symptoms ▁ , ▁to ▁make ▁it ▁easier ▁to ▁breath e ▁again ▁ .
▁each ▁vi al ▁provides ▁100 ▁micro gram s ▁/ ▁0.5 ▁ml ▁of ▁pe g inter fer on ▁alfa -2 b ▁when ▁recon stitu ted ▁as ▁recommended ▁ .
▁each ▁tablet ▁contain s ▁40 ▁mg ▁of ▁la ctos e ▁( ▁as ▁an hydro us ▁) ▁ .
▁patients ▁should ▁be ▁monitor ed ▁and ▁dose ▁re duction ▁may ▁be ▁required ▁ .
▁this ▁type ▁of ▁heart ▁failure ▁occur s ▁when ▁the ▁heart ▁is ▁we ak ▁and ▁cannot ▁pump ▁enough ▁blood ▁to ▁the ▁lung s ▁and ▁the ▁rest ▁of ▁the ▁body ▁ .
▁if ▁you ▁stop ▁taking ▁su box one
▁the ▁table ▁presente d ▁below ▁is ▁according ▁to ▁the ▁med dra ▁system ▁organ ▁classifica tion ▁( ▁soc ▁and ▁prefer red ▁term ▁level ▁) ▁ .
▁cap e cita bine ▁should ▁be ▁permanent ly ▁dis continu ed ▁in ▁patients ▁who ▁experience ▁a ▁severe ▁skin ▁reaction ▁during ▁treatment ▁ .
▁the ▁use ▁of ▁ne par vis ▁is ▁not ▁recommended ▁during ▁the ▁first ▁tri mester ▁of ▁pre gna ncy ▁and ▁is ▁contra indica ted ▁during ▁the ▁second ▁and ▁third ▁tri mester s ▁of ▁pre gna ncy ▁( ▁see ▁section ▁4.3 ▁) ▁ .
▁tag ris so ▁40 ▁mg ▁tablets ▁osim er tin ib
▁step ▁3 ▁: ▁choose ▁the ▁correct ▁amount ▁for ▁your ▁child ▁' s ▁weight
▁like ▁other ▁similar ▁medicine s ▁( ▁anti thro mbo tic ▁agents ▁) ▁ , ▁xa rel to ▁may ▁cause ▁ble ed ing ▁which ▁may ▁potential ly ▁be ▁life ▁threat en ing ▁ .
▁name ▁and ▁address ▁of ▁the ▁manufacture r ▁responsible ▁for ▁bat ch ▁release
▁container s ▁and ▁residu al ▁content s ▁should ▁be ▁dispose d ▁of ▁along ▁with ▁collect ed ▁domestic ▁refuse ▁to ▁avoid ▁contamina tion ▁of ▁any ▁water ▁courses ▁ .
▁the ▁recommended ▁starting ▁dose ▁is ▁0.5 ▁mi u ▁( ▁5 ▁μ g ▁) ▁/ ▁kg ▁/ ▁day ▁sub cuta ne ously ▁as ▁a ▁single ▁dose ▁or ▁in ▁divide d ▁dos es ▁ .
▁each ▁pi og lita zone ▁accord ▁30 ▁mg ▁tablet ▁contain s ▁30 ▁mg ▁of ▁pi og lita zone ▁( ▁as ▁hydro ch lor ide ▁) ▁ .
▁first ▁dose ▁: ▁at ▁an ▁ele cted ▁date
▁in ▁some ▁women ▁withdraw al ▁ble ed ing ▁may ▁not ▁occur ▁during ▁this ▁trans der mal ▁patch ▁free ▁period ▁ .
▁most ▁of ▁the ▁side ▁effects ▁are ▁mild ▁and ▁will ▁generally ▁disappear ▁over ▁time ▁ .
▁dose ▁to ▁be ▁ad minister ed
▁a ▁ pharma cok ine tic ▁study ▁has ▁shown ▁that ▁instan yl ▁single - dos e ▁and ▁multi - dos e ▁na sal ▁spray ▁are ▁bio e qui valent ▁ .
▁if ▁you ▁accident ally ▁take ▁too ▁much ▁ , ▁tell ▁your ▁doctor ▁or ▁your ▁ pharma ci st ▁ , ▁or ▁contact ▁your ▁near est ▁hospital ▁emergency ▁department ▁for ▁further ▁advice ▁ .
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁use ▁prometa x ▁do ▁not ▁use ▁prometa x ▁if ▁you ▁are ▁allergi c ▁to ▁ri va stig mine ▁( ▁the ▁active ▁substance ▁in ▁prometa x ▁) ▁or ▁any ▁of ▁the ▁other ▁ingredients ▁of ▁this ▁medicine ▁( ▁listed ▁in ▁section ▁6 ▁) ▁ .
▁the ▁product ▁may ▁in ▁very ▁rare ▁cases ▁cause ▁at ▁the ▁application ▁site ▁a ▁sensation ▁result ing ▁in ▁trans ient ▁behaviour al ▁changes ▁such ▁as ▁le thar gy ▁ , ▁agita tion ▁ , ▁and ▁ina ppet ence ▁ .
▁you ▁should ▁tell ▁your ▁doctor ▁immediately ▁if ▁you ▁experience ▁any ▁of ▁the ▁following ▁symptoms ▁after ▁receiving ▁your ▁treatment ▁; ▁sud den ▁w he ezi ness ▁ , ▁difficult y ▁in ▁breath ing ▁ , ▁pain ▁in ▁the ▁che st ▁ , ▁swe lling ▁of ▁eye lid s ▁ , ▁face ▁or ▁lips ▁ , ▁ rash ▁or ▁it ching ▁( ▁especially ▁affect ing ▁the ▁whole ▁body ▁) ▁ .
▁there ▁are ▁no ▁reliable ▁data ▁on ▁the ▁use ▁of ▁vor apa xar ▁in ▁pregnant ▁women ▁ .
▁4 ▁x ▁1 ▁oro dis per sible ▁tablet ▁: ▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 551 ▁/ ▁0 15
▁study ▁am d 3 100 -3 102 ▁- ▁proportion ▁of ▁patients ▁who ▁achieve d ▁ ≥ ▁6 ▁x ▁106 ▁cd 34 ▁+ ▁cell s ▁/ ▁kg ▁by ▁ap here sis ▁day ▁in ▁multiple ▁mye loma ▁patients
▁dose ▁interrupt ions ▁are ▁recommended ▁for ▁management ▁of ▁ct ca e ▁grade ▁3 ▁or ▁greater ▁ toxic ities ▁or ▁into ler able ▁grade ▁2 ▁ toxic ities ▁ .
▁each ▁capsule ▁contain s ▁250 ▁mg ▁ .
▁treatment ▁may ▁only ▁be ▁resume d ▁if ▁the ▁reaction ▁has ▁resolve d ▁to ▁grade ▁2 ▁ .
▁the ▁concentrat e ▁is ▁a ▁clear ▁ , ▁colour less ▁to ▁pale ▁yellow ▁solution ▁ .
▁the ▁vaccin e ▁strain ▁v cp 2017 ▁is ▁a ▁reco mbin ant ▁can ary po x ▁virus ▁express ing ▁the ▁prem ▁/ ▁e ▁gene s ▁of ▁west ▁ni le ▁virus ▁ .
▁ha e modi al ysis ▁may ▁be ▁helpful ▁in ▁remo ving ▁to bra my cin ▁from ▁the ▁body ▁ .
▁prometa x ▁ 4.6 ▁mg ▁/ ▁24 ▁h ▁trans der mal ▁patch ▁prometa x ▁ 9.5 ▁mg ▁/ ▁24 ▁h ▁trans der mal ▁patch ▁prometa x ▁13. 3 ▁mg ▁/ ▁24 ▁h ▁trans der mal ▁patch ▁ri va stig mine
▁the ▁k 65 r ▁and ▁also ▁the ▁k 70 e ▁substitut ion ▁result ▁in ▁reduce d ▁sus cept i bility ▁to ▁a baca vir ▁ , ▁di dano sine ▁ , ▁la mi vu dine ▁ , ▁em trici ta bine ▁ , ▁and ▁te no fo vir ▁ , ▁but ▁reta in ▁ sensitiv ity ▁to ▁zid ovu dine ▁ .
▁anti - eme tics ▁ , ▁used ▁to ▁treat ▁na use a ▁and ▁vom i ting ▁( ▁e . g . ▁met oc lop ram ide ▁)
▁take ▁your ▁next ▁capsule s ▁at ▁the ▁usual ▁time ▁the ▁next ▁day ▁ .
▁very ▁rare ▁( ▁may ▁affect ▁up ▁to ▁1 ▁in ▁10,000 ▁people ▁) ▁: ▁decrease d ▁vitamin ▁b 12 ▁levels ▁ , ▁hepatitis ▁( ▁a ▁problem ▁with ▁your ▁ liver ▁) ▁ , ▁skin ▁reaction ▁as ▁red ness ▁of ▁the ▁skin ▁( ▁er y thema ▁ , ▁ rash ▁) ▁and ▁ur tica ria ▁ .
▁un open ed ▁cart ridge s ▁: ▁store ▁in ▁a ▁refrigera tor ▁ .
▁at rio ven tri cular ▁block s ▁ , ▁intra ven tri cular ▁con duction ▁de lay s ▁ , ▁and ▁con ges tive ▁heart ▁failure ▁can ▁occur ▁with ▁more ▁severe ▁pois o ning ▁ .
▁tu mo urs ▁of ▁the ▁hypo thala mus ▁or pit uit ary ▁g land
▁apply ▁up ▁to ▁0.5 ▁ml ▁on to ▁the ▁skin ▁without ▁moving ▁the ▁applica tor ▁tip ▁ .
▁immediately ▁withdraw ▁the ▁need le ▁and ▁clean ▁the ▁skin ▁with ▁an ▁alcohol ▁s wab ▁using ▁a ▁circular ▁motion ▁ .
▁pack s ▁contain ing ▁20 ▁ , ▁30 ▁ , ▁50 ▁ , ▁60 ▁ , ▁80 ▁or ▁100 ▁film - co ated ▁tablets ▁or ▁multi pack s ▁contain ing ▁200 ▁( ▁2 ▁pack s ▁of ▁100 ▁) ▁film - co ated ▁tablets ▁ .
▁bu cco lam ▁may ▁make ▁the ▁patient ▁sleep y ▁ , ▁forget ful ▁or ▁affect ▁their ▁concentration ▁and ▁co - ordina tion ▁ .
▁rena gel ▁is ▁used ▁to ▁control ▁the ▁levels ▁of ▁ phos pha te ▁in ▁the ▁blood ▁of ▁adult ▁ki dne y ▁failure ▁patients ▁on ▁ha e modi al ysis ▁or ▁per ito ne al ▁di al ysis ▁treatment ▁ .
▁if ▁you ▁we igh ▁more ▁than ▁100 ▁kg ▁then ▁follow ▁the ▁dose ▁that ▁your ▁doctor ▁has ▁pre scribe d ▁ .
▁zar zio ▁works ▁by ▁en cour aging ▁the ▁bone ▁mar row ▁to ▁produce ▁more ▁white ▁blood ▁cell s ▁ .
▁however ▁ , ▁without ▁new ▁en fu virti de ▁some ▁patients ▁began ▁to ▁los e ▁anti vir al ▁activity ▁between ▁weeks ▁4 ▁and ▁8 ▁ .
▁to ▁ensure ▁effective ▁er y thro po ies is ▁ , ▁ir on ▁status ▁has ▁to ▁be ▁evaluat ed ▁for ▁all ▁patients ▁prior ▁to ▁and ▁during ▁treatment ▁ .
▁lan tus ▁100 ▁unit s ▁/ ▁ml ▁solution ▁for ▁inject ion ▁in ▁a ▁cart ridge ▁for ▁op tic lik
▁other ▁medicine s ▁and ▁fos avance
▁on ▁day ▁1 ▁ , ▁possibly ▁repeat ed ▁once
▁do ▁not ▁use ▁in ▁animals ▁suffering ▁from ▁gastro inte stin al ▁disorder s ▁such ▁as ▁irrita tion ▁and ▁ha e mor r hage ▁ , ▁im pair ed ▁he pati c ▁ , ▁cardiac ▁or ▁renal ▁function ▁and ▁ha e mor r hagi c ▁disorder s ▁ , ▁or ▁where ▁there ▁is ▁evidence ▁of ▁individual ▁hyper sensitiv ity ▁to ▁the ▁product ▁ .
▁care ful ▁selection ▁of ▁blood ▁and ▁plasma ▁donor s ▁to ▁make ▁sure ▁those ▁at ▁risk ▁of ▁carry ing ▁infection s ▁are ▁exclu ded ▁ .
▁precau tions ▁must ▁be ▁taken ▁to ▁avoid ▁exposure ▁of ▁skin ▁and ▁eyes ▁to ▁direct ▁sun light ▁or ▁bright ▁in door ▁light ▁during ▁the ▁first ▁15 ▁days ▁after ▁inject ion ▁ .
▁have ▁ever ▁had ▁a ▁stroke
▁further more ▁ , ▁rare ▁increase s ▁in ▁pr ▁interval ▁have ▁been ▁reported ▁during ▁kale tra ▁ therapy ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁in ▁case ▁of ▁surgery ▁or ▁ana es the sia ▁ , ▁you ▁should ▁tell ▁your ▁doctor ▁that ▁you ▁are ▁taking ▁mi card is ▁ .
▁reta crit ▁2 ▁000 ▁iu
▁i va bra dine ▁has ▁no ▁influence ▁on ▁the ▁ability ▁to ▁use ▁machines ▁ .
▁institut e ▁support ive ▁measure s ▁immediately ▁ .
▁if ▁you ▁have ▁accident ally ▁taken ▁too ▁many ▁tablets ▁ , ▁talk ▁to ▁your ▁doctor ▁straight ▁away ▁ .
▁your ▁doctor ▁will ▁discuss ▁the ▁potential ▁benefits ▁and ▁risk s ▁of ▁taking ▁stri bild ▁to ▁you ▁and ▁your ▁child ▁ .
▁after ▁hearing ▁the ▁" ▁click ▁ , ▁" ▁count ▁to ▁5 ▁to ▁deliver ▁the ▁full ▁dose ▁ .
▁special ▁instructions ▁to ▁support ▁accurate ▁preparation
▁an ▁increase ▁in ▁minute ▁ventilation ▁and ▁a ▁decrease ▁in ▁oxygen ▁satu ration ▁were ▁observe d ▁ , ▁and ▁the ▁most ▁frequent ▁advers e ▁event ▁was ▁dys p no e a ▁ , ▁which ▁resolve d ▁with ▁dis continu ation ▁of ▁bo sent an ▁ .
▁no ▁dose ▁adjust ment ▁is ▁necessary ▁for ▁patients ▁with ▁mild ▁or ▁moderat e ▁renal ▁im pair ment ▁( ▁cl cr ▁equal ▁or ▁above ▁30 ▁ml ▁/ ▁min ▁) ▁ .
▁name ▁and ▁address ▁of ▁the ▁manufacture r ▁( ▁s ▁) ▁responsible ▁for ▁bat ch ▁release
▁eu ▁/ ▁1 ▁/ ▁00 ▁/ ▁156 ▁/ ▁ 002 ▁tri zi vir ▁- -1 ▁film - co ated
▁bre tari s ▁genu air ▁3 22 ▁m c g ▁in hal ation ▁powder ▁ac li dini um ▁( ▁ac li dini um ▁brom ide ▁)
▁variation s ▁in ▁colour ▁within ▁this ▁range ▁do ▁not ▁affect ▁the ▁potenc y ▁of ▁the ▁product ▁ .
▁a ▁significant ▁re duction ▁of ▁the ▁absolute ▁risk ▁of ▁any ▁diabetes - related ▁complica tion ▁in ▁the ▁met form in ▁group ▁( ▁29. 8 ▁events ▁/ ▁1,000 ▁patient - year s ▁) ▁versus ▁die t ▁alone ▁( ▁4 3.3 ▁events ▁/ ▁1,000 ▁patient - year s ▁) ▁ , ▁p ▁= ▁ 0.00 23 ▁ , ▁and ▁versus ▁the ▁combine d ▁sul phon y lu rea ▁and ▁insulin ▁mono therapy ▁groups ▁( ▁4 0.1 ▁events ▁/ ▁1,000 ▁patient - year s ▁) ▁ , ▁p ▁= ▁ 0.00 34
▁forta cin ▁provides ▁topic al ▁ana es the sia ▁to ▁the ▁glan s ▁penis ▁ .
▁combination ▁ therapy ▁with ▁riba vir in ▁and ▁inter fer on ▁alfa -2 b ▁result ed ▁in ▁a ▁sustain ed ▁vir ological ▁response ▁that ▁was ▁ten - fold ▁higher ▁than ▁that ▁with ▁inter fer on ▁alfa -2 b ▁alone ▁( ▁49 ▁% ▁vs ▁5 ▁% ▁ , ▁p ▁< ▁0.0 001 ▁) ▁ .
▁ze pati er ▁( ▁ad minister ed ▁alone ▁or ▁in ▁combination ▁with ▁riba vir in ▁) ▁is ▁not ▁likely ▁to ▁have ▁an ▁effect ▁on ▁the ▁ability ▁to ▁drive ▁and ▁use ▁machines ▁ .
▁h . ▁ lund beck ▁a ▁/ ▁s ▁ott ilia vej ▁9
▁u gar ▁in ▁urin e ▁ , ▁protein s ▁in ▁urin e
▁patients ▁should ▁be ▁advise d ▁to ▁dis continu e ▁in fusion ▁of ▁the ▁product ▁and ▁contact ▁their ▁physician ▁if ▁these ▁symptoms ▁occur ▁ .
▁patients ▁with ▁rare ▁heredita ry ▁problems ▁of ▁fruct ose ▁in tolerance ▁ , ▁gluco se - gala ctos e ▁mala b sor p tion ▁or ▁suc rase - iso malt ase ▁insu ffi cie ncy ▁should ▁not ▁take ▁this ▁medicine ▁ .
▁very ▁common ▁: ▁irrita bility ▁; ▁any ▁vaccin ation - site ▁er y thema ▁; ▁in dur ation ▁/ ▁swe lling ▁or ▁pain ▁/ ▁tender ness ▁; ▁som nol ence ▁; ▁poor ▁quality ▁sleep ▁; ▁vaccin ation - site ▁tender ness ▁( ▁including ▁im pair ed ▁movement ▁)
▁it ▁is ▁ad vis able ▁to ▁take ▁your ▁medicine ▁at ▁the ▁same ▁time ▁each ▁day ▁ .
▁veg f ▁levels ▁are ▁eleva ted ▁in ▁response ▁causing ▁the ▁le ak age ▁of ▁fluid ▁into ▁the ▁retin a ▁and ▁there by ▁causing ▁ma cular ▁oed ema ▁ .
▁ phen y to in ▁ , ▁for ▁treat ing ▁epi le psy
▁un com mon ▁: ▁mic turi tion ▁disorder ▁ , ▁pol laki uria
▁re activa tion ▁of ▁hepatitis ▁b ▁has ▁occur red ▁in ▁patients ▁receiving ▁a ▁t n f - anta gon ist ▁including ▁si mpon i ▁ , ▁who ▁are ▁chronic ▁car rier s ▁of ▁this ▁virus ▁( ▁i . e . ▁surface ▁anti gen ▁positive ▁) ▁ .
▁if ▁you ▁are ▁nur sing ▁during ▁ne ul asta ▁treatment ▁ , ▁you ▁may ▁be ▁encourage d ▁to ▁en rol ▁in ▁am gen ▁' s ▁lac tation ▁sur ve illa nce ▁programme ▁ .
▁table ▁2 ▁: ▁interaction s ▁between ▁el vite grav ir ▁and ▁other ▁medicinal ▁products
▁the ▁following ▁advers e ▁reaction s ▁were ▁observe d ▁in ▁a ▁poole d ▁analysis ▁of ▁the ▁he c ▁and ▁mec ▁studies ▁at ▁a ▁greater ▁incide nce ▁with ▁apre pitan t ▁than ▁with ▁standard ▁ therapy ▁in ▁adults ▁or ▁pa e dia tric ▁patients ▁or ▁in ▁post marketing ▁use ▁ .
▁all ▁parent er al ▁medicinal ▁products ▁should ▁be ▁inspect ed ▁visual ly ▁for ▁parti cula te ▁matter ▁and ▁disco lor ation ▁prior ▁to ▁administration ▁ .
▁no ▁special ▁storage ▁condition ▁required ▁ .
▁it ▁is ▁not ▁known ▁if ▁xul to phy ▁passe s ▁into ▁breast ▁milk ▁ .
▁keto con a zole ▁ , ▁i trac ona zole ▁ , ▁posa con a zole ▁or ▁vor ico na zole ▁ , ▁used ▁to ▁treat ▁fun gal ▁infection s
▁cau tion ▁should ▁be ▁used ▁with ▁we ak ▁cy p 3 a ▁inhibi tors ▁( ▁e . g . ▁am lo pidi ne ▁ , ▁ cil osta zol ▁ , ▁flu vo xa mine ▁ , ▁golden se al ▁ , ▁is onia zi d ▁ , ▁ra niti dine ▁ , ▁rano lazi ne ▁) ▁in ▁pm s ▁ .
▁keep ▁using ▁your ▁medicine ▁until ▁your ▁doctor ▁tell s ▁you ▁to ▁stop ▁ .
▁anti cho liner gi c ▁medicinal ▁products ▁can ▁work ▁syn er gi st ically ▁with ▁levo do pa ▁ , ▁in ▁order ▁to ▁improve ▁tre mor ▁ .
▁the ▁safety ▁and ▁ef fica cy ▁of ▁can a gli flo zin ▁in ▁patients ▁with ▁type ▁1 ▁diabetes ▁have ▁not ▁been ▁established ▁and ▁vo kana met ▁should ▁not ▁be ▁used ▁for ▁treatment ▁of ▁patients ▁with ▁type ▁1 ▁diabetes ▁ .
▁how ▁to ▁recognize ▁your ▁kwi k pen ▁:
▁if ▁a ▁patient ▁develop s ▁sign s ▁and ▁symptoms ▁indicati ve ▁of ▁n ms ▁ , ▁or ▁present s ▁with ▁un exp lain ed ▁high ▁fe ver ▁without ▁additional ▁clinic al ▁manifestation s ▁of ▁n ms ▁ , ▁all ▁anti psy cho tic ▁active ▁substance s ▁ , ▁including ▁ar ipi pra zole ▁ , ▁must ▁be ▁dis continu ed ▁ .
▁do ▁not ▁take ▁revol ade ▁with ▁dair y ▁food s ▁or ▁drink s ▁as ▁the ▁calci um ▁in ▁dair y ▁products ▁affect s ▁the ▁ab sor p tion ▁of ▁the ▁medicine ▁ .
▁the ▁predict ed ▁oral ▁clear ance ▁was ▁17. 7 ▁l ▁/ ▁h ▁in ▁women ▁and ▁22. 1 ▁l ▁/ ▁h ▁in ▁men ▁ , ▁with ▁39 ▁% ▁inter - sub ject ▁variabil ity ▁in ▁m f ▁patients ▁ .
▁je nta du eto ▁2.5 ▁mg ▁/ ▁1,000 ▁mg ▁film - co ated ▁tablets
▁do ▁not ▁use ▁in ▁pregnant ▁or ▁la cta ting ▁dog s ▁or ▁in ▁bit ches ▁intended ▁for ▁breed ing ▁ .
▁con geni tal ▁aid s ▁with ▁re current ▁bacteria l ▁infection s ▁ .
▁if ▁you ▁inject ▁yourself ▁with ▁fer ta vid ▁ , ▁follow ▁the ▁instructions ▁carefully ▁to ▁give ▁fer ta vid ▁properly ▁and ▁with ▁minimal ▁disco m fort ▁ .
▁the ▁co administration ▁of ▁da pag lif lozi n ▁and ▁met form in ▁has ▁been ▁studie d ▁in ▁subject s ▁with ▁type ▁2 ▁diabetes ▁in adequa tely ▁control led ▁on ▁met form in ▁alone ▁or ▁in ▁combination ▁with ▁a ▁d pp -4 ▁inhibi tor ▁( ▁si tag lip tin ▁) ▁ , ▁sul phon y lu rea ▁or ▁insulin ▁ .
▁depression ▁ , ▁hal lucina tion ▁ , ▁anxiety ▁ , ▁ insomni a ▁ , ▁agita tion ▁ , ▁confusion al ▁state
▁all ▁patients ▁treated ▁with ▁stale vo ▁should ▁be ▁monitor ed ▁carefully ▁for ▁the ▁development ▁of ▁mental ▁changes ▁ , ▁depression ▁with ▁suicida l ▁tendenci es ▁ , ▁and ▁other ▁serious ▁anti social ▁behaviour ▁ .
▁in ▁adult ▁and ▁ adolescent ▁patients ▁with ▁allergi c ▁r hin itis ▁ , ▁a erius ▁tablets ▁were ▁effective ▁in ▁reli e ving ▁symptoms ▁such ▁as ▁sne ez ing ▁ , ▁na sal ▁dis charge ▁and ▁it ching ▁ , ▁as ▁well ▁as ▁o cular ▁it ching ▁ , ▁te aring ▁and ▁red ness ▁ , ▁and ▁it ching ▁of ▁pala te ▁ .
▁if ▁you ▁forget ▁to ▁take ▁en var sus
▁om e pra zole ▁c max ▁↑ ▁116 ▁% ▁om e pra zole ▁au c τ ▁↑ ▁280 ▁% ▁vor ico na zole ▁c max ▁↑ ▁15 ▁% ▁vor ico na zole ▁au c τ ▁↑ ▁41 ▁%
▁olan za pine ▁is ▁metabol ised ▁in ▁the ▁ liver ▁by ▁conjuga tive ▁and ▁oxid ative ▁path ways ▁ .
▁olan za pine ▁is ▁an ▁anti psy cho tic ▁ , ▁anti man ic ▁and ▁mood ▁stabili sing ▁agent ▁that ▁demonstrat es ▁a ▁broad ▁ pharma c ologic ▁profile ▁across ▁a ▁number ▁of ▁receptor ▁systems ▁ .
▁dose ▁of ▁co - ▁ad minister ed
▁what ▁cre se mba ▁is ▁and ▁what ▁it ▁is ▁used ▁for ▁what ▁cre se mba ▁is
▁external ▁heat ▁loss ▁from ▁the ▁li mb ▁should ▁be ▁prevent ed ▁by ▁application ▁of ▁the r mal ▁blank ets ▁and ▁li mb ▁temperature ▁continu ously ▁monitor ed ▁by ▁the rmi stor ▁pro bes ▁insert ed ▁into ▁sub cuta ne ous ▁tissu e ▁and ▁muscle ▁ .
▁the ▁results ▁from ▁this ▁trial ▁are ▁summa ris ed ▁below ▁ .
▁in ▁view ▁of ▁the ▁possible ▁risk ▁of ▁micro bi al ▁contamina tion ▁ , ▁ni vesti m ▁sy ring es ▁are ▁for ▁single ▁use ▁only ▁ .
▁fax ▁: ▁+ ▁49 ▁80 24 ▁90 8 -12 90 ▁a il ▁: ▁service ▁@ ▁he xal . com
▁do ▁not ▁re start ▁breast feed ing ▁until ▁the ▁doctor ▁tell s ▁you ▁it ▁is ▁safe ▁to ▁do ▁so ▁ .
▁visu dy ne ▁is ▁also ▁contra indica ted ▁in ▁patients ▁with ▁por phy ria ▁and ▁in ▁patients ▁with ▁severe ▁he pati c ▁im pair ment ▁( ▁see ▁" ▁he pati c ▁im pair ment ▁" ▁under ▁section ▁4.2 ▁) ▁ .
▁it ▁may ▁therefore ▁be ▁necessary ▁ , ▁particularly ▁in ▁patients ▁with ▁dys kin esia ▁ , ▁to ▁reduce ▁levo do pa ▁dose ▁by ▁10 -30 ▁% ▁within ▁the ▁first ▁days ▁to ▁first ▁weeks ▁after ▁initiat ing ▁cor bil ta ▁treatment ▁ .
▁co - administration ▁of ▁sa quina vir ▁/ ▁rito na vir ▁and ▁a trip la ▁is ▁not ▁recommended ▁ .
▁the ▁clear ▁solution ▁is ▁orang e ▁to ▁dark ▁orang e ▁in ▁colour ▁ .
▁ inflammation ▁ , ▁irrita tion ▁and ▁/ ▁or ▁tight ness ▁of ▁the ▁lung s ▁ , ▁ thro at ▁and ▁/ ▁or ▁sinus es ▁ , ▁too ▁little ▁oxygen ▁reach ing ▁the ▁body ▁organ s ▁ , ▁co ugh ing ▁ , ▁co ugh ing ▁up ▁of ▁blood
▁the ▁marketing ▁author isation ▁holder ▁must ▁ , ▁following ▁discussion s ▁and ▁agreement ▁with ▁the ▁national ▁ competent ▁authorities ▁in ▁each ▁member ▁state ▁where ▁tys abri ▁is ▁market ed ▁ , ▁ensure ▁that ▁all ▁physician s ▁who ▁intend ▁to ▁pre scribe ▁tys abri ▁are ▁provided ▁with ▁a ▁physician ▁pack ▁contain ing ▁the ▁following ▁elements ▁:
▁similar ▁finding s ▁were ▁not ▁observe d ▁in ▁rabbi ts ▁ .
▁the ▁complete ▁syndrome ▁includes ▁ste ator r ho e a ▁ , ▁an ▁ab normal ▁small ▁bo wel ▁pattern ▁on ▁x - ray ▁ , ▁vill us ▁a trop hy ▁ , ▁de press ed ▁cholesterol ▁ , ▁reduce d ▁d - xy lose ▁and ▁ir on ▁ab sor p tion ▁ .
▁the ▁main ▁target ▁organ s ▁of ▁ toxic ity ▁in ▁dog s ▁are ▁the ▁gastro inte stin al ▁tract ▁ , ▁the ▁ha e mato po e tic ▁system ▁ , ▁the ▁ki dne y ▁and ▁the ▁ liver ▁ .
▁inside ▁your ▁to bi ▁pod hal er ▁week ly ▁pack
▁the ▁ toxic ological ▁properties ▁of ▁lu te tium ▁( ▁177 lu ▁) ▁- label led ▁medicinal ▁products ▁prepared ▁by ▁radio label ling ▁with ▁en do luci n beta ▁prior ▁to ▁administration ▁ , ▁will ▁be ▁dependent ▁on ▁the ▁nature ▁of ▁the ▁medicinal ▁product ▁to ▁be ▁radio label led ▁ .
▁co - administration ▁with ▁medicinal ▁products ▁that ▁are ▁substrat es ▁of ▁p - gp ▁ , ▁ bc rp ▁ , ▁o at p 1 b 1 ▁and ▁o at p 1 b 3 ▁may ▁result ▁in ▁increased ▁plasma ▁concentration s ▁of ▁these ▁products ▁ .
▁in ▁rat s ▁ , ▁insulin ▁de glu dec ▁was ▁secret ed ▁in ▁milk ▁; ▁the ▁concentration ▁in ▁milk ▁was ▁lower ▁than ▁in ▁plasma ▁ .
▁olan za pine ▁ci pla ▁15 ▁mg ▁co ated ▁tablets
▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 573 ▁/ ▁ 002 ▁6 ▁pre - fill ed ▁sy ring es ▁with ▁safety ▁device ▁eu ▁/ ▁1 ▁/ ▁09 ▁/ ▁ 573 ▁/ ▁0 29 ▁6 ▁pre - fill ed ▁sy ring es ▁with ▁safety ▁need le
▁card board ▁box ▁of ▁1 ▁vi al ▁of ▁50 ▁ml ▁( ▁25 ▁dos es ▁) ▁ , ▁100 ml ▁( ▁50 ▁dos es ▁) ▁or ▁250 ▁ml ▁( ▁125 ▁dos es ▁) ▁ .
▁you ▁can ▁breast - feed ▁during ▁treatment ▁with ▁ca y ston ▁because ▁the ▁amount ▁of ▁ca y ston ▁likely ▁to ▁be ▁passed ▁to ▁your ▁child ▁during ▁breast - feed ing ▁will ▁be ▁extremely ▁small ▁ .
▁these ▁medicine s ▁may ▁put ▁you ▁at ▁higher ▁risk ▁of ▁in fusion ▁reaction ▁ .
▁study ▁features ▁and ▁results ▁are ▁presente d ▁in ▁the ▁table ▁below ▁ .
▁contact ▁a ▁doctor ▁as ▁soon ▁as ▁possible ▁ .
▁in r ▁eleva tions ▁and ▁/ ▁or ▁ble ed ing ▁events ▁have ▁been ▁reported ▁in ▁some ▁patients ▁con com i tant ly ▁taking ▁war far in ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁each ▁bag ▁of ▁100 ▁ml ▁contain s ▁5 ▁mg ▁zo le dro nic ▁acid ▁( ▁as ▁mono hydrat e ▁) ▁ .
▁unde sir able ▁effects ▁in ▁table ▁7 ▁were ▁considered ▁by ▁the ▁investiga tors ▁to ▁have ▁at ▁least ▁a ▁possible ▁or ▁probable ▁causa l ▁relationship ▁to ▁vel cade ▁ .
▁if ▁you ▁are ▁given ▁too ▁much ▁bort ez om ib ▁sun
▁in ▁these ▁patient ▁population s ▁ , ▁a ▁re duction ▁in ▁the ▁rate ▁of ▁the ▁progression ▁of ▁joint ▁damage ▁ , ▁as ▁measure d ▁by ▁x - ray ▁ , ▁has ▁been ▁demonstrat ed ▁( ▁see ▁section ▁5.1 ▁) ▁ .
▁anxiety ▁ ‐ ▁related ▁reaction s ▁ , ▁including ▁vas ova gal ▁reaction s ▁( ▁syn co pe ▁) ▁ , ▁hyper ventil ation ▁or ▁stress ▁ ‐ ▁related ▁reaction s ▁may ▁occur ▁in ▁association ▁with ▁vaccin ation ▁as ▁a ▁psycho ge nic ▁response ▁to ▁the ▁need le ▁inject ion ▁( ▁see ▁section ▁4. 8 ▁unde sir able ▁effects ▁) ▁ .
▁it ▁is ▁particularly ▁important ▁to ▁try ▁to ▁ensure ▁that ▁maximal ▁plasma ▁levels ▁are ▁achieve d ▁in ▁patients ▁infect ed ▁with ▁a sper gi llus ▁( ▁see ▁section s ▁4.2 ▁and ▁5.2 ▁on ▁recommended ▁dose ▁regime ns ▁and ▁the ▁effects ▁of ▁food ▁on ▁ab sor p tion ▁) ▁ .
▁always ▁give ▁this ▁medicine ▁to ▁your ▁child ▁exactly ▁as ▁your ▁doctor ▁or ▁ pharma ci st ▁has ▁told ▁you ▁ .
▁advers e ▁events ▁of ▁the ▁ha e mat ologic ▁system ▁ , ▁including ▁med ically ▁significant ▁cy to po enia ▁( ▁e . g . ▁ thro mbo cy to pa enia ▁ , ▁le uc opa enia ▁) ▁have ▁been ▁reported ▁with ▁hum ira ▁ .
▁pat ho logist s ▁should ▁be ▁made ▁aware ▁of ▁a ▁history ▁of ▁las o fox ife ne ▁use ▁when ▁assess ing ▁end ometri al ▁his t ology ▁ , ▁to ▁ensure ▁an ▁accurate ▁ diagnos is ▁of ▁benign ▁cyst ic ▁a trop hy ▁when ▁present ▁ .
▁ri va stig mine ▁be long s ▁to ▁a ▁class ▁of ▁substance s ▁called ▁cho line ster ase ▁inhibi tors ▁ .
▁treatment ▁against ▁is os pora ▁should ▁a im ▁to ▁min imize ▁the ▁she dding ▁of ▁oo cy st s ▁into ▁the ▁environment ▁ , ▁there by ▁ reducing ▁the ▁risk ▁for ▁re infect ion ▁in ▁groups ▁/ ▁kenne ls ▁with ▁known ▁and ▁re curr ing ▁is os pora ▁infection s ▁ .
▁this ▁type ▁2 ▁diabetes ▁usually ▁develop s ▁in ▁adult hood ▁particularly ▁as ▁a ▁result ▁of ▁the ▁person ▁being ▁over weight ▁and ▁where ▁the ▁body ▁either ▁does ▁not ▁produce ▁enough ▁insulin ▁( ▁a ▁hormone ▁that ▁control s ▁blood ▁sugar ▁levels ▁) ▁ , ▁or ▁cannot ▁effectively ▁use ▁the ▁insulin ▁it ▁produce s ▁ .
▁in ▁accordance ▁with ▁article ▁114 ▁of ▁direct ive ▁2001 ▁/ ▁83 ▁/ ▁ec ▁ , ▁the ▁official ▁bat ch ▁release ▁will ▁be ▁taken ▁by ▁a ▁state ▁laborator y ▁or ▁a ▁laborator y ▁design ated ▁for ▁that ▁purpose ▁ .
▁advers e ▁reaction s ▁have ▁been ▁rank ed ▁under ▁head ings ▁of ▁fre que ncy ▁using ▁the ▁following ▁convention ▁: ▁very ▁common ▁( ▁ ≥ ▁1 ▁/ ▁10 ▁) ▁; ▁common ▁( ▁ ≥ ▁1 ▁/ ▁100 ▁to ▁< ▁1 ▁/ ▁10 ▁) ▁; ▁un com mon ▁( ▁ ≥ ▁1 ▁/ ▁1,000 ▁to ▁< ▁1 ▁/ ▁100 ▁) ▁; ▁rare ▁( ▁ ≥ ▁1 ▁/ ▁10,000 ▁to ▁< ▁1 ▁/ ▁1,000 ▁) ▁; ▁very ▁rare ▁( ▁< ▁1 ▁/ ▁10,000 ▁) ▁ , ▁not ▁known ▁( ▁cannot ▁be ▁estima ted ▁from ▁the ▁available ▁data ▁) ▁ .
▁the ▁remain der ▁was ▁ex cre ted ▁as ▁metabol ites ▁ .
▁do ▁not ▁use ▁if ▁the ▁solution ▁contain s ▁parti cles ▁or ▁is ▁not ▁clear ▁ .
▁re mica de ▁is ▁indicate d ▁for ▁treatment ▁of ▁active ▁and ▁progressive ▁ps oria tic ▁ar thri tis ▁in ▁adult ▁patients ▁when ▁the ▁response ▁to ▁previous ▁d mar d ▁ therapy ▁has ▁been ▁in adequa te ▁ .
▁in ▁the ▁same ▁study ▁ , ▁the ▁au c ▁was ▁un change d ▁but ▁the ▁mean ▁c max ▁was ▁14 ▁% ▁lower ▁when ▁50 ▁mg ▁oro dis per sible ▁tablets ▁were ▁ad minister ed ▁with ▁water ▁compared ▁to ▁50 ▁mg ▁film - co ated ▁tablet ▁ .
▁subject s ▁with ▁vas ▁= ▁0 ▁at ▁all ▁times
▁there ▁should ▁be ▁an ▁interval ▁of ▁at ▁least ▁2 ▁months ▁between ▁primary ▁dos es ▁ .
▁pack ▁size s ▁of ▁30 ▁or ▁90 ▁film - co ated ▁tablets ▁in ▁bli sters ▁ .
▁twin rix ▁pa e dia tric ▁is ▁available ▁in ▁pack s ▁of ▁1 ▁ , ▁10 ▁and ▁50 ▁with ▁or ▁without ▁need les ▁ .
▁the ▁inject ion ▁should ▁be ▁ad minister ed ▁as ▁soon ▁as ▁possible ▁and ▁then ▁resume ▁monthly ▁inject ion ▁schedule ▁ .
▁how ▁to ▁store ▁ra ne xa
▁following ▁administration ▁of ▁an ▁oral ▁[ ▁14 c ▁] ▁si tag lip tin ▁dose ▁to ▁healthy ▁subject s ▁ , ▁approximately ▁100 ▁% ▁of ▁the ▁ad minister ed ▁radio activ ity ▁was ▁elimina ted ▁in ▁fa e ces ▁( ▁13 ▁% ▁) ▁or ▁urin e ▁( ▁87 ▁% ▁) ▁within ▁one ▁week ▁of ▁dos ing ▁ .
▁administration ▁of ▁( ▁rec ▁) ▁f sh ▁on ▁the ▁day ▁of ▁human ▁cho rio nic ▁go nado trop in ▁( ▁h c g ▁) ▁administration ▁can ▁be ▁om it ted ▁ , ▁de pending ▁on ▁the ▁ova rian ▁response ▁ .
▁store ▁in ▁a ▁refrigera tor ▁between ▁2 ▁° ▁c ▁and ▁8 ▁° ▁c
▁ phen yla ce tate ▁is ▁also ▁hydro ly sed ▁by ▁este ras es ▁in ▁ liver ▁and ▁blood ▁ .
▁v te ▁including ▁deep ▁ve in ▁ thro mbo sis ▁( ▁d vt ▁) ▁and ▁pulmonar y ▁e mbol ism ▁( ▁in fre quen t ly ▁fatal ▁) ▁have ▁been ▁reported ▁in ▁patients ▁treated ▁with ▁af liber cept ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁the ▁twice - daily ▁weight - band ▁dos ing ▁without ▁ne vira pine ▁provided ▁lo pina vir ▁plasma ▁concentration s ▁similar ▁to ▁those ▁obtain ed ▁in ▁adult ▁patients ▁receiving ▁the ▁400 ▁/ ▁100 ▁mg ▁twice - daily ▁regime n ▁without ▁ne vira pine ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁out er ▁carton ▁and ▁on ▁the ▁pre - fill ed ▁sy ringe ▁after ▁exp ▁ .
▁du ration ▁of ▁treatment ▁depend s ▁on ▁the ▁response ▁to ▁treatment ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁ir essa ▁contain s
▁it ▁is ▁an ▁inhibi tor ▁of ▁the ▁structura l ▁re arrangement ▁of ▁hi v -1 ▁ gp 41 ▁and ▁function s ▁by ▁specifically ▁ binding ▁to ▁this ▁virus ▁protein ▁extra cel lular ly ▁there by ▁block ing ▁fusion ▁between ▁the ▁viral ▁cell ▁membran e ▁and ▁the ▁target ▁cell ▁membran e ▁ , ▁prevent ing ▁the ▁viral ▁ rna ▁from ▁en tering ▁into ▁the ▁target ▁cell ▁ .
▁tam i flu ▁45 ▁mg ▁hard ▁capsule s ▁o selt ami vir
▁ef fica cy ▁results ▁at ▁week ▁12 ▁in ▁un cover -3
▁due ▁to ▁the ▁nit rate ▁component ▁it ▁has ▁the ▁potential ▁to ▁result ▁in ▁a ▁serious ▁interaction ▁with ▁sil den a fil ▁ .
▁rin se ▁the ▁sy ringe ▁and ▁plu nger ▁with ▁clean ▁water ▁ .
▁accident al ▁exposure ▁to ▁free zing ▁temperature s ▁does ▁not ▁advers ely ▁affect ▁the ▁stabilit y ▁of ▁fil gra s tim ▁he xal ▁ .
▁patients ▁and ▁care rs ▁should ▁be ▁made ▁aware ▁of ▁the ▁behaviour al ▁symptoms ▁of ▁impuls e ▁control ▁disorder s ▁that ▁were ▁observe d ▁in ▁patients ▁treated ▁with ▁rasa gi line ▁ , ▁including ▁cases ▁of ▁comp ul sions ▁ , ▁obses sive ▁thoughts ▁ , ▁path ological ▁gambling ▁ , ▁increased ▁libido ▁ , ▁hyper sexual ity ▁ , ▁impuls ive ▁behaviour ▁and ▁comp ul sive ▁spending ▁or ▁buying ▁ .
▁in ▁the ▁event ▁of ▁a cute ▁over dos e ▁ , ▁the ▁patient ▁should ▁be ▁carefully ▁observe d ▁and ▁given ▁standard ▁support ive ▁treatment ▁as ▁required ▁ .
▁co - administration ▁of ▁rey ata z ▁and ▁in dina vir ▁is ▁not ▁recommended ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁do ▁not ▁remove ▁the ▁cap ▁until ▁you ▁are ▁ready ▁to ▁ad minister ▁the ▁inject ion ▁ .
▁tax o tere ▁160 ▁mg ▁/ ▁8 ▁ml ▁concentrat e ▁for ▁solution ▁for ▁in fusion ▁doce ta xel
▁higher ▁degree s ▁of ▁clinic al ▁response ▁( ▁ac r 50 ▁and ▁ac r 70 ▁) ▁were ▁observe d ▁in ▁all ▁in flix ima b ▁groups ▁at ▁30 ▁and ▁54 ▁weeks ▁compared ▁with ▁met ho tre xa te ▁alone ▁ .
▁keep ▁the ▁bottle ▁tight ly ▁closed ▁ .
▁a ▁la ctos e - free ▁bara clu de ▁oral ▁solution ▁is ▁available ▁for ▁these ▁individuals ▁ .
▁if ▁you ▁forget ▁to ▁take ▁a ▁dose ▁ , ▁take ▁it ▁as ▁soon ▁as ▁you ▁remember ▁ , ▁unless ▁it ▁is ▁nearly ▁time ▁for ▁your ▁next ▁dose ▁ .
▁further ▁ , ▁the ▁c max ▁and ▁elimina tion ▁half - life ▁for ▁na lm ef ene ▁was ▁up ▁to ▁1.6 ▁times ▁higher ▁in ▁patients ▁with ▁severe ▁renal ▁im pair ment ▁ .
▁the ▁mix ture ▁should ▁be ▁used ▁immediately ▁after ▁preparation ▁ .
▁ci ▁= ▁confidence ▁interval ▁; ▁e ot ▁= ▁end ▁of ▁treatment ▁; ▁hr ▁= ▁hazard ▁ratio ▁; ▁i . v . ▁= ▁intra ven ous ▁; ▁pah ▁= ▁pulmonar y ▁arterial ▁hyper tension ▁; ▁s . c . ▁= ▁sub cuta ne ous ▁ .
▁keep ▁taking ▁bond ron at ▁for ▁as ▁long ▁as ▁your ▁doctor ▁tell s ▁you ▁ .
▁each ▁tablet ▁contain s ▁29 9.7 ▁mg ▁sor bit ol ▁( ▁e 420 ▁) ▁and ▁114 ▁mg ▁la ctos e ▁ .
▁one ▁way ▁to ▁do ▁that ▁is ▁to ▁note ▁the ▁inject ion ▁site ▁on ▁the ▁en close d ▁medication ▁record ▁card ▁ .
▁the ▁use ▁of ▁are pan rix ▁may ▁be ▁considered ▁during ▁pre gna ncy ▁if ▁this ▁is ▁thought ▁to ▁be ▁necessary ▁ , ▁taking ▁into ▁account ▁official ▁recommendations ▁ .
▁be lly ▁ , ▁except ▁for ▁a ▁5 ▁cm ▁( ▁2- in ch ▁) ▁area ▁right ▁around ▁your ▁be lly ▁button ▁ .
▁breast - feed ing ▁is ▁not ▁recommended ▁during ▁treatment ▁with ▁stay ve er ▁ .
▁infection ▁( ▁se psis ▁) ▁may ▁be ▁severe ▁and ▁could ▁lead ▁to ▁death ▁ .
▁di ar r ho e a ▁: ▁di ar r ho e a ▁is ▁a ▁dose - related ▁advers e ▁reaction ▁for ▁ali ski ren ▁ .
▁date ▁of ▁inf lec tra ▁ therapy ▁initiat ion ▁:
▁when ▁a sena pine ▁was ▁ad minister ed ▁intra ven ously ▁to ▁pregnant ▁rabbi ts ▁ , ▁no ▁sign s ▁of ▁em bry o toxic ity ▁were ▁observe d ▁ .
▁each ▁vi al ▁contain s ▁18 ▁mg ▁of ▁as fo tase ▁alfa ▁( ▁18 ▁mg ▁/ ▁0 . 45 ▁ml ▁) ▁ .
▁if ▁you ▁begin ▁to ▁get ▁migra ine - like ▁head ach es ▁ , ▁or ▁severe ▁head ach es
▁keep ▁the ▁le a flet ▁and ▁alert ▁card ▁with ▁you ▁during ▁treatment ▁and ▁for ▁six ▁months ▁after ▁the ▁last ▁dose ▁of ▁tys abri ▁ , ▁since ▁side ▁effects ▁may ▁occur ▁even ▁after ▁you ▁have ▁stopped ▁treatment ▁ .
▁in ▁single ▁dose ▁volunteer ▁studies ▁ , ▁dos es ▁up ▁to ▁and ▁including ▁80 ▁mg ▁var den a fil ▁( ▁film - co ated ▁tablets ▁) ▁per ▁day ▁were ▁to ler ated ▁without ▁exhibi ting ▁serious ▁advers e ▁reaction s ▁ .
▁inter stiti al ▁lung ▁disease ▁( ▁including ▁rapid ly ▁progressive ▁disease ▁ , ▁lung ▁fibro sis ▁and ▁pneu moni tis ▁) ▁ .
▁there ▁have ▁been ▁no ▁studies ▁on ▁the ▁effect ▁of ▁im pair ed ▁renal ▁or ▁he pati c ▁function ▁on ▁the ▁ pharma cok ine tics ▁of ▁xo la ir ▁ .
▁an ence pha ly ▁and ▁unilateral ▁ano ph thal mia ▁with ▁seconda ry ▁en lar ge ment ▁of ▁the ▁ton gue ▁were ▁observe d ▁in ▁one ▁fo etus ▁ , ▁micro op h thal mia ▁was ▁observe d ▁in ▁another ▁fo etus ▁ , ▁and ▁cle ft ▁pala te ▁was ▁observe d ▁in ▁a ▁third ▁fo etus ▁ .
▁lumi gan ▁0.3 ▁mg ▁/ ▁ml ▁single - dos e ▁has ▁not ▁been ▁test ed ▁in ▁children ▁under ▁the ▁age ▁of ▁18 ▁and ▁therefore ▁should ▁not ▁be ▁used ▁by ▁patients ▁under ▁18 ▁years ▁ .
▁drug ▁withdraw al ▁syndrome ▁ne ona tal ▁( ▁see ▁section ▁ 4.6 ▁)
▁do ▁not ▁start ▁using ▁ple grid y ▁if ▁you ▁are ▁already ▁pregnant ▁ .
▁for ▁inject ion ▁only ▁poly propyl ene ▁sy ring es ▁may ▁be ▁used ▁ .
▁out er ▁carton ▁( ▁for ▁both ▁bli sters ▁and ▁bottle ▁)
▁a im ▁the ▁na sal ▁spray ▁away ▁from ▁you ▁( ▁and ▁any ▁other ▁people ▁) ▁ .
▁this ▁is ▁to ▁make ▁sure ▁that ▁you ▁get ▁your ▁full ▁dose ▁ .
▁studies ▁in ▁the ▁rat ▁have ▁shown ▁that ▁mig lusta t ▁advers ely ▁affect s ▁sperm ▁parameter s ▁( ▁mot ility ▁and ▁ morph ology ▁) ▁there by ▁ reducing ▁fertil ity ▁( ▁see ▁section s ▁4.4 ▁and ▁5.3 ▁) ▁ .
▁xal up rine ▁should ▁only ▁be ▁given ▁to ▁you ▁by ▁a ▁specialist ▁doctor ▁who ▁is ▁experienced ▁in ▁treat ing ▁blood ▁problems ▁ .
▁do ▁not ▁use ▁in ▁dog s ▁less ▁than ▁6 ▁weeks ▁of ▁age ▁ .
▁ cyclo spor in ▁and ▁tac rol imus ▁( ▁medicine s ▁which ▁sup press ▁the ▁immun e ▁system ▁) ▁may ▁be ▁affected ▁by ▁the ▁number ▁of ▁red ▁cell s ▁in ▁your ▁blood ▁ .
▁au c ▁1. 26 ▁( ▁0 . 97 ▁ , ▁1. 64 ▁)
▁no ▁accumula tion ▁of ▁h gh ▁following ▁multiple ▁dos ing ▁of ▁this ▁medicinal ▁product ▁has ▁been ▁observe d ▁ .
▁very ▁common ▁: ▁inject ion ▁site ▁pain ▁ , ▁inject ion ▁site ▁red ness ▁ , ▁muscle ▁pain ▁un com mon ▁: ▁influenza ▁like ▁illness
▁safety ▁and ▁ef fica cy ▁of ▁fa bly n ▁have ▁not ▁been ▁evaluat ed ▁in ▁patients ▁with ▁severe ▁renal ▁insu ffi cie ncy ▁; ▁therefore ▁ , ▁fa bly n ▁should ▁be ▁used ▁with ▁cau tion ▁in ▁these ▁patients ▁( ▁see ▁section ▁4.2 ▁and ▁section ▁5.2 ▁) ▁ .
▁always ▁use ▁new ▁ , ▁un open ed ▁need les ▁and ▁sy ring es ▁ .
▁body ▁weight ▁( ▁kg ▁) ▁base line ▁→ ▁end ▁of ▁trial ▁mean ▁change ▁estima ted ▁difference
▁an ▁increased ▁risk ▁of ▁bone ▁fra c ture ▁has ▁been ob serve d ▁in ▁patients ▁taking ▁this ▁type ▁of ▁medicine s ▁ .
▁detailed ▁description ▁of ▁the ▁recon stitu tion ▁and ▁preparation ▁procedure s ▁of ▁bli ncy to ▁in fusion ▁solution ▁for ▁intra ven ous ▁administration ▁under ▁a se ptic ▁conditions ▁ , ▁using ▁a se ptic ▁techniques ▁ .
▁the ▁other ▁ingredients ▁are ▁man ni tol ▁( ▁e 4 21 ▁) ▁ , ▁micro c ry stal line ▁cell ul ose ▁ , ▁car mel lose ▁calci um ▁ , ▁su cra lose ▁ , ▁magnesium ▁stea rate ▁and ▁collo i dal ▁an hydro us ▁si lica ▁ .
▁if ▁you ▁are ▁allergi c ▁( ▁hyper sensitiv e ▁) ▁to ▁clo pido gre l ▁or ▁any ▁of ▁the ▁other ▁ingredients ▁of ▁this ▁medicine ▁( ▁listed ▁in ▁section ▁6 ▁) ▁ .
▁ma cular ▁oed ema ▁( ▁swe lling ▁in ▁the ▁central ▁vision ▁area ▁of ▁the ▁retin a ▁at ▁the ▁back ▁of ▁the ▁eye ▁) ▁with ▁symptoms ▁such ▁as ▁shadow s ▁or ▁blind ▁spot ▁in ▁the ▁centre ▁of ▁the ▁vision ▁ , ▁blu r red ▁vision ▁ , ▁problems ▁seeing ▁colour s ▁or ▁details
▁consult ▁the ▁summary ▁of ▁product ▁character istic s ▁of ▁ata zana vir ▁or ▁dar una vir ▁for ▁further ▁information ▁on ▁use ▁in ▁combination ▁with ▁these ▁medicinal ▁products ▁ .
▁reaction s ▁at ▁the ▁site ▁of ▁inject ion ▁including ▁peeling ▁of ▁the ▁skin ▁ , ▁skin ▁disco lou ration ▁ , ▁infection ▁ , ▁pain ▁ , ▁skin ▁tight ness ▁ , ▁nu mb ness ▁ , ▁irrita tion ▁or ▁no dul es ▁ , ▁sc ab ▁ , ▁wo und
▁however ▁ , ▁a ▁re duction ▁in ▁blood ▁pressure ▁can ▁occur ▁in ▁individual ▁patients ▁ , ▁leading ▁in ▁rare ▁cases ▁to ▁syn co pe ▁ .
▁total ▁metal s ▁* ▁50 ▁pp m
▁60 ▁x ▁1 ▁film - co ated ▁tablet
▁restriction ▁to ▁open ▁surgery ▁and ▁- ▁if ▁the ▁minimum ▁spray ▁distance ▁of ▁4 ▁cm ▁can ▁be ▁accurate ly ▁judge d ▁- ▁la paro s copy
▁tri zi vir ▁is ▁indicate d ▁for ▁the ▁treatment ▁of ▁human ▁immun o de fici en cy ▁virus ▁( ▁hi v ▁) ▁infection ▁in ▁adults ▁( ▁see ▁section s ▁4.4 ▁and ▁5.1 ▁) ▁ .
▁the ▁primary ▁vaccin ation ▁schedule ▁consist s ▁of ▁three ▁dos es ▁within ▁the ▁first ▁six ▁months ▁of ▁life ▁ .
▁how ▁to ▁store ▁vir a cept
▁two ▁subject s ▁with ▁confirm ed ▁vir ologic ▁re bound ▁developed ▁n n rti ▁resist ance - as soci ated ▁substitut ions ▁to ▁efa vir enz ▁including ▁k 103 n ▁ , ▁v 106 v ▁/ ▁i ▁/ ▁m ▁and ▁y 188 y ▁/ ▁c ▁rever se ▁tran script ase ▁substitut ions ▁at ▁week ▁240 ▁( ▁96 ▁weeks ▁on ▁a trip la ▁) ▁and ▁week ▁204 ▁( ▁60 ▁weeks ▁on ▁a trip la ▁) ▁ .
▁experts ▁in ▁ liver ▁disease ▁should ▁be ▁consulte d ▁before ▁treatment ▁is ▁initiat ed ▁in ▁patients ▁with ▁positive ▁hepatitis ▁b ▁ser ology ▁( ▁including ▁those ▁with ▁active ▁disease ▁) ▁ .
▁follow ▁the ▁instructions ▁below ▁carefully ▁to ▁ensure ▁proper ▁recon stitu tion ▁of ▁signifo r ▁powder ▁and ▁solve nt ▁for ▁suspens ion ▁for ▁inject ion ▁before ▁deep ▁intra mus cular ▁inject ion ▁ .
▁three ▁grade ▁ ≥ ▁3 ▁events ▁ , ▁including ▁one ▁fatal ▁ , ▁have ▁been ▁reported ▁across ▁the ▁clinic al ▁development ▁programme ▁of ▁olar atum ab ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁second ▁or ▁third ▁degree ▁at rio ven tri cular ▁( ▁av ▁) ▁block ▁ .
▁tabula ted ▁list ▁of ▁advers e ▁reaction s ▁in ▁breast ▁cancer ▁for ▁taxe spira ▁100 ▁mg ▁/ ▁m ▁2 ▁single ▁agent
▁medicinal ▁product ▁subject ▁to ▁restrict ed ▁medical ▁pre scription ▁( ▁see ▁ann ex ▁i ▁: ▁summary ▁of ▁product ▁character istic s ▁ , ▁section ▁4.2 ▁) ▁ .
▁put ▁the ▁original ▁package ▁with ▁any ▁un used ▁pre - fill ed ▁sy ring es ▁back ▁in ▁the ▁refrigera tor ▁ .
▁bon vi va ▁should ▁not ▁be ▁used ▁during ▁pre gna ncy ▁ .
▁ab se a med ▁is ▁presente d ▁as ▁a ▁clear ▁ , ▁colour less ▁solution ▁for ▁inject ion ▁in ▁a ▁pre - fill ed ▁sy ringe ▁ .
▁the ▁most ▁common ▁advers e ▁reaction s ▁were ▁mild ▁to ▁moderat e ▁na use a ▁ , ▁di zzi ness ▁ , ▁and ▁head ache ▁ .
▁the ▁highest ▁incide nce ▁of ▁advers e ▁reaction s ▁associated ▁with ▁re bi f ▁ therapy ▁is ▁related ▁to ▁flu - like ▁syndrome ▁ .
▁at ▁least ▁14 ▁days ▁old ▁and ▁< ▁30 ▁kg
▁do ▁not ▁use ▁ava mys ▁if ▁you ▁are ▁breast ▁feed ing ▁unless ▁your ▁doctor ▁or ▁ pharma ci st ▁tell s ▁you ▁to ▁ .
▁amb er ▁glass ▁bottle s ▁with ▁plastic ▁screw ▁cap ▁contain ing ▁270 ▁capsule s ▁of ▁in vira se ▁ .
▁the ▁european ▁medicine s ▁agency ▁has ▁de fer red ▁the ▁obliga tion ▁to ▁submit ▁the ▁results ▁of ▁studies ▁with ▁sir tur o ▁in ▁one ▁or ▁more ▁sub set s ▁of ▁the ▁pa e dia tric ▁population ▁in ▁the ▁treatment ▁of ▁multi - drug ▁resist ant ▁my coba cter ium ▁tubercul osis ▁( ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁) ▁ .
▁of ▁the ▁126 ▁patients ▁ , ▁96 ▁received ▁the ▁recommended ▁dose ▁of ▁is en tress ▁( ▁see ▁section ▁4.2 ▁) ▁ .
▁increase ▁these ▁anti neo plast ic ▁plasma
▁do ▁not ▁stop ▁the ▁in take ▁of ▁pra da xa ▁® ▁without ▁talking ▁to ▁your ▁doctor ▁ .
▁the ▁effects ▁of ▁con com i tant ▁administration ▁of ▁er lo tin ib ▁with ▁h 2 ▁anta gon ists ▁and ▁anta cid s ▁are ▁un know n ▁; ▁however ▁ , ▁reduce d ▁bio ava il ability ▁is ▁likely ▁ .
▁if ▁you ▁have ▁to ▁mix ▁two ▁types ▁of ▁insulin
▁the ▁metabol ic ▁activa tion ▁path way ▁involve s ▁sequenti al ▁hydro lys is ▁of ▁the ▁car box yl ▁este r ▁moi ety ▁cata ly sed ▁by ▁human ▁ca the psi n ▁a ▁or ▁car box yle ster ase ▁1 ▁and ▁ phos phor ami date ▁cle ava ge ▁by ▁his ti dine ▁tri ad ▁nucleo ti de - binding ▁protein ▁1 ▁followed ▁by ▁ phos phor y lation ▁by ▁the ▁py rimi dine ▁nucleo ti de ▁bio syn the sis ▁path way ▁ .
▁anti hi stamine s ▁to ▁treat ▁allergi es ▁( ▁a stem izol ▁ , ▁mi zola stin ▁ , ▁ter fen a din ▁)
▁the ▁key ▁results ▁of ▁the ▁trial ▁are ▁listed ▁in ▁figure ▁1 ▁and ▁table ▁3 ▁ .
▁at ▁dos es ▁which ▁were ▁low ▁enough ▁to ▁maintain ▁ge station ▁in ▁the ▁animal ▁species ▁ , ▁no ▁ter ato ge nic ▁potential ▁was ▁observe d ▁ .
▁the ▁blood ▁pressure ▁lower ing ▁effect ▁of ▁ir besar tan ▁is ▁evident ▁within ▁1-2 ▁weeks ▁ , ▁with ▁the ▁maximal ▁effect ▁occur ring ▁by ▁4-6 ▁weeks ▁after ▁start ▁of ▁ therapy ▁ .
▁brochure ▁for ▁women ▁patients ▁who ▁are ▁not ▁of ▁child be aring ▁potential
▁in ▁the ▁rhe sus ▁mon key ▁ , ▁whole ▁body ▁radi ography ▁following ▁administration ▁of ▁radio label led ▁taso ner min ▁indicate d ▁no ▁specific ▁distribution ▁pattern ▁ .
▁this ▁means ▁that ▁before ▁or encia ▁is ▁given ▁to ▁you ▁ , ▁it ▁is ▁first ▁disso l ved ▁in ▁water ▁for ▁inject ions ▁ , ▁then ▁further ▁dilu ted ▁with ▁so dium ▁chlor ide ▁9 ▁mg ▁/ ▁ml ▁( ▁ 0.9 ▁% ▁) ▁solution ▁for ▁inject ion ▁ .
▁infection s ▁of ▁the ▁upp er ▁respirator y ▁tract
▁these ▁are ▁listed ▁under ▁do ▁not ▁take ▁sus tiva ▁ , ▁at ▁the ▁start ▁of ▁section ▁2 ▁ .
▁antico a gul ants ▁ , ▁used ▁to ▁thi n ▁the ▁blood ▁ , ▁such ▁as ▁:
▁be ▁care ful ▁with ▁the ▁powder ▁ , ▁because ▁it ▁may ▁irrita te ▁your ▁skin ▁and ▁eyes ▁ .
▁met form in ▁ , ▁when ▁met form in ▁alone ▁ , ▁with ▁die t ▁and ▁exercise ▁ , ▁does ▁not ▁provide ▁adequat e ▁gly ca e mic ▁control ▁ .
▁other ▁side ▁effects ▁include ▁( ▁fre que ncy ▁anno t ▁be ▁estima ted ▁from ▁the ▁available ▁data ▁)
▁major ▁ depressiv e ▁disorder ▁: ▁xer ista r ▁was ▁studie d ▁in ▁a ▁clinic al ▁programme ▁in vol ving ▁3 , 158 ▁patients ▁( ▁1,2 85 ▁patient - year s ▁of ▁exposure ▁) ▁meeting ▁d s m - iv ▁criteri a ▁for ▁major ▁depression ▁ .
▁a ▁re duction ▁of ▁the ▁starting ▁dose ▁of ▁i clusi g ▁in ▁patients ▁with ▁he pati c ▁im pair ment ▁is ▁not ▁necessary ▁( ▁see ▁section s ▁4.2 ▁and ▁4.4 ▁) ▁ .
▁the ▁natural ▁history ▁of ▁gauche r ▁disease ▁usually ▁shows ▁progression ▁ , ▁with ▁the ▁risk ▁of ▁irre ver sible ▁complica tions ▁ar ising ▁in ▁various ▁organ s ▁over ▁time ▁ .
▁in ▁the ▁population ▁ pk ▁analysis ▁ , ▁mean ▁se rum ▁clear ance ▁was ▁0.0 161 ▁l ▁/ ▁hr ▁ .
▁fas lo dex ▁and ▁other ▁formula tions ▁of ▁ful vest rant ▁were ▁well ▁to ler ated ▁in ▁animal ▁species ▁used ▁in ▁multiple ▁dose ▁studies ▁ .
▁co - administration ▁of ▁or encia ▁with ▁biologi c ▁immun os up press ive ▁or ▁immun o modul ator y ▁agents ▁could ▁potentia te ▁the ▁effects ▁of ▁a bata cept ▁on ▁the ▁immun e ▁system ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁the ▁incide nce ▁of ▁stroke ▁mortal ity ▁was ▁2.2 ▁per ▁1,000 ▁women ▁per ▁year ▁for ▁ra lo xi fen e ▁versus ▁1.5 ▁per ▁1,000 ▁women ▁per ▁year ▁for ▁place bo ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁if ▁taken ▁together ▁with ▁alcohol ▁or ▁central ▁ner vous ▁system ▁de press ants ▁ , ▁the ▁effect ▁is ▁likely ▁to ▁be ▁more ▁prono un ced ▁( ▁see ▁section s ▁4.4 ▁and ▁4.5 ▁) ▁ .
▁if ▁you ▁vom it ▁less ▁than ▁1 ▁hour ▁after ▁taking ▁gen vo ya ▁ , ▁take ▁another ▁tablet ▁with ▁food ▁ .
▁due ▁to ▁the ▁metabol ic ▁path way ▁of ▁tel bi vu dine ▁ , ▁no ▁clinic ally ▁relevant ▁drug - drug ▁interaction ▁is ▁expected ▁ .
▁skin ▁hyper trop hy ▁ , ▁ rash ▁ , ▁ac ne ▁ , ▁a lo pecia ▁ ,
▁bero mun ▁1 ▁mg ▁/ ▁5 ▁ml ▁powder ▁for ▁in fusion ▁taso ner min
▁how ▁to ▁care ▁for ▁your ▁pen ▁handle ▁your ▁pen ▁with ▁care
▁additional ly ▁ , ▁parti al ▁cy to gene tic ▁response ▁( ▁pc yr ▁) ▁was ▁observe d ▁in ▁16 ▁% ▁for ▁a ▁m cy r ▁of ▁81 ▁% ▁ .
▁each ▁s coop ▁deliver s ▁one ▁gram ▁of ▁granul es ▁which ▁contain s ▁33 ▁mg ▁of ▁te no fo vir ▁di so prox il ▁( ▁as ▁fumar ate ▁) ▁ .
▁vin flu nine ▁is ▁moderat ely ▁ bound ▁to ▁human ▁plasma ▁protein s ▁( ▁6 7.2 ▁ ± ▁1.1 ▁% ▁) ▁with ▁a ▁ratio ▁between ▁plasma ▁and ▁whole ▁blood ▁concentration s ▁of ▁0 . 80 ▁0.1 2 ▁ .
▁in dina vir ▁+ ▁nel fina vir ▁has ▁not
▁the ▁advers e ▁reaction ▁profile ▁seen ▁during ▁pa e dia tric ▁clinic al ▁trial s ▁was ▁similar ▁to ▁that ▁for ▁adults ▁ .
▁what ▁novo thir teen ▁is ▁used ▁for
▁ex cip ient ▁with ▁known ▁effect ▁: ▁each ▁film - co ated ▁tablet ▁contain s ▁189 . 50 ▁mg ▁la ctos e ▁ .
▁anti vir al ▁activity ▁in ▁cell ▁culture
▁date ▁of ▁first ▁author isation ▁: ▁17 ▁april ▁2013
▁non - clin ical ▁data ▁reveal ▁no ▁special ▁hazard s ▁for ▁humans ▁based ▁on ▁convention al ▁studies ▁of ▁safety ▁ pharma c ology ▁and ▁ toxic ology ▁ .
▁beta fer on ▁with ▁food ▁and ▁drink
▁volume ▁( ▁ml ▁) ▁= ▁body ▁weight ▁( ▁kg ▁) ▁x ▁dose ▁( ▁4 ▁mg ▁/ ▁kg ▁for ▁load ing ▁or ▁2 ▁mg ▁/ ▁kg ▁for ▁maintenance ▁)
▁in ▁very ▁rare ▁cases ▁ , ▁serious ▁hyper sensitiv ity ▁reaction s ▁have ▁been ▁observe d ▁which ▁could ▁be ▁fatal ▁ .
▁con com i tant ▁disease s ▁in ▁the ▁ki dne y ▁ , ▁ liver ▁or ▁affect ing ▁the ▁ad ren al ▁ , ▁pit uit ary ▁or ▁thy roid ▁g land ▁can ▁require ▁changes ▁in ▁the ▁insulin ▁dose ▁ .
▁your ▁doctor ▁may ▁therefore ▁have ▁to ▁monitor ▁the ▁condition ▁of ▁your ▁ liver ▁ .
▁mir vas o ▁should ▁not ▁be ▁used ▁in ▁children ▁or ▁adolescents ▁a ged ▁2 ▁to ▁18 ▁years ▁ .
▁in ▁the ▁er t - na ï ve ▁trial ▁ , ▁gala fold ▁result ed ▁in ▁a ▁statistic ally ▁significant ▁decrease ▁in ▁ lv mi ▁( ▁p ▁< ▁0.0 5 ▁) ▁; ▁the ▁mean ▁change ▁from ▁base line ▁in ▁ lv mi ▁at ▁month ▁18 ▁to ▁24 ▁was ▁- 7.7 ▁( ▁95 ▁% ▁ci ▁: ▁ -15 . 4 ▁ , ▁- 0.01 ▁; ▁n ▁= ▁27 ▁) ▁ .
▁test ▁your ▁urin e ▁for ▁keto nes ▁ .
▁completed ▁suicide ▁ , ▁personal ity ▁disorder ▁ , ▁thinking ▁ab normal
▁refer ▁to ▁the ▁summary ▁of ▁product ▁character istic s ▁for ▁ata zana vir ▁for ▁further ▁details ▁ .
▁survival ▁was ▁define d ▁as ▁patients ▁who ▁were ▁ali ve ▁ , ▁not ▁in tuba ted ▁for ▁mechanic al ▁ventilation ▁and ▁tra che oto my - free ▁ .
▁measure ment ▁of ▁stron tium ▁concentration ▁in ▁ili ac ▁cre st ▁bone ▁bio psi es ▁from ▁patients ▁treated ▁for ▁up ▁to ▁60 ▁months ▁with ▁stron tium ▁ra ne late ▁2 ▁g ▁/ ▁day ▁indicate ▁that ▁bone ▁stron tium ▁concentration s ▁may ▁reach ▁a ▁plate au ▁after ▁about ▁3 ▁years ▁of ▁treatment ▁ .
▁night time ▁sleep ▁on ▁25 ▁% ▁most ▁symptom a tic ▁night s ▁( ▁minutes ▁) ▁( ▁3 ▁)
▁paa ▁ , ▁the ▁active ▁metabol ite ▁of ▁gly cer ol ▁ phen yl but y rate ▁ , ▁is ▁associated ▁with ▁sign s ▁and ▁symptoms ▁of ▁neuro toxic ity ▁( ▁see ▁section ▁4.4 ▁) ▁and ▁could ▁accumula te ▁in ▁patients ▁who ▁receive ▁an ▁over dos e ▁ .
▁ex cre tion ▁data ▁from ▁the ▁14 c ▁study ▁indicate d ▁that ▁at ▁least ▁about ▁82 ▁to ▁95 ▁% ▁of ▁the ▁dose ▁is ▁absorb ed ▁ .
▁the ▁capsule s ▁must ▁not ▁be ▁opened ▁due ▁to ▁risk ▁of ▁ter ato geni city ▁( ▁see ▁section ▁5.3 ▁) ▁ .
▁table ▁3 ▁shows ▁the ▁ef fica cy ▁results ▁for ▁fast -3 ▁ .
▁each ▁bottle ▁contain s ▁3 1.5 ▁mg ▁of ▁ propyl hydro xy ben zo ate ▁( ▁e 2 16 ▁) ▁each ▁bottle ▁contain s ▁315 ▁mg ▁of ▁met hyl hydro xy ben zo ate ▁( ▁e 2 18 ▁) ▁each ▁bottle ▁contain s ▁10. 15 ▁g ▁of ▁suc rose
▁residu al ▁activity ▁in ▁the ▁mid s agit tal ▁sinus ▁can ▁be ▁sometimes ▁observe d ▁likely ▁due ▁to ▁the ▁presence ▁of ▁tra cer ▁in ▁the ▁blood ▁pool ▁ .
▁1 ▁vi al ▁of ▁suspens ion ▁+ ▁1 ▁vi al ▁of ▁em ul sion ▁correspond ing ▁to ▁10 ▁ml ▁of ▁recon stitu ted ▁product ▁ .
▁please ▁talk ▁to ▁your ▁doctor ▁since ▁blood ▁clo ts ▁can ▁lead ▁to ▁heart ▁attack ▁and ▁stroke ▁ .
▁elimina tion ▁: ▁ade fo vir ▁is ▁ex cre ted ▁renal ly ▁by ▁a ▁combination ▁of ▁glo mer ular ▁filtr ation ▁and ▁active ▁tub ular ▁secret ion ▁ .
▁of ▁the ▁other ▁4 ▁cases ▁ , ▁detailed ▁information ▁was ▁missing ▁ .
▁nep hro tic ▁syndrome ▁( ▁see ▁section ▁4.4 ▁) ▁; ▁focal ▁segment al ▁glo mer ulo - ▁sc ler osis ▁*
▁following ▁corona ry ▁arter y ▁by pass ▁graf t ▁surgery ▁ , ▁patients ▁ad minister ed ▁dyna stat ▁have ▁a ▁higher ▁risk ▁of ▁advers e ▁reaction s ▁such ▁as ▁: ▁cardiovascular ▁/ ▁ thro mbo e mbol ic ▁events ▁( ▁including ▁my o card ial ▁in far ction ▁ , ▁stroke ▁/ ▁tia ▁ , ▁pulmonar y ▁embo lus ▁ , ▁and ▁deep ▁ve in ▁ thro mbo sis ▁; ▁see ▁section s ▁4.3 ▁and ▁5.1 ▁) ▁ , ▁deep ▁sur g ical ▁infection s ▁ , ▁and ▁ster nal ▁wo und ▁hea ling ▁complica tions ▁ .
▁rasi lez ▁may ▁be ▁used ▁alone ▁or ▁in ▁combination ▁with ▁other ▁anti hy per tensi ve ▁agents ▁with ▁the ▁exception ▁of ▁use ▁in ▁combination ▁with ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁( ▁ac ei ▁) ▁or ▁ang io ten sin ▁i i ▁receptor ▁block ers ▁( ▁ar b ▁) ▁in ▁patients ▁with ▁diabetes ▁mell itus ▁or ▁renal ▁im pair ment ▁( ▁glo mer ular ▁filtr ation ▁rate ▁( ▁g fr ▁) ▁< ▁60 ▁ml ▁/ ▁min ▁/ ▁1. 73 ▁m 2 ▁) ▁( ▁see ▁section s ▁4.3 ▁ , ▁4.4 ▁and ▁5.1 ▁) ▁ .
▁there ▁were ▁no ▁significant ▁ pharma cok ine tic ▁interaction s ▁between ▁baze do xi fen e ▁and ▁the ▁following ▁medicinal ▁products ▁: ▁ibu profe n ▁ , ▁ ator vasta tin ▁ , ▁azi thro my cin ▁ , ▁or ▁an ▁anta cid ▁contain ing ▁aluminium ▁and ▁magnesium ▁hydro xi de ▁ .
▁in ▁clinic al ▁trial s ▁in vol ving ▁ 481 ▁patients ▁ , ▁no ▁patients ▁have ▁developed ▁anti bo dies ▁to ▁thy ro trop in ▁alfa ▁either ▁after ▁single ▁or ▁repeat ed ▁limited ▁( ▁27 ▁patients ▁) ▁use ▁of ▁the ▁product ▁ .
▁c max ▁1. 11 ▁( ▁0 . 99 ▁ , ▁1. 26 ▁)
▁keep ▁the ▁bli ster ▁in ▁the ▁out er ▁carton ▁ .
▁advers e ▁reaction s ▁are ▁listed ▁below ▁by ▁system ▁organ ▁class ▁and ▁fre que ncy ▁group ing ▁ .
▁in ▁patients ▁with ▁severe ▁he pati c ▁im pair ment ▁the ▁benefits ▁and ▁risk s ▁of ▁treatment ▁with ▁jina rc ▁must ▁be ▁evaluat ed ▁carefully ▁ .
▁upp er ▁respirator y ▁tract ▁infection s ▁ , ▁sore ▁ thro at ▁or ▁ho arse ness ▁ , ▁run ny ▁nos e
▁dose ▁or ▁dose ▁interval ▁adjust ment ▁is ▁required ▁in ▁all ▁patients ▁with ▁creati nine ▁clear ance ▁< ▁30 ▁ml ▁/ ▁min ▁( ▁see ▁section s ▁4.2 ▁ , ▁4.4 ▁and ▁5.2 ▁) ▁ .
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁zone gran
▁tap ▁the ▁sy ringe ▁gent ly ▁to ▁bring ▁any ▁bu bble s ▁to ▁the ▁top ▁ .
▁che st ▁symptoms ▁such ▁as ▁a ▁dry ▁co ugh ▁or ▁breath less ness ▁( ▁possible ▁sign s ▁of ▁inter stiti al ▁lung ▁disease ▁ , ▁a ▁condition ▁of ▁damage ▁to ▁the ▁tissu es ▁around ▁the ▁air ▁sac s ▁in ▁the ▁lung s ▁)
▁if ▁you ▁have ▁a ▁history ▁of ▁ab normal ▁heart ▁ rhythm s ▁( ▁ar rhythm ias ▁) ▁if ▁you ▁are ▁taking ▁other ▁medicine s ▁that ▁may ▁affect ▁your ▁heart ▁( ▁see ▁section ▁2 ▁other ▁medicine s ▁and ▁fare ston ▁) ▁ .
▁please ▁talk ▁to ▁your ▁doctor ▁as ▁soon ▁as ▁you ▁real ise ▁that ▁you ▁for got ▁a ▁dose ▁ .
▁the ▁need le - shield ▁may ▁not ▁have ▁lock ed ▁ .
▁take ▁your ▁third ▁dose ▁in ▁the ▁evening ▁ .
▁2 ▁mg ▁capsule ▁ shell ▁contain s ▁gelatin ▁ , ▁titan ium ▁ dioxid e ▁( ▁e 171 ▁) ▁ , ▁indi go tine ▁( ▁e 132 ▁) ▁ , ▁yellow ▁ir on ▁oxid e ▁( ▁e 172 ▁) ▁ , ▁er y thro sin ▁( ▁e 127 ▁) ▁and ▁white ▁in k ▁ .
▁if ▁you ▁have ▁ever ▁had ▁ liver ▁problems ▁ .
▁inhibi tion ▁of ▁the ▁key ▁contribu tors ▁of ▁in da cate rol ▁clear ance ▁ , ▁cy p 3 a 4 ▁and ▁p - gly co prote in ▁( ▁p - gp ▁) ▁raise s ▁the ▁system ic ▁exposure ▁of ▁in da cate rol ▁by ▁up ▁to ▁two - fold ▁ .
▁in ▁these ▁studies ▁ , ▁no ▁clinic ally ▁relevant ▁ pharma cok ine tic ▁interaction s ▁were ▁observe d ▁after ▁co - administration ▁with ▁vil dag lip tin ▁ .
▁the ▁natural ly ▁occur ring ▁ phos pho lip ids ▁in ▁lumin ity ▁( ▁see ▁section ▁6.1 ▁) ▁are ▁distribu ted ▁in ▁the ▁end ogen ous ▁lipid ▁pool s ▁in ▁the ▁body ▁( ▁for ▁example ▁ , ▁ liver ▁) ▁where as ▁the ▁synth e tic ▁component ▁( ▁mp eg 5000 ▁) ▁has ▁been ▁shown ▁to ▁be ▁ex cre ted ▁in ▁the ▁urin e ▁in ▁pre clin ical ▁studies ▁ .
▁dermatit is ▁ex folia tive ▁ , ▁a lo pecia ▁ , ▁ rash ▁ma culo - pap ular ▁ , ▁pru ritu s ▁ , ▁er y thema
▁5 ▁pre - fill ed ▁sy ring es ▁of ▁1 ▁ml ▁solve nt ▁ .
▁is avu con a zole ▁is ▁a ▁mild ▁inhibi tor ▁of ▁the ▁organic ▁ cation ▁transporter ▁2 ▁( ▁o ct 2 ▁) ▁ .
▁the ▁reported ▁advers e ▁events ▁following ▁the ▁use ▁of ▁opt ison ▁in ▁phase ▁i ii ▁human ▁clinic al ▁studies ▁have ▁been ▁mild ▁to ▁moderat e ▁with ▁subsequent ▁full ▁recovery ▁ .
▁decrease d ▁libido ▁in ▁male s ▁and ▁female s
▁then ▁carry ▁on ▁taking ▁your ▁capsule s ▁at ▁regular ▁times ▁as ▁usual ▁ .
▁how ▁to ▁ad minister ▁the ▁dilu ted ▁solution
▁you ▁have ▁poor ▁dental ▁health ▁ , ▁gum ▁disease ▁ , ▁a ▁planned ▁dental ▁extra ction ▁or ▁you ▁don ▁' t ▁receive ▁routine ▁dental ▁care ▁ ,
▁limited ▁data ▁are ▁available ▁on ▁use ▁in ▁patients ▁a ged ▁ ≥ ▁75 ▁years ▁( ▁see ▁also ▁section ▁4. 8 ▁ , ▁other ▁special ▁population s ▁) ▁ .
▁ phos pho lip idos is ▁was ▁seen ▁main ly ▁in ▁the ▁lung s ▁in ▁rod ents ▁( ▁at ▁exposure s ▁similar ▁to ▁humans ▁) ▁and ▁mon key s ▁( ▁at ▁exposure s ▁greater ▁than ▁12 ▁ fold ▁higher ▁than ▁human ▁) ▁ .
▁how ▁often ▁zo le dro nic ▁acid ▁med ac ▁is ▁given
▁an ▁increased ▁rate ▁of ▁fatal ▁events ▁was ▁observe d ▁in ▁patients ▁with ▁moderat e ▁and ▁severe ▁he pati c ▁im pair ment ▁ .
▁please ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁ .
▁tablet ▁coa ting ▁: ▁la ctos e ▁mono hydrat e ▁( ▁milk ▁sugar ▁) ▁ , ▁hy pro mel lose ▁( ▁e 464 ▁) ▁ , ▁tri ace tin ▁( ▁e 15 18 ▁) ▁ , ▁red ▁ir on ▁oxid e ▁( ▁e 172 ▁) ▁and ▁titan ium ▁ dioxid e ▁( ▁e 171 ▁) ▁ ,
▁pra mi pe xo le ▁may ▁be ▁associated ▁with ▁libido ▁disorder s ▁( ▁increased ▁or ▁decrease d ▁) ▁ .
▁non - clin ical ▁data ▁reveal ▁no ▁special ▁hazard ▁for ▁humans ▁based ▁on ▁convention al ▁studies ▁of ▁safety ▁ pharma c ology ▁ , ▁repeat ed ▁dose ▁ toxic ity ▁ , ▁geno toxic ity ▁and ▁car cino ge nic ▁potential ▁ .
▁percent ▁re duction ▁rate ▁ratio ▁( ▁95 ▁% ▁ci ▁)
▁in ▁a ▁pre - ▁and ▁post na tal ▁development al ▁study ▁in ▁rat s ▁ , ▁sax ag lip tin ▁caused ▁decrease d ▁pup ▁weight ▁at ▁matern ally ▁ toxic ▁dos es ▁ , ▁with ▁no el ▁ 488 ▁and ▁45 ▁times ▁the ▁human ▁exposure ▁for ▁sax ag lip tin ▁and ▁the ▁major ▁metabol ite ▁ , ▁respective ly ▁at ▁r hd ▁ .
▁no ▁response ▁at ▁treatment ▁week
▁xi ap ex ▁is ▁given ▁as ▁part ▁of ▁a ▁treatment ▁cycle ▁ .
▁because ▁of ▁the ▁risk ▁of ▁allergi c ▁reaction s ▁with ▁factor ▁ ix ▁ , ▁your ▁initial ▁administration s ▁of ▁bene fix ▁should ▁be ▁perform ed ▁under ▁medical ▁observation ▁where ▁proper ▁medical ▁care ▁for ▁allergi c ▁reaction s ▁can ▁be ▁provided ▁ .
▁dis continu ation ▁of ▁treatment ▁with ▁ben ly sta ▁should ▁be ▁considered ▁if ▁there ▁is ▁no ▁improvement ▁in ▁disease ▁control ▁after ▁6 ▁months ▁of ▁treatment ▁ .
▁any ▁un used ▁solution ▁should ▁be ▁disc ard ed ▁ .
▁patients ▁with ▁a ▁recent ▁history ▁of ▁lung ▁infiltra tes ▁or ▁pneu monia ▁may ▁be ▁at ▁higher ▁risk ▁ .
▁dar una vir ▁exposure ▁( ▁and ▁also ▁rito na vir ▁exposure ▁) ▁may ▁increase ▁on ▁stop ping ▁st ▁joh n ▁' s ▁ wort ▁ .
▁in ▁a ▁clinic al ▁drug ▁interaction ▁study ▁ , ▁c max ▁and ▁au c ▁of ▁oral ▁mida zola m ▁( ▁a ▁cy p 3 a 4 ▁substrat e ▁) ▁decrease d ▁by ▁61 ▁% ▁and ▁74 ▁% ▁ , ▁respective ly ▁with ▁co - administration ▁of ▁repeat - dos e ▁da bra fen ib ▁using ▁a ▁formula tion ▁with ▁lower ▁bio ava il ability ▁than ▁da bra fen ib ▁formula tion ▁ .
▁the ▁use ▁of ▁the ▁product ▁should ▁be ▁based ▁on ▁the ▁confirm ed ▁ diagnos is ▁of ▁mix ed ▁infection ▁( ▁or ▁risk ▁of ▁infection ▁ , ▁where ▁pre vention ▁app lies ▁) ▁at ▁the ▁same ▁time ▁( ▁see ▁also ▁section s ▁4 ▁and ▁8 ▁) ▁ .
▁a erius ▁oral ▁solution ▁ , ▁is ▁suppli ed ▁in ▁30 ▁ , ▁50 ▁ , ▁60 ▁ , ▁100 ▁ , ▁120 ▁ , ▁150 ▁ , ▁225 ▁and ▁300 ▁ml ▁size ▁type ▁i ii ▁amb er ▁glass ▁bottle s ▁closed ▁with ▁a ▁plastic ▁child ▁resist ant ▁( ▁c ▁/ ▁r ▁) ▁screw ▁ closure ▁having ▁a ▁multi - ply ▁poly e thy lene - ▁face d ▁ liner ▁ .
▁avoid ▁shak ing ▁and ▁je tting ▁so dium ▁chlor ide ▁9 ▁mg ▁/ ▁ml ▁( ▁ 0.9 ▁% ▁) ▁solution ▁for ▁inject ion ▁into ▁the ▁vi al ▁ .
▁in ▁addition ▁to ▁the ▁advers e ▁reaction s ▁seen ▁with ▁lumi gan ▁0.3 ▁mg ▁/ ▁ml ▁single - dos e ▁ , ▁table ▁3 ▁list s ▁additional ▁advers e ▁reaction s ▁that ▁were ▁seen ▁with ▁lumi gan ▁0.3 ▁mg ▁/ ▁ml ▁( ▁multi - dos e ▁formula tion ▁) ▁ .
▁in ▁healthy ▁subject s ▁ , ▁bo sent an ▁display s ▁dose - ▁and ▁time - dependent ▁ pharma cok ine tics ▁ .
▁administration ▁with ▁food ▁( ▁a ▁high - fat ▁meal ▁) ▁result ed ▁in ▁no ▁change ▁in ▁sax ag lip tin ▁c max ▁and ▁a ▁27 ▁% ▁increase ▁in ▁au c ▁compared ▁with ▁the ▁fast ed ▁state ▁ .
▁c max ▁↑ ▁1. 46 ▁( ▁1. 38 -1 . 56 ▁)
▁in ▁patients ▁with ▁severe ▁renal ▁im pair ment ▁( ▁creati nine ▁clear ance ▁< ▁30 ▁ml ▁/ ▁min ▁) ▁a ▁starting ▁dose ▁of ▁viva nza ▁5 ▁mg ▁film - co ated ▁tablets ▁should ▁be ▁considered ▁ .
▁renal ▁function ▁ , ▁as ▁measure d ▁by ▁media n ▁eg fr ▁ , ▁increased ▁during ▁soli ris ▁ therapy ▁ .
▁overall ▁ , ▁7 33 ▁patients ▁were ▁treated ▁with ▁oma liz um ab ▁for ▁up ▁to ▁12 ▁weeks ▁and ▁ 490 ▁patients ▁for ▁up ▁to ▁24 ▁weeks ▁ .
▁co - administration ▁of ▁te no fo vir ▁di so prox il ▁fumar ate ▁with ▁co bici stat ▁is ▁expected ▁to ▁increase ▁te no fo vir ▁plasma ▁concentration ▁ .
▁what ▁sil ody x ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁ir on ▁oxid e ▁yellow ▁ir on ▁oxid e ▁black
▁he xa cima ▁in ▁vi als ▁eu ▁/ ▁1 ▁/ ▁13 ▁/ ▁ 828 ▁/ ▁ 001
▁these ▁changes ▁are ▁not ▁associated ▁with ▁im pair ed ▁neutro phil ▁function ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁vi al ▁ , ▁the ▁card board ▁box ▁and ▁the ▁carton ▁after ▁exp ▁ .
▁the ▁sul cal ▁and ▁gy ral ▁pattern ▁is ▁not ▁discern ible ▁in ▁the ▁positive ▁images ▁on ▁the ▁right ▁ .
▁tram etin ib ▁in ▁combination ▁with ▁da bra fen ib ▁in ▁patients ▁with ▁brain ▁metas tas es
▁muscular ▁we ak ness ▁( ▁my as th enia ▁gravi s ▁) ▁tell ▁your ▁doctor ▁before ▁you ▁have ▁an ▁operation ▁that ▁you ▁are ▁using ▁az ar ga ▁as ▁ timo lol ▁may ▁change ▁effects ▁of ▁some ▁medicine s ▁used ▁during ▁ana es the sia . ▁if ▁you ▁have ▁a ▁history ▁of ▁ato py ▁( ▁a ▁tende ncy ▁to ▁develop ▁an ▁allergi c ▁reaction ▁) ▁and ▁severe ▁allergi c ▁reaction s ▁you ▁may ▁be ▁more ▁sensitive ▁to ▁developing ▁an ▁allergi c ▁reaction ▁whilst ▁using ▁az ar ga ▁and ▁adrenalin e ▁may ▁not ▁be ▁as ▁effective ▁to ▁treat ▁an ▁allergi c ▁reaction ▁ .
▁stiri pen tol ▁should ▁not ▁be ▁taken ▁with ▁milk ▁or ▁dair y ▁products ▁( ▁yoghurt ▁ , ▁soft ▁cream ▁cheese ▁ , ▁etc ▁ . ▁) ▁ , ▁carbon ated ▁drink s ▁ , ▁fruit ▁juice ▁or ▁food ▁and ▁drink s ▁that ▁contain ▁ca ffe ine ▁or ▁the op hyl line ▁ .
▁if ▁you ▁are ▁not ▁sure ▁ , ▁talk ▁to ▁your ▁doctor ▁or ▁ pharma ci st ▁before ▁taking ▁oly sio ▁ .
▁the ▁other ▁ingredients ▁are ▁micro c ry stal line ▁cell ul ose ▁( ▁e 460 ▁) ▁ , ▁la ctos e ▁an hydro us ▁( ▁see ▁section ▁2 ▁) ▁ , ▁medium ▁chain ▁tri gly ceri des ▁ , ▁gelatin ▁ , ▁cro scar mel lose ▁so dium ▁ , ▁suc rose ▁( ▁see ▁section ▁2 ▁) ▁ , ▁collo i dal ▁si li con ▁ dioxid e ▁ , ▁magnesium ▁stea rate ▁( ▁e 572 ▁) ▁ , ▁but yl hydro xy to lu ene ▁( ▁e 321 ▁) ▁ , ▁modifi ed ▁star ch ▁( ▁mai ze ▁) ▁ , ▁and ▁so dium ▁aluminium ▁si lica te ▁( ▁e 554 ▁) ▁ .
▁therefore ▁ , ▁the ▁mah ▁' s ▁proposal ▁to ▁include ▁this ▁ad r ▁in ▁the ▁product ▁information ▁is ▁en dors ed ▁ .
▁you ▁should ▁monitor ▁their ▁test ▁results ▁and ▁remain ▁vigila nt ▁for ▁symptoms ▁of ▁advers e ▁events ▁ .
▁as ▁a ▁consequ ence ▁ , ▁there ▁is ▁no ▁fol li cular ▁fol lic le ▁growth ▁( ▁hen ce ▁no ▁o est rus ▁is ▁observe d ▁) ▁and ▁no ▁ovu lation ▁ .
▁content s ▁of ▁the ▁pack ▁and ▁other ▁information ▁what ▁ac trap hane ▁30 ▁contain s
▁decrease ▁of ▁blood ▁pressure ▁ , ▁brain ▁oed ema ▁( ▁brain ▁swe lling ▁) ▁ .
▁there ▁is ▁no ▁specific ▁anti do te ▁for ▁over dos e ▁with ▁lo pina vir ▁/ ▁rito na vir ▁ .
▁how ▁to ▁store ▁de fit elio ▁ .
▁the ▁product ▁information ▁( ▁section s ▁4.4 ▁and ▁4. 8 ▁of ▁the ▁sm pc ▁) ▁provides ▁already ▁information ▁on ▁clinic al ▁trial ▁results ▁in ▁which ▁showed ▁an ▁increased ▁fra c ture ▁risk ▁in ▁women ▁only ▁ .
▁lo pina vir ▁/ ▁rito na vir ▁tablets ▁/ ▁efa vir enz ▁( ▁400 ▁/ ▁100 ▁mg ▁b . i . d . ▁/ ▁600 ▁mg ▁q . d . ▁)
▁multiple ▁fo e tal ▁soft ▁tissu e ▁and ▁skelet al ▁altera tions ▁were ▁also ▁observe d ▁at ▁matern al ▁non toxic ▁dos ages ▁ .
▁as ▁dose ▁adjust ments ▁of ▁la mi vu dine ▁and ▁zid ovu dine ▁may ▁be ▁necessary ▁it ▁is ▁recommended ▁that ▁separate ▁preparation s ▁of ▁a baca vir ▁ , ▁la mi vu dine ▁and ▁zid ovu dine ▁be ▁ad minister ed ▁to ▁patients ▁with ▁reduce d ▁renal ▁function ▁( ▁creati nine ▁clear ance ▁50 ▁ml ▁/ ▁min ▁) ▁ .
▁ ator vasta tin ▁is ▁less ▁dependent ▁on ▁cy p 3 a 4 ▁for ▁metabolism ▁than ▁lo vasta tin ▁or ▁sim vasta tin
▁serious ▁advers e ▁reaction s ▁have ▁been ▁reported ▁with ▁the ▁con com i tant ▁use ▁of ▁s s ris ▁ , ▁s n ris ▁ , ▁tri cycli c ▁/ ▁te tra cycli c ▁anti de press ants ▁and ▁ma o ▁inhibi tors ▁ .
▁tell ▁your ▁doctor ▁before ▁using ▁kad cy la ▁if ▁you ▁are ▁pregnant ▁ , ▁think ▁you ▁may ▁be ▁pregnant ▁or ▁are ▁planning ▁to ▁have ▁a ▁baby ▁ .
▁for ▁patients ▁receiving ▁a ▁total ▁of ▁48 ▁weeks ▁of ▁treatment ▁ , ▁pe g inter fer on ▁alfa ▁and ▁riba vir in ▁should ▁be ▁dis continu ed ▁if ▁h c v ▁ rna ▁is ▁detect able ▁at ▁week ▁24 ▁or ▁week ▁36 ▁ .
▁currently ▁available ▁data ▁are ▁described ▁in ▁section ▁5.1 ▁and ▁5.2 ▁but ▁no ▁recommend ation ▁on ▁a ▁pos ology ▁can ▁be ▁made ▁ .
▁treatment ▁of ▁pig let s ▁with ▁meta cam ▁before ▁castra tion ▁reduce s ▁post - operativ e ▁pain ▁ .
▁a ▁comparativ e ▁study ▁between ▁the ▁free zed ried ▁and ▁the ▁liquid ▁formula tion ▁showed ▁bio e qui val ence ▁between ▁the ▁two ▁formula tions ▁ .
▁if ▁you ▁suffer ▁from ▁a ▁condition ▁called ▁" ▁or tho static ▁hypo tension ▁" ▁( ▁a ▁drop ▁in ▁blood ▁pressure ▁on ▁standing ▁up ▁from ▁a ▁sitting ▁or ▁ly ing ▁position ▁result ing ▁in ▁di zzi ness ▁or ▁fa int ness ▁) ▁your ▁condition ▁may ▁worse n ▁if ▁you ▁take ▁tel mis ar tan ▁teva ▁ pharma ▁in ▁combination ▁with ▁:
▁benign ▁cyst s ▁a ▁severe ▁rever sible ▁brain ▁condition ▁which ▁includes ▁se iz ures ▁ , ▁high ▁blood ▁pressure ▁ , ▁head ach es ▁ , ▁tired ness ▁ , ▁confusion ▁ , ▁blind ness ▁or ▁other ▁vision ▁problems ▁ .
▁for ▁dog s ▁we igh ing ▁more ▁than ▁4 ▁kg ▁a ▁sy ringe ▁with ▁0.5 ▁ml ▁gradu ations ▁can ▁be ▁used ▁ .
▁skin ▁allergi es ▁such ▁as ▁ rash ▁with ▁or ▁without ▁pale ness ▁ , ▁red ness ▁ , ▁patch es ▁ , ▁severe ▁it ching ▁; ▁and ▁skin ▁er up tions ▁such ▁as ▁wel ts ▁or ▁hi ves ▁have ▁also ▁been ▁reported ▁after ▁receiving ▁neuro blo c ▁ .
▁do ▁not ▁free ze ▁the ▁solution ▁ , ▁and ▁do ▁not ▁wait ▁longer ▁than ▁3 ▁hours ▁to ▁inject ▁it ▁ .
▁what ▁luce ntis ▁is ▁and ▁what ▁it ▁is ▁used ▁for ▁what ▁luce ntis ▁is
▁one ▁serious ▁incident ▁of ▁sub a cute ▁ thro mbo sis ▁was ▁reported ▁in ▁early ▁studies ▁ , ▁but ▁no ▁serious ▁cardiac ▁events ▁were ▁associated ▁with ▁mi fa mur ti de ▁in ▁a ▁large ▁random ised ▁control led ▁study ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁follow ▁up ▁period ▁for ▁a ▁maximum ▁of ▁40 ▁months ▁from ▁2 ▁weeks ▁after ▁third ▁primary ▁dose
▁therefore ▁ , ▁cau tion ▁should ▁be ▁made ▁when ▁ad minister ing ▁higher ▁dos es ▁of ▁ nsa ids ▁or ▁a ce tyl sali cy lic ▁acid ▁ , ▁concurrent ly ▁with ▁pe metre x ed ▁to ▁patients ▁with ▁normal ▁function ▁( ▁creati nine ▁clear ance ▁> ▁80 ▁ml ▁/ ▁min ▁) ▁ .
▁im lyg ic ▁is ▁not ▁recommended ▁for ▁children ▁and ▁adolescents ▁since ▁the ▁effects ▁of ▁im lyg ic ▁in ▁people ▁young er ▁than ▁18 ▁years ▁old ▁are ▁not ▁known ▁ .
▁you ▁can ▁di al ▁your ▁dose ▁one ▁unit ▁at ▁a ▁time ▁ .
▁these ▁can ▁be ▁symptoms ▁of ▁neuro le ptic ▁malign ant ▁syndrome ▁( ▁n ms ▁ , ▁a ▁rare ▁severe ▁reaction ▁to ▁medicine s ▁used ▁to ▁treat ▁disorder s ▁of ▁the ▁central ▁ner vous ▁system ▁) ▁or ▁r hab dom yo lisi s ▁( ▁a ▁rare ▁severe ▁muscle ▁disorder ▁)
▁tell ▁your ▁doctor ▁before ▁you ▁are ▁given ▁nu cala ▁ .
▁not ▁known ▁: ▁hepatitis ▁ , ▁ab normal ▁ liver ▁function
▁if ▁a ▁significant ▁in fusion ▁reaction ▁occur s ▁ , ▁the ▁in fusion ▁should ▁be ▁slow ed ▁down ▁or ▁interrupt ed ▁and ▁appropriate ▁medical ▁ therapie s ▁should ▁be ▁ad minister ed ▁ .
▁fast ▁or ▁irregular ▁heart beat s ▁ , ▁fe ver ▁with ▁increased ▁risk ▁of ▁infection ▁ , ▁lower ing ▁of ▁red ▁blood ▁cell s ▁ .
▁a 77 17 26 ▁dis place d ▁ibu profe n ▁ , ▁di clo fen ac ▁and ▁tol but ami de ▁but ▁the ▁un bound ▁ fraction ▁of ▁these ▁drugs ▁is ▁only ▁increased ▁by ▁10 ▁% ▁to ▁50 ▁% ▁ .
▁within ▁each ▁fre que ncy ▁group ing ▁ , ▁unde sir able ▁effects ▁are ▁presente d ▁in ▁order ▁of ▁de cre as ing ▁serious ness ▁ .
▁tel ▁: ▁+ ▁49 ▁( ▁0 ▁) ▁89 ▁ 889 ▁ 690 ▁ 680
▁ve drop ▁is ▁ad minister ed ▁oral ly ▁with ▁or ▁without ▁water ▁ .
▁other ▁medicine s ▁and ▁kan uma
▁when ▁treat ing ▁hi v ▁infection ▁ , ▁it ▁is ▁not ▁always ▁easy ▁to ▁identify ▁what ▁side ▁effects ▁are ▁caused ▁by ▁evo ta z ▁ , ▁by ▁the ▁other ▁medicine s ▁you ▁are ▁taking ▁ , ▁or ▁by ▁the ▁hi v ▁infection ▁itself ▁ .
▁facit - fati gue ▁score ▁at ▁base line ▁( ▁media n ▁)
▁ta dala fil ▁is ▁a ▁select ive ▁ , ▁rever sible ▁inhibi tor ▁of ▁ cycli c ▁gua no sine ▁mono phos pha te ▁( ▁c g mp ▁) ▁- specific ▁ phos pho dies tera se ▁type ▁5 ▁( ▁p de 5 ▁) ▁ .
▁they ▁may ▁include ▁cold ▁sweat s ▁ , ▁cool ▁pale ▁skin ▁ , ▁fatigue ▁ , ▁ner vous ness ▁or ▁tre mor ▁ , ▁an xio us ness ▁ , ▁unusual ▁tired ness ▁or ▁we ak ness ▁ , ▁confusion ▁ , ▁difficult y ▁in ▁concentrat ing ▁ , ▁ drow si ness ▁ , ▁excessive ▁hun ger ▁ , ▁vision ▁changes ▁ , ▁head ache ▁ , ▁na use a ▁and ▁palp i tation ▁ .
▁as ▁with ▁a ce ▁inhibi tors ▁ , ▁con com i tant ▁use ▁of ▁ang io ten sin ▁i i ▁anta gon ists ▁and ▁ nsa ids ▁may ▁lead ▁to ▁an ▁increased ▁risk ▁of ▁worse ning ▁of ▁renal ▁function ▁ , ▁including ▁possible ▁a cute ▁renal ▁failure ▁ , ▁and ▁an ▁increase ▁in ▁se rum ▁po tas s ium ▁ , ▁especially ▁in ▁patients ▁with ▁poor ▁pre - exist ing ▁renal ▁function ▁ .
▁like ▁all ▁medicine s ▁ , ▁ huma log ▁mix 25 ▁can ▁cause ▁side ▁effects ▁ , ▁although ▁not ▁everybody ▁gets ▁them ▁ .
▁the ▁recommended ▁du ration ▁of ▁treatment ▁with ▁bi therapy ▁is ▁1 ▁year ▁ .
▁de hydrat ion ▁ , ▁decrease d ▁appetit e ▁ , ▁hypo kala emia
▁treat me ▁ nt ▁in ▁patients ▁with ▁a cute ▁stem i
▁the ▁use ▁of ▁la cos ami de ▁is ▁associated ▁with ▁dose - related ▁increase ▁in ▁the ▁pr ▁interval ▁ .
▁a ▁reduce d ▁number ▁of ▁plate let s ▁in ▁the ▁blood ▁( ▁ thro mbo cy top enia ▁) ▁which ▁are ▁important ▁to ▁stop ▁ble ed ing ▁and ▁work ▁by ▁ clu mping ▁and ▁clo tting ▁blood ▁ves sel ▁injuries ▁gastro inte stin al ▁problems ▁ .
▁it ▁must ▁have ▁an ▁even ly ▁mil ky - white ▁appearance ▁ .
▁each ▁oro dis per sible ▁tablet ▁contain s ▁5 ▁mg ▁olan za pine
▁taking ▁these ▁medicine s ▁together ▁with ▁brin telli x ▁may ▁increase ▁the ▁risk ▁of ▁serotonin ▁syndrome ▁ .
▁1 ▁pre - fill ed ▁sy ringe ▁with ▁an ▁automatic ▁safety ▁( ▁need le ▁injury ▁pre vention ▁) ▁system ▁and ▁a ▁steril e ▁inject ion ▁need le ▁ .
▁patients ▁with ▁opera ble ▁no de - posi tive ▁breast ▁cancer ▁( ▁tax ▁316 ▁)
▁contact ▁with ▁soft ▁contact ▁l enses ▁should ▁be ▁avoid ed ▁ .
▁as ▁for ▁other ▁qui nol ones ▁ , ▁due ▁to ▁possible ▁advers e ▁effects ▁on ▁the ▁articula r ▁carti lage ▁of ▁weight ▁bear ing ▁joint s ▁ , ▁di flo xa cin ▁should ▁not ▁be ▁used ▁during ▁the ▁rapid ▁growth ▁phase ▁ , ▁that ▁is ▁ , ▁do ▁not ▁use ▁in ▁small - and ▁medium ▁breed ▁dog s ▁up ▁to ▁and ▁including ▁8 ▁months ▁of ▁age ▁ , ▁in ▁large ▁breed s ▁up ▁to ▁1 ▁year ▁of ▁age ▁and ▁in ▁gian t ▁breed s ▁up ▁to ▁18 ▁months ▁of ▁age ▁ .
▁l - h isti dine ▁mono hydro ch lor ide ▁mono hydrat e ▁poly sor bate ▁80
▁in ▁studies ▁implement ing ▁routine ▁anti bac teria l ▁so a king ▁of ▁the ▁treatment ▁area ▁before ▁and ▁after ▁ne xo brid ▁application ▁( ▁see ▁section ▁4.2 ▁) ▁py re xia ▁or ▁hyper ther mia ▁was ▁reported ▁in ▁19. 1 ▁% ▁of ▁patients ▁treated ▁with ▁ne xo brid ▁and ▁in ▁15. 8 ▁% ▁of ▁the ▁control ▁patients ▁treated ▁according ▁standard ▁of ▁care ▁ .
▁upp er ▁respirator y ▁tract ▁infection
▁in ▁addition ▁ , ▁doce ta xel ▁was ▁found ▁to ▁be ▁active ▁on ▁some ▁but ▁not ▁all ▁cell ▁lines ▁over ▁express ing ▁the ▁p - gly co prote in ▁which ▁is ▁en code d ▁by ▁the ▁multi drug ▁resist ance ▁gene ▁ .
▁multi pack ▁of ▁180 ▁( ▁3 ▁pack s ▁of ▁60 ▁hard - cap s ules ▁) ▁- ▁without ▁blue ▁box ▁- ▁110 ▁mg ▁hard ▁capsule s
▁eu ▁/ ▁1 ▁/ ▁02 ▁/ ▁213 ▁/ ▁0 14 ▁90 ▁x ▁1 ▁tablets
▁if ▁you ▁experience ▁any ▁of ▁these ▁symptoms ▁ , ▁you ▁should ▁immediately ▁contact ▁your ▁doctor ▁or ▁the ▁near est ▁hospital ▁emergency ▁department ▁for ▁support ive ▁treatment ▁ .
▁la mi vu dine ▁is ▁clear ed ▁renal ly ▁ .
▁a ▁consistent ▁treatment ▁effect ▁f avour ing ▁sil tu xim ab ▁treated ▁patients ▁across ▁all ▁major ▁seconda ry ▁end point s ▁was ▁shown ▁in ▁the ▁hy a line ▁vas cular ▁sub group ▁ .
▁if ▁you ▁take ▁more ▁kep pra ▁than ▁you ▁should
▁example ▁: ▁if ▁your ▁daily ▁dose ▁is ▁1,000 ▁mg ▁ , ▁your ▁reduce d ▁starting ▁dose ▁is ▁2 ▁tablets ▁of ▁250 ▁mg ▁in ▁the ▁morning ▁and ▁2 ▁tablets ▁of ▁250 ▁mg ▁in ▁the ▁evening ▁ .
▁talk ▁to ▁your ▁doctor ▁or ▁ pharma ci st ▁before ▁taking ▁ rist for ▁:
▁q t ▁prolong ation ▁ , ▁vent ri cular ▁ar ry th mi as ▁( ▁vent ri cular ▁fi bril lation ▁ , ▁vent ri cular ▁ta chy car dia ▁) ▁ , ▁sud den ▁un exp lain ed ▁death ▁ , ▁cardiac ▁arrest ▁and ▁tor sade ▁de ▁point es ▁may ▁occur ▁with ▁anti psy cho tics ▁ .
▁the ▁safety ▁and ▁ef fica cy ▁of ▁en ox apa rin ▁so dium ▁in ▁children ▁below ▁the ▁age ▁of ▁12 ▁years ▁has ▁not ▁been ▁established ▁ .
▁the ▁effect ▁should ▁gradual ly ▁disappear ▁within ▁a ▁few ▁days ▁in ▁most ▁cases ▁ .
▁bone ▁mar row ▁sup pression ▁was ▁identified ▁in ▁some ▁of ▁the ▁cases ▁of ▁pa ncy top enia ▁ .
▁up ▁to ▁50 ▁% ▁of ▁the ▁el der ly ▁subject s ▁immun ised ▁with ▁a flu nov ▁were ▁ser o protec ted ▁at ▁six ▁months ▁ .
▁there ▁are ▁no ▁or ▁limited ▁amount ▁of ▁data ▁( ▁less ▁than ▁300 ▁pre gna ncy ▁outcome s ▁) ▁from ▁the ▁use ▁of ▁the ▁combination ▁of ▁des lor ata dine ▁and ▁pseudo ep hed rine ▁sul pha te ▁in ▁pregnant ▁women ▁ .
▁the ▁2- year ▁os ▁rate ▁was ▁6 1.9 ▁% ▁( ▁95 ▁% ▁ci ▁ , ▁5 1.1 - 72 . 7 ▁% ▁) ▁] ▁ .
▁following ▁dis continu ation ▁of ▁a baca vir ▁ , ▁the ▁symptoms ▁of ▁the ▁reaction ▁should ▁be ▁treated ▁according ▁to ▁local ▁standard ▁of ▁care ▁ .
▁envia ge ▁is ▁available ▁in ▁pack s ▁contain ing ▁7 ▁ , ▁14 ▁ , ▁28 ▁ , ▁30 ▁ , ▁50 ▁ , ▁56 ▁ , ▁84 ▁ , ▁90 ▁ , ▁98 ▁or ▁280 ▁tablets ▁ .
▁nor vir ▁film - co ated ▁tablets ▁- ▁multi pack ▁contain ing ▁90 ▁( ▁3 ▁bottle s ▁of ▁30 ▁) ▁film - co ated ▁tablets ▁with ▁blue ▁box
▁the ▁ pharma cok ine tic ▁character istic s ▁of ▁ar ipi pra zole ▁and ▁de hydro - ari pi pra zole ▁were ▁found ▁to ▁be ▁similar ▁in ▁patients ▁with ▁severe ▁renal ▁disease ▁compared ▁to ▁young ▁healthy ▁subject s ▁ .
▁after ▁each ▁complete ▁turn ▁make ▁sure ▁that ▁the ▁tri angle ▁is ▁opposite ▁the ▁dos age ▁indicator ▁( ▁see ▁diagram ▁o ▁) ▁ .
▁terms ▁marked ▁with ▁a ▁star ▁( ▁* ▁) ▁refer ▁to ▁the ▁advers e ▁reaction s ▁that ▁were ▁additional ly ▁reported ▁in ▁> ▁2 ▁% ▁of ▁diabet ic ▁hyper tensi ve ▁patients ▁with ▁chronic ▁renal ▁insu ffi cie ncy ▁and ▁over t ▁protein uria ▁and ▁in ▁excess ▁of ▁place bo ▁ .
▁temo zo lom ide ▁teva ▁20 ▁mg ▁hard ▁capsule s ▁: ▁each ▁capsule ▁contain s ▁20 ▁mg ▁temo zo lom ide ▁ .
▁with ▁200 ▁mg ▁to lca pone ▁ , ▁maximum ▁inhibi tion ▁of ▁er y thro cy te ▁com t ▁activity ▁is ▁ , ▁on ▁average ▁ , ▁greater ▁than ▁80 ▁% ▁ .
▁ever e ▁hyper sensitiv ity ▁reaction s ▁ , ▁such ▁as ▁ana phy la xis ▁( ▁rare ▁) ▁including ▁ana phy la ctic ▁shock ▁( ▁fre que ncy ▁not ▁known ▁) ▁which ▁may ▁be ▁fatal
▁patients ▁with ▁c ll ▁have ▁too ▁many ▁ab normal ▁lymph o cy tes ▁ , ▁which ▁accumula te ▁main ly ▁in ▁the ▁bone ▁mar row ▁and ▁blood ▁ .
▁geno ty pic ▁and ▁ phen oty pic ▁analysis ▁of ▁virus es ▁selected ▁in ▁these ▁passage s ▁suggest ▁that ▁the ▁presence ▁of ▁rito na vir ▁ , ▁at ▁these ▁concentration ▁ratio s ▁ , ▁does ▁not ▁mea sur ably ▁influence ▁the ▁selection ▁of ▁lo pina vir - re si stant ▁virus es ▁ .
▁de po cy te ▁patients ▁received ▁a ▁media n ▁of ▁5 ▁cycle s ▁( ▁dos es ▁) ▁per ▁patient ▁( ▁range ▁1 ▁to ▁10 ▁dos es ▁) ▁with ▁a ▁media n ▁time ▁on ▁ therapy ▁of ▁90 ▁days ▁( ▁range ▁1 ▁to ▁207 ▁days ▁) ▁ .
▁un com mon ▁: ▁ang io ede ma ▁ , ▁ur tica ria ▁ , ▁ rash ▁ , ▁p sori asi form ▁ rash ▁ , ▁psoriasis ▁( ▁including ▁new ▁ons et ▁or ▁worse ning ▁and ▁pust ular ▁ , ▁primari ly ▁palm s ▁and ▁sole s ▁)
▁no ▁dose ▁adjust ment ▁is ▁necessary ▁for ▁efa vir enz ▁ .
▁side ▁effects ▁related ▁to ▁the ▁gastro inte stin al ▁system
▁however ▁ , ▁individual ▁values ▁were ▁well ▁within ▁the ▁range ▁observe d ▁in ▁the ▁ex tensi ve ▁metabol iser ▁subject s ▁ .
▁do ▁not ▁try ▁to ▁touch ▁the ▁need le ▁house d ▁in ▁the ▁barre l ▁ .
▁the ▁product ▁has ▁a ▁long ▁du ration ▁of ▁action ▁; ▁however ▁ , ▁the ▁exact ▁clinic al ▁effect ▁du ration ▁after ▁a ▁single ▁inject ion ▁is ▁un know n ▁ .
▁table ▁6 ▁- ▁ef fica cy ▁results ▁from ▁the ▁phase ▁i ii ▁( ▁recours e ▁) ▁clinic al ▁trial
▁studies ▁of ▁immediate - release ▁ex en ati de ▁in ▁combination ▁with ▁bas al ▁insulin
▁insu man ▁in fus at ▁must ▁not ▁be ▁used ▁in ▁per ista l tic ▁pump s ▁with ▁silicone ▁tu bing ▁ .
▁infection ▁of ▁the ▁hair ▁root s ▁; ▁influenza ▁; ▁skin ▁infection ▁due ▁to ▁virus ▁; ▁upp er ▁respirator y ▁tract ▁infection ▁( ▁such ▁as ▁ inflammation ▁of ▁the ▁na sal ▁cavi ty ▁or ▁sinus es ▁located ▁around ▁the ▁nos e ▁; ▁common ▁cold ▁) ▁; ▁infection ▁in ▁the ▁lymph ▁no de ▁( ▁g land ▁in ▁the ▁ne ck ▁ , ▁arm pit ▁ , ▁or ▁gro in ▁)
▁inner ▁carton ▁of ▁multi pack ▁of ▁120 ▁( ▁3 ▁pack s ▁of ▁40 ▁) ▁200 ▁mg ▁/ ▁50 ▁mg ▁film - co ated ▁tablets ▁) ▁- ▁without ▁blue ▁box
▁vaccin e ▁against ▁classic al ▁s win e ▁fe ver
▁recon stitu ted ▁vida za ▁should ▁be ▁inject ed ▁sub cuta ne ously ▁( ▁insert ▁the ▁need le ▁at ▁a ▁45 -90 ▁° ▁angle ▁) ▁using ▁a ▁25- ga uge ▁need le ▁into ▁the ▁upp er ▁arm ▁ , ▁th igh ▁or ▁ab dom en ▁ .
▁table ▁1 ▁: ▁advers e ▁reaction s ▁reported ▁with ▁a dem pas ▁in ▁the ▁phase ▁i ii ▁studies
▁on gly za ▁2.5 ▁mg ▁film - co ated ▁tablets
▁it ▁should ▁be ▁taken ▁with ▁food ▁ .
▁las o fox ife ne ▁was ▁not ▁geno toxic ▁in ▁any ▁of ▁the ▁battery ▁of ▁tests ▁applied ▁ .
▁there ▁is ▁no ▁clinic al ▁experience ▁in ▁patients ▁with ▁child - p ugh ▁class ▁c ▁( ▁severe ▁) ▁he pati c ▁im pair ment ▁ .
▁the ▁bag ▁should ▁be ▁gent ly ▁invert ed ▁to ▁mix ▁the ▁solution ▁in ▁order ▁to ▁avoid ▁excessive ▁fo am ing ▁ .
▁it ▁is ▁likely ▁that ▁certain ▁advers e ▁events ▁of ▁thi ote pa ▁like ▁di zzi ness ▁ , ▁head ache ▁and ▁blu r red ▁vision ▁could ▁affect ▁your ▁ability ▁to ▁drive ▁and ▁use ▁machines ▁ .
▁ torem ife ne ▁is ▁a ▁non steroid al ▁trip hen yle thy lene ▁deriva tive ▁ .
▁detailed ▁information ▁on ▁this ▁medicine ▁is ▁available ▁on ▁the ▁european ▁medicine s ▁agency ▁web ▁site ▁: ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu
▁increase ▁in ▁bilir u bin ▁( ▁a ▁substance ▁produced ▁by ▁the ▁ liver ▁)
▁cases ▁of ▁infection s ▁have ▁been ▁reported ▁un com mon ly ▁in ▁association ▁with ▁the ▁use ▁of ▁i ker vis ▁ .
▁storage ▁of ▁recon stitu ted ▁solutions ▁: ▁upon ▁recon stitu tion ▁with ▁steril e ▁water ▁for ▁inject ions ▁or ▁so dium ▁chlor ide ▁9 ▁mg ▁/ ▁ml ▁( ▁ 0.9 ▁% ▁) ▁solution ▁for ▁inject ion ▁ , ▁dori bax ▁suspens ion ▁in ▁the ▁vi al ▁may ▁be ▁held ▁for ▁up ▁to ▁1 ▁hour ▁below ▁30 ▁c ▁prior ▁to ▁transfer ▁and ▁dilu tion ▁in ▁the ▁in fusion ▁bag ▁ .
▁talk ▁to ▁your ▁doctor ▁before ▁using ▁ri va stig mine ▁3 m ▁health ▁care ▁l t d ▁ . ▁:
▁co - administration ▁of ▁te no fo vir ▁di so prox il ▁and ▁di dano sine ▁at ▁a ▁dose ▁of ▁400 ▁mg ▁daily ▁has ▁been ▁associated ▁with ▁a ▁significant ▁decrease ▁in ▁cd 4 ▁cell ▁count ▁ , ▁possibly ▁due ▁to ▁an ▁intra cel lular ▁interaction ▁increasing ▁ phos phor yla ted ▁( ▁i . e . ▁active ▁) ▁di dano sine ▁ .
▁rhe umo cam ▁15 ▁mg ▁/ ▁ml ▁oral ▁suspens ion ▁for ▁horse s
▁therefore ▁ , ▁the ▁used ▁trans der mal ▁patch ▁should ▁be ▁disc ard ed ▁carefully ▁ .
▁an ▁a dhe sive ▁plast er ▁a ▁proper ▁disposa l ▁container ▁for ▁used ▁need les ▁ , ▁sy ringe ▁and ▁vi als ▁( ▁sharp s ▁container ▁)
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁take ▁gli di pion ▁do ▁not ▁take ▁gli di pion ▁if ▁you ▁are ▁hyper sensitiv e ▁( ▁allergi c ▁) ▁to ▁pi og lita zone ▁or ▁any ▁of ▁the ▁other ▁ingredients ▁of ▁gli di pion ▁( ▁see ▁section ▁6 ▁for ▁a ▁list ▁of ▁ingredients ▁) ▁ .
▁pre - tre at ment ▁height ▁veloci ty ▁data ▁were ▁available ▁for ▁75 ▁subject s ▁ .
▁when ▁flu ticas one ▁propi onate ▁is ▁in hal ed ▁ .
▁requirements ▁for ▁home ▁in fusion ▁( ▁home ▁condition ▁ , ▁patient ▁assessment ▁ , ▁emergency ▁treatment ▁) ▁;
▁not ▁all ▁smo ke ▁in hal ation ▁victim s ▁necessarily ▁will ▁have ▁c yan ide ▁pois o ning ▁ , ▁but ▁may ▁present ▁with ▁burn s ▁ , ▁trauma ▁ , ▁and ▁exposure ▁to ▁additional ▁ toxic ▁substance s ▁ag grav ating ▁the ▁clinic al ▁picture ▁ .
▁the ▁tissu e ▁around ▁the ▁eyes ▁may ▁be ▁more ▁sensitive ▁ , ▁and ▁therefore ▁ , ▁it ▁is ▁not ▁recommended ▁that ▁the ▁face ▁be ▁used ▁for ▁testing ▁ .
▁hyper sensitiv ity ▁reaction ▁to ▁the ▁medication ▁ , ▁heart ▁attack ▁ , ▁ inflammation ▁of ▁the ▁pan cre as ▁ , ▁pain ▁in ▁bone ▁and ▁diabetes ▁mell itus ▁ , ▁cotton ▁wo ol ▁spot s ▁( ▁white ▁deposit s ▁on ▁the ▁retin a ▁) ▁ .
▁the ▁dose ▁used ▁should ▁also ▁be ▁record ed ▁ .
▁combination ▁with ▁other ▁d m ts ▁ .
▁summary ▁of ▁product ▁character istic s ▁( ▁sm pc ▁) ▁and ▁package ▁le a flet ▁and ▁label ling
▁clinic al ▁data ▁obtain ed ▁from ▁a ▁limited ▁number ▁of ▁patients ▁also ▁indicate ▁that ▁adult ▁ pid ▁patients ▁may ▁ tolera te ▁an ▁in fusion ▁rate ▁of ▁up ▁to ▁8 ▁ml ▁/ ▁kg ▁bw ▁/ ▁hr ▁ .
▁the ▁end - user ▁may ▁remove ▁the ▁medicinal ▁product ▁from ▁refrigera tion ▁for ▁storage ▁at ▁a ▁temperature ▁not ▁above ▁30 ▁° ▁c ▁for ▁one ▁single ▁period ▁of ▁1 ▁month ▁ .
▁if ▁you ▁forget ▁to ▁take ▁az om yr ▁oro dis per sible ▁tablet
▁the ▁ mist - release ▁button ▁must ▁be ▁presse d ▁firm ly ▁all ▁the ▁way ▁in ▁ , ▁to ▁release ▁the ▁ mist ▁through ▁the ▁no zz le ▁- ▁see ▁picture ▁c ▁ .
▁some ▁patients ▁have ▁had ▁the ▁following ▁side ▁effects ▁while ▁taking ▁ jal ra ▁and ▁met form in ▁:
▁multi pack ▁: ▁180 ▁( ▁3 ▁pack s ▁of ▁60 ▁) ▁film - co ated ▁tablets
▁rito na vir ▁is ▁not ▁a ▁cure ▁for ▁hi v -1 ▁infection ▁or ▁aid s ▁ .
▁as ▁use ▁in ▁patients ▁with ▁severe ▁he pati c ▁im pair ment ▁may ▁be ▁associated ▁with ▁increased ▁exposure ▁of ▁net upi tant ▁ , ▁a ky nze o ▁should ▁be ▁used ▁with ▁cau tion ▁in ▁these ▁patients ▁( ▁see ▁section s ▁4.4 ▁and ▁5.2 ▁) ▁ .
▁if ▁you ▁take ▁too ▁much ▁spe dra ▁ , ▁you ▁should ▁tell ▁your ▁doctor ▁straight ▁away ▁ .
▁no ▁significant ▁cross - re si stance ▁has ▁been ▁demonstrat ed ▁between ▁ri lp ivi rine - re si stant ▁hi v -1 ▁variant s ▁and ▁em trici ta bine ▁or ▁te no fo vir ▁ , ▁or ▁between ▁em trici ta bine - ▁or ▁te no fo vir - re si stant ▁variant s ▁and ▁ri lp ivi rine ▁ .
▁the ▁plasma ▁protein ▁ binding ▁in ▁patients ▁at ▁stea dy ▁state ▁is ▁similar ▁: ▁5 3.1 ▁% ▁( ▁ 3.6 ▁) ▁and ▁5 1.1 ▁% ▁( ▁4.5 ▁) ▁at ▁1.5 ▁and ▁6 ▁hours ▁post - dos e ▁ , ▁respective ly ▁ .
▁hep s era ▁can ▁affect ▁the ▁way ▁your ▁ki dne ys ▁work ▁ .
▁bri moni dine ▁is ▁a ▁highly ▁select ive ▁al pha 2- ad r energi c ▁receptor ▁ago nist ▁that ▁is ▁1000 - fold ▁more ▁select ive ▁for ▁the ▁al pha 2- ad r energi c ▁receptor ▁than ▁the ▁al pha 1- ad r energi c ▁receptor ▁ .
▁always ▁use ▁ema dine ▁exactly ▁as ▁your ▁doctor ▁has ▁told ▁you ▁ .
▁make ▁sure ▁no ▁air ▁is ▁in ▁the ▁oral ▁dispens er ▁( ▁if ▁air ▁is ▁present ▁ , ▁remove ▁) ▁ .
▁what ▁cep lene ▁is ▁and ▁what ▁is ▁used ▁for
▁if ▁necessary ▁ , ▁a ▁steril e ▁spa tul a ▁can ▁be ▁used ▁to ▁break ▁the ▁dry ▁ne xo brid ▁powder ▁cake ▁in ▁its ▁vi al ▁prior ▁to ▁transfer ▁ .
▁pr ca ▁caused ▁by ▁neutral ising ▁anti - ery thro po i etin ▁anti bo dies ▁has ▁been ▁reported ▁in ▁association ▁with ▁er y thro po i etin ▁ therapy ▁ , ▁including ▁ne ore cor mon ▁ .
▁using ▁bude son ide ▁/ ▁form ote rol ▁teva ▁ pharma ▁b . v . ▁and ▁a ▁separate ▁' ▁reli ever ▁in hal er '
▁si mpon i ▁works ▁by ▁block ing ▁the ▁action ▁of ▁a ▁protein ▁called ▁' ▁tum our ▁nec rosi s ▁factor ▁al pha ▁' ▁( ▁t n f - α ▁) ▁ .
▁it ▁is ▁therefore ▁recommended ▁that ▁the ▁diabet ic ▁patient ▁always ▁car ries ▁sugar - conta ining ▁products ▁ .
▁ ted izol id ▁ phos pha te ▁is ▁an ▁o xa zol idin one ▁ phos pha te ▁pro drug ▁ .
▁continue ▁taking ▁cer del ga ▁every ▁day ▁for ▁as ▁long ▁as ▁your ▁doctor ▁tell s ▁you ▁ .
▁each ▁prolong ed - release ▁tablet ▁contain s ▁3 ▁mg ▁pali peri done
▁{ ▁bli ster ▁pack ▁( ▁14 ▁ , ▁21 ▁ , ▁56 ▁ , ▁84 ▁ , ▁90 ▁ , ▁100 ▁and ▁112 ▁) ▁and ▁perfor ated ▁unit ▁dose ▁bli ster ▁pack ▁( ▁100 ▁) ▁for ▁200 ▁mg ▁hard ▁capsule s ▁- ▁p vc ▁/ ▁aluminium ▁}
▁non - st ▁segment ▁eleva tion ▁a cute ▁corona ry ▁syndrome ▁( ▁uns table ▁ang ina ▁or ▁non - q - wa ve ▁my o card ial ▁in far ction ▁) ▁ , ▁including ▁patients ▁under go ing ▁a ▁sten t ▁place ment ▁following ▁per cuta ne ous ▁corona ry ▁intervention ▁ , ▁in ▁combination ▁with ▁a ce tyl sali cy lic ▁acid ▁( ▁asa ▁) ▁ .
▁do ▁not ▁crush ▁or ▁che w ▁the ▁tablets ▁ .
▁patients ▁with ▁severe ▁he pati c ▁im pair ment ▁must ▁be ▁carefully ▁monitor ed ▁for ▁drug ▁ toxic ity ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁if ▁large ▁quanti ties ▁have ▁been ▁inge sted ▁ , ▁gas tric ▁lava ge ▁is ▁indicate d ▁ , ▁followed ▁by ▁activa ted ▁char co al ▁and ▁so dium - sul pha te ▁ .
▁changes ▁in ▁blood ▁test ▁results ▁including ▁decrease d ▁levels ▁of ▁a ▁protein ▁in ▁the ▁red ▁blood ▁cell s ▁( ▁ha emo glob in ▁) ▁ .
▁because ▁wild - type ▁h sv -1 ▁does ▁not ▁integrat e ▁into ▁the ▁host ▁genom e ▁ , ▁the ▁risk ▁of ▁inser tional ▁muta gene sis ▁with ▁tal imo gene ▁la her pare p vec ▁is ▁negli gi ble ▁ .
▁other ▁medicine s ▁and ▁ulu nar ▁bre ezh a ler
▁component ▁of ▁a ▁multi pack ▁compris ing ▁5 ▁pack s ▁ , ▁each ▁contain ing ▁10 ▁single - dos e ▁( ▁0.5 ▁ml ▁) ▁pre - fill ed ▁sy ring es ▁without ▁need le ▁ .
▁avoid ▁the ▁application ▁of ▁more ▁than ▁1 ▁ml ▁of ▁solution ▁at ▁any ▁one ▁spot ▁as ▁it ▁could ▁cause ▁some ▁of ▁the ▁solution ▁to ▁run ▁or ▁d rip ▁off ▁the ▁dog ▁ .
▁if ▁you ▁forget ▁to ▁take ▁ri lu tek
▁do ▁not ▁eat ▁or ▁drink ▁for ▁10 ▁minutes ▁after ▁taking ▁the ▁tablet ▁ .
▁overall ▁survival ▁was ▁longer ▁for ▁z y tiga ▁than ▁place bo ▁with ▁a ▁25 ▁% ▁re duction ▁in ▁risk ▁of ▁death ▁( ▁hr ▁= ▁ 0.7 52 ▁; ▁95 ▁% ▁ci ▁: ▁[ ▁0 . 606 ▁; ▁ 0.9 34 ▁] ▁ , ▁p ▁= ▁ 0.00 97 ▁) ▁ , ▁but ▁os ▁was ▁not ▁mature ▁and ▁inter im ▁results ▁did ▁not ▁meet ▁the ▁pre - spec ified ▁stop ping ▁ bound ary ▁for ▁statistic al ▁significa nce ▁( ▁see ▁table ▁4 ▁) ▁ .
▁the ▁table ▁below ▁list s ▁all ▁advers e ▁reaction s ▁occur ring ▁within ▁7 ▁days ▁after ▁treatment ▁with ▁ru con est ▁ , ▁as ▁reported ▁in ▁the ▁six ▁treatment ▁studies ▁ .
▁in ▁studies ▁perform ed ▁with ▁the ▁individual ▁active ▁substance s ▁ , ▁both ▁a log lip tin ▁and ▁pi og lita zone ▁were ▁ex cre ted ▁in ▁the ▁milk ▁of ▁la cta ting ▁rat s ▁ .
▁no ▁dose ▁adjust ment ▁required ▁for ▁du treb is ▁or ▁met ha done ▁ .
▁if ▁the ▁circula ting ▁av ian ▁influenza ▁field ▁virus ▁has ▁a ▁different ▁n ▁component ▁to ▁the ▁n 2 ▁included ▁in ▁the ▁vaccin e ▁ , ▁it ▁may ▁be ▁possible ▁to ▁differenti ate ▁between ▁vaccin ated ▁and ▁infect ed ▁bir ds ▁by ▁using ▁a ▁diagnostic ▁test ▁to ▁detect ▁ne ur amini das e ▁anti bo dies ▁ .
▁non - clin ical ▁data ▁reveal ▁no ▁special ▁hazard ▁for ▁humans ▁based ▁on ▁convention al ▁studies ▁of ▁safety ▁ , ▁specific ▁ toxic ity ▁ , ▁repeat ed ▁dose ▁ toxic ity ▁and ▁compatibil ity ▁of ▁ingredients ▁ .
▁a ▁severe ▁form ▁of ▁allergi c ▁reaction ▁( ▁ana phy la ctic ▁reaction ▁) ▁with ▁additional ▁symptoms ▁such ▁as ▁breath ing ▁problems ▁ , ▁swe lling ▁of ▁ thro at ▁and ▁face ▁ , ▁fast ▁heart beat ▁ , ▁etc ▁ .
▁the ▁use ▁of ▁medical ▁devices ▁contain ing ▁silicone ▁oil ▁as ▁a ▁lub rica nt ▁( ▁i . e . ▁sy ring es ▁and ▁i v ▁bags ▁) ▁to ▁recon stitu te ▁and ▁ad minister ▁a bra xan e ▁may ▁result ▁in ▁the ▁formation ▁of ▁protein ace ous ▁strand s ▁ .
▁ki dne y ▁failure ▁ , ▁ki dne y ▁sto nes ▁ , ▁difficult ▁dis charge ▁of ▁urin e ▁ , ▁frequent ▁or ▁excessive ▁passage ▁of ▁urin e ▁ , ▁sometimes ▁at ▁night
▁unde sir able ▁effects ▁where ▁the ▁fre que ncy ▁is ▁not ▁known ▁are ▁: ▁head ache ▁ , ▁ring ing ▁in ▁the ▁ear s ▁ , ▁co ugh ▁ , ▁taste ▁disturb ance ▁ , ▁indi gestion ▁ , ▁pain ▁in ▁joint s ▁and ▁muscle s ▁ , ▁ liver ▁function ▁ab normal ▁and ▁im pair ed ▁ki dne y ▁function ▁ , ▁increased ▁level ▁of ▁po tas s ium ▁in ▁your ▁blood ▁and ▁allergi c ▁reaction s ▁such ▁as ▁ rash ▁ , ▁hi ves ▁ , ▁swe lling ▁of ▁the ▁face ▁ , ▁lips ▁ , ▁mouth ▁ , ▁ton gue ▁or ▁ thro at ▁ .
▁te roid s ▁( ▁e . g . ▁bude son ide ▁ , ▁de xa met has one ▁ , ▁flu ticas one ▁propi onate ▁ , ▁et hin yl ▁o est radio l ▁) ▁; ▁medicine s ▁that ▁cause ▁a ▁reaction ▁with ▁alcohol ▁( ▁e . g . ▁di sul fi ram ▁) ▁ .
▁omni trop e ▁is ▁a ▁clear ▁and ▁colour less ▁solution ▁for ▁inject ion ▁ .
▁temo med ac ▁250 ▁mg ▁hard ▁capsule s ▁: ▁gelatin ▁ , ▁titan ium ▁ dioxid e ▁( ▁e ▁171 ▁) ▁ , ▁ shell ac ▁ , ▁ propyl ene ▁gly col ▁ , ▁black ▁ir on ▁oxid e ▁( ▁e ▁172 ▁) ▁ .
▁moderat e ▁to ▁severe ▁man ic ▁episode s ▁ , ▁a ▁condition ▁with ▁symptoms ▁of ▁excitement ▁or ▁eu pho ria
▁as tella s ▁ pharma ▁a ▁/ ▁s ▁dan ija
▁if ▁you ▁notice ▁any ▁of ▁these ▁symptoms ▁ , ▁tell ▁your ▁doctor ▁ .
▁laborator y ▁finding s ▁suggest ive ▁of ▁ tma ▁include ▁decrease d ▁plate let ▁count s ▁ , ▁increased ▁se rum ▁lac tate ▁de hydro gen ase ▁( ▁l dh ▁) ▁due ▁to ▁ha em ol ysis ▁and ▁sch isto cy tes ▁( ▁er y thro cy te ▁fragment ation ▁) ▁on ▁a ▁blood ▁film ▁ .
▁b ▁/ ▁phu ket ▁/ ▁30 73 ▁/ ▁2013 ▁- ▁like ▁strain ▁( ▁b ▁/ ▁ut ah ▁/ ▁9 ▁/ ▁2014 ▁ , ▁wild ▁type ▁) ▁15 ▁micro gram s ▁ha ▁* ▁* ▁per ▁0.5 ▁ml ▁dose
▁hold ▁the ▁sy ringe ▁so ▁that ▁the ▁need le ▁is ▁point ing ▁down ward s ▁( ▁vertical ly ▁at ▁a ▁90 o ▁angle ▁) ▁ .
▁do ▁not ▁touch ▁the ▁need le ▁or ▁the ▁cap ▁ .
▁other ▁medicine s ▁and ▁nu loj ix
▁len vati ni b ▁is ▁for ▁oral ▁use ▁ .
▁each ▁kit ▁is ▁for ▁single ▁use ▁only ▁ .
▁package ▁le a flet ▁: ▁information ▁for ▁the ▁patient ▁leve ti race tam ▁ho spira ▁100 ▁mg ▁/ ▁ml ▁concentrat e ▁for ▁solution ▁for ▁in fusion
▁use ▁of ▁gl p -1 ▁receptor ▁ago nist s ▁has ▁been ▁associated ▁with ▁a ▁risk ▁of ▁developing ▁a cute ▁pan creati tis ▁ .
▁7 th ▁nerv e ▁para lys is ▁ , ▁di zzi ness
▁in ▁the ▁olar atum ab ▁plus ▁do xor ubi cin ▁arm ▁ , ▁the ▁most ▁serious ▁( ▁grade ▁ ≥ ▁3 ▁) ▁advers e ▁drug ▁reaction s ▁( ▁ad rs ▁) ▁observe d ▁were ▁neutro p enia ▁( ▁54 . 7 ▁% ▁) ▁and ▁mus culos kelet al ▁pain ▁( ▁ 7.8 ▁% ▁) ▁ .
▁a ▁clinic al ▁study ▁( ▁d - h 5 n 1-0 09 ▁) ▁evaluat ed ▁the ▁react ogen i city ▁in ▁children ▁3 ▁to ▁5 ▁and ▁6 ▁to ▁9 ▁years ▁of ▁age ▁who ▁received ▁either ▁two ▁adult ▁( ▁i . e ▁ .
▁explanation ▁of ▁un know n ▁risk ▁of ▁neuro pathy ▁with ▁long ▁term ▁use
▁male ▁patients ▁should ▁use ▁effective ▁contra ception ▁and ▁not ▁father ▁a ▁child ▁for ▁up ▁to ▁6 ▁months ▁after ▁stop ping ▁treatment ▁ .
▁powder ▁and ▁solve nt ▁for ▁solution ▁for ▁inject ion ▁/ ▁in fusion ▁human ▁coa g ulation ▁factor ▁vii i ▁ ,
▁the ▁pen ▁is ▁for ▁inject ing ▁the ▁medicine ▁under ▁the ▁skin ▁only ▁( ▁sub cuta ne ous ▁) ▁ .
▁ser o con version ▁by ▁el isa ▁and ▁pr nt ▁were ▁as ▁follow s ▁:
▁o selt ami vir ▁carb oxy late ▁inhibi ts ▁influenza ▁a ▁and ▁b ▁ne ur amini das es ▁in ▁vi tro ▁ .
▁the ▁survival ▁rate ▁at ▁day ▁180 ▁was ▁8 0.0 ▁% ▁( ▁32 ▁/ ▁40 ▁) ▁and ▁at ▁1 ▁year ▁was ▁7 0.0 ▁% ▁( ▁28 ▁/ ▁40 ▁) ▁ .
▁do ▁this ▁by ▁light ly ▁ta pping ▁on ▁the ▁upp er ▁half ▁of ▁the ▁sy ringe ▁ .
▁in sufficient ▁data ▁are ▁available ▁to ▁make ▁a ▁recommend ation ▁for ▁patients ▁with ▁a ▁creati nine ▁clear ance ▁< ▁20 ▁ml ▁/ ▁min ▁ .
▁one ▁vi al ▁contain ing ▁1 g ▁of ▁powder ▁( ▁3.3 ▁mg ▁e pto termin ▁alfa ▁) ▁; ▁one ▁vi al ▁contain ing ▁230 ▁mg ▁car mel lose ▁powder ▁ .
▁op io ids ▁act ▁by ▁block ing ▁the ▁pain ▁signal s ▁to ▁the ▁brain ▁ .
▁the ▁ pharma cok ine tic ▁properties ▁of ▁bi vali rudi n ▁have ▁been ▁evaluat ed ▁and ▁found ▁to ▁be ▁linear ▁in ▁patients ▁under go ing ▁per cuta ne ous ▁corona ry ▁intervention ▁and ▁in ▁patients ▁with ▁ac s ▁ .
▁preparation ▁of ▁the ▁les ions ▁: ▁before ▁administration ▁of ▁a mel uz ▁all ▁les ions ▁should ▁be ▁carefully ▁wi ped ▁with ▁an ▁et han ol ▁or ▁iso prop an ol - s oak ed ▁cotton ▁pad ▁to ▁ensure ▁deg rea sing ▁of ▁the ▁skin ▁ .
▁the ▁mean ▁estima ted ▁vor apa xar ▁c max ▁and ▁au c ▁were ▁24 ▁% ▁and ▁22 ▁% ▁higher ▁in ▁asian ▁patients ▁compared ▁to ▁that ▁of ▁cau cas ians ▁ .
▁gly cer ol ▁ phen ol ▁meta cre sol ▁z inc ▁chlor ide
▁ion sys ▁should ▁only ▁be ▁activa ted ▁by ▁the ▁patient ▁ .
▁medicine s ▁that ▁may ▁damage ▁your ▁ki dne ys ▁ , ▁example s ▁include ▁:
▁dis continu ation ▁of ▁stri bild ▁ therapy ▁in ▁patients ▁co - infect ed ▁with ▁hi v ▁and ▁ hb v ▁may ▁be ▁associated ▁with ▁severe ▁a cute ▁ex ace rb ations ▁of ▁hepatitis ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁the ▁mah ▁shall ▁ensure ▁that ▁in ▁each ▁member ▁state ▁where ▁up tra vi ▁is ▁market ed ▁ , ▁all ▁health care ▁professionals ▁who ▁are ▁expected ▁to ▁pre scribe ▁and ▁/ ▁or ▁dispens e ▁up tra vi ▁are ▁provided ▁with ▁a ▁pre scribe r ▁kit ▁contain ing ▁the ▁following ▁:
▁patients ▁who ▁have ▁taken ▁very ▁high ▁dos es ▁of ▁ammo nap s ▁experienced ▁:
▁i clusi g ▁45 ▁mg ▁film - co ated ▁tablets ▁pon atin ib
▁consideration ▁should ▁therefore ▁be ▁given ▁to ▁means ▁of ▁minimi sing ▁problems ▁of ▁ad ren al ▁insu ffi cie ncy ▁following ▁the ▁withdraw al ▁of ▁treatment ▁ .
▁renal ▁clear ance ▁is ▁a ▁minor ▁elimina tion ▁path way ▁ , ▁with ▁14 ▁% ▁of ▁the ▁radio label led ▁dose ▁ex cre ted ▁in ▁urin e ▁( ▁< ▁0.2 ▁% ▁of ▁the ▁radio label led ▁dose ▁is ▁parent ▁compound ▁) ▁ .
▁viagra ▁is ▁indicate d ▁in ▁adult ▁men ▁with ▁er ect ile ▁dys function ▁ , ▁which ▁is ▁the ▁in ability ▁to ▁achieve ▁or ▁maintain ▁a ▁pen ile ▁er ection ▁ sufficient ▁for ▁satisfac tory ▁sexual ▁performance ▁ .
▁ke pi vance ▁treatment ▁should ▁be ▁super vis ed ▁by ▁a ▁physician ▁experienced ▁in ▁the ▁use ▁of ▁anti - cancer ▁ therapy ▁ .
▁patients ▁taking ▁voli bris ▁should ▁have ▁their ▁ha emo glob in ▁and ▁/ ▁or ▁ha e mato crit ▁levels ▁measure d ▁regularly ▁ .
▁the ▁combination ▁of ▁ev ip lera ▁and ▁da biga tran ▁et ex ila te ▁should ▁be ▁used ▁with ▁cau tion ▁ .
▁medicine s ▁used ▁to ▁treat ▁fun gal ▁infection s ▁( ▁anti fung als ▁) ▁: ▁vor ico na zole ▁ .
▁other ▁mono amine ▁oxid ase ▁( ▁ma o ▁) ▁inhibi tors ▁( ▁including ▁medicinal ▁and ▁natural ▁products ▁) ▁( ▁see ▁section ▁" ▁do ▁not ▁take ▁xa da go ▁" ▁)
▁da cla tas vir ▁+ ▁sof os bu vir ▁12 ▁weeks
▁the ▁clinic al ▁relevan ce ▁of ▁this ▁effect ▁in ▁patients ▁receiving ▁ami oda rone ▁treatment ▁remain s ▁un know n ▁ .
▁for ▁example ▁ , ▁if ▁you ▁we igh ▁60 ▁kg ▁your ▁daily ▁dose ▁will ▁be ▁60 ▁million ▁international ▁unit s ▁( ▁mi u ▁) ▁ .
▁there ▁have ▁been ▁no ▁formal ▁clinic al ▁trial s ▁under tak en ▁in ▁children ▁or ▁adolescents ▁ .
▁age ▁does ▁not ▁appear ▁to ▁affect ▁tem si rol imus ▁and ▁si rol imus ▁ pharma cok ine tics ▁significantly ▁ .
▁cau tion ▁should ▁be ▁exercise d ▁in ▁patients ▁being ▁treated ▁with ▁bene pali ▁who ▁have ▁a ▁previous ▁history ▁of ▁blood ▁dys cra sia s ▁ .
▁ab se a med ▁should ▁be ▁ad minister ed ▁by ▁the ▁intra ven ous ▁route ▁ .
▁it ▁is ▁suppli ed ▁in ▁a ▁120 - ml ▁amb er ▁glass ▁bottle ▁ , ▁with ▁a ▁child ▁resist ant ▁screw - cap ▁ .
▁patients ▁who ▁met ▁all ▁of ▁the ▁criteri a ▁for ▁a ▁cr ▁except ▁for ▁recovery ▁of ▁plate let ▁count s ▁to ▁> ▁100 ▁x ▁109 ▁/ ▁l
▁the ▁che mo therapy ▁should ▁be ▁given ▁after ▁the ▁mab ther a ▁administration ▁ .
▁clinic al ▁evaluation ▁may ▁reveal ▁hypo vola emia ▁ , ▁ha emo con centr ation ▁ , ▁electro ly te ▁im balance s ▁ , ▁as cite s ▁ , ▁ha emo peri tone um ▁ , ▁ple ural ▁ef fusion s ▁ , ▁hydro t hora x ▁ , ▁or ▁a cute ▁pulmonar y ▁di stress ▁ .
▁zal mo xis ▁is ▁prepared ▁from ▁human ▁blood ▁of ▁a ▁specific ▁donor ▁and ▁it ▁consist s ▁of ▁genetic ally ▁modifi ed ▁cell s ▁ .
▁effect ▁of ▁other ▁medicinal ▁products ▁on ▁im no vid
▁pneu moni tis ▁c ▁ , ▁e pista xis ▁ , ▁co ugh
▁in ▁rabbi ts ▁ , ▁vaginal ▁ble ed ings ▁and ▁abort ions ▁possibly ▁associated ▁to ▁prolong ed ▁ha emos tas is ▁ , ▁but ▁no ▁fo e tal ▁ab normal ities ▁were ▁not ed ▁ .
▁the ▁usual ▁dose ▁of ▁la mi vu dine ▁teva ▁ pharma ▁b . v . ▁is ▁150 ▁mg ▁a ▁day ▁ .
▁ting ling ▁and ▁nu mb ness ▁( ▁per i pher al ▁poly n europa thy ▁) ▁ .
▁transfer ring ▁a ▁patient ▁to ▁another ▁type ▁or ▁brand ▁of ▁insulin ▁should ▁be ▁done ▁under ▁strict ▁medical ▁super vision ▁ .
▁ask ▁your ▁ pharma ci st ▁if ▁you ▁are ▁unsur e ▁ .
▁date ▁of ▁first ▁author isation ▁: ▁23 ▁april ▁2014
▁apply ▁only ▁to ▁und ama ged ▁skin ▁ .
▁the ▁study ▁population ▁was ▁64 ▁% ▁female ▁ , ▁with ▁a ▁media n ▁age ▁of ▁58 ▁years ▁ , ▁4.4 ▁% ▁had ▁a ▁creati nine ▁clear ance ▁< ▁50 ml ▁/ ▁min ▁ .
▁low ▁blood ▁measure ments ▁for ▁red ▁blood ▁cell s
▁speak ▁to ▁your ▁doctor ▁for ▁advice ▁ .
▁never the less ▁ , ▁the ▁concentration ▁of ▁this ▁metabol ite ▁remain s ▁low ▁ .
▁at rial ▁fi bril lation ▁( ▁an ▁ab normal ▁heart ▁ rhythm ▁) ▁ , ▁irregular ▁heart ▁beat
▁patients ▁should ▁be ▁monitor ed ▁clinic ally ▁ , ▁including ▁by ▁en dos copy ▁ .
▁what ▁cre se mba ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁in ▁a ▁study ▁completed ▁in ▁1996 ▁recruit ing ▁less ▁advanced ▁hi v -1 ▁infect ed ▁patients ▁( ▁cd 4 ▁200 -500 ▁cell s ▁/ ▁l ▁) ▁without ▁previous ▁anti ret rovi ral ▁ therapy ▁ , ▁rito na vir ▁in ▁combination ▁with ▁zid ovu dine ▁or ▁alone ▁reduce d ▁viral ▁load ▁in ▁plasma ▁and ▁increased ▁cd 4 ▁count ▁ .
▁like ▁all ▁medicine s ▁ , ▁photo bar r ▁can ▁cause ▁side ▁effects ▁ , ▁although ▁not ▁everybody ▁gets ▁them ▁ .
▁se rum ▁album in ▁is ▁considered ▁to ▁be ▁the ▁major ▁ binding ▁protein ▁ .
▁following ▁sub cuta ne ous ▁administration ▁ , ▁the ▁absolute ▁bio ava il ability ▁is ▁about ▁70 ▁% ▁ .
▁before ▁you ▁use ▁y trac is
▁the ▁use ▁of ▁rasa gi line ▁ratio ph arm ▁together ▁with ▁the ▁anti de press ants ▁contain ing ▁flu o xe tine ▁or ▁flu vo xa mine ▁should ▁be ▁avoid ed ▁ .
▁in ▁studies ▁in ▁patients ▁with ▁re lapse d ▁multiple ▁mye loma ▁treated ▁with ▁bort ez om ib ▁and ▁in ▁patients ▁with ▁previously ▁un tre ated ▁m cl ▁treated ▁with ▁bort ez om ib ▁in ▁combination ▁with ▁ ritu xim ab ▁ , ▁ cyclo phos pha mi de ▁ , ▁do xor ubi cin ▁ , ▁and ▁pred nis one ▁( ▁br - cap ▁) ▁ , ▁one ▁of ▁the ▁most ▁common ▁ha e mat ologic ▁ toxic ity ▁was ▁trans ient ▁ thro mbo cy top enia ▁ .
▁visit ▁3 ▁- ▁blood ▁cell ▁collection ▁( ▁leuk ap here sis ▁) ▁visit ▁4 ▁- ▁proven ge ▁in fusion
▁it ▁is ▁used ▁in ▁combination ▁with ▁ever ol imus ▁to ▁treat ▁patients ▁with ▁advanced ▁ki dne y ▁cancer ▁( ▁advanced ▁renal ▁cell ▁car cino ma ▁) ▁where ▁other ▁treatment s ▁( ▁so - call ed ▁" ▁veg f - tar get ed ▁ therapy ▁" ▁) ▁have ▁not ▁helped ▁stop ▁the ▁disease ▁ .
▁cases ▁of ▁increased ▁bilir u bin ▁ , ▁problems ▁with ▁bile ▁flow ▁( ▁cho les tas is ▁) ▁ , ▁hepatitis ▁and ▁injury ▁to ▁the ▁ liver ▁ , ▁including ▁fatal ▁ liver ▁failure ▁ , ▁have ▁been ▁un com mon ly ▁reported ▁ .
▁a ▁treatment ▁di ary ▁is ▁included ▁on ▁the ▁last ▁page ▁ .
▁based ▁on ▁all ▁field ▁studies ▁ , ▁the ▁proportion ▁of ▁masti tis ▁prevent ed ▁due ▁to ▁her d ▁treatment ▁with ▁im re stor ▁( ▁prevent ed ▁ fraction ▁) ▁is ▁0.2 5 ▁( ▁with ▁95 ▁% ▁confidence ▁interval ▁0.1 4 ▁- ▁0.3 5 ▁) ▁ .
▁el vite grav ir ▁: ▁au c ▁: ▁ ↓ ▁69 ▁%
▁if ▁to ler ated ▁without ▁reaction ▁ , ▁the ▁in fusion ▁rate ▁was ▁double d ▁for ▁the ▁next ▁15 ▁minutes ▁ .
▁the ▁ef fica cy ▁of ▁pra mi pe xo le ▁( ▁0.0 62 5- 0.5 ▁mg ▁/ ▁day ▁) ▁with ▁pa e dia tric ▁patients ▁a ged ▁6 -17 ▁years ▁with ▁tour ette ▁disorder ▁was ▁evaluat ed ▁in ▁a ▁6- week ▁ , ▁double - blind ▁ , ▁random ised ▁ , ▁place bo - control led ▁flexible ▁dose ▁study ▁ .
▁given ▁the ▁low ▁system ic ▁exposure ▁to ▁bri moni dine ▁following ▁topic al ▁o cular ▁administration ▁ , ▁it ▁is ▁expected ▁that ▁changes ▁in ▁plasma ▁exposure ▁would ▁not ▁be ▁clinic ally ▁relevant ▁ .
▁the ▁incide nce ▁of ▁advers e ▁reaction s ▁and ▁laborator y ▁ab normal ities ▁( ▁with ▁the ▁exception ▁of ▁eleva tions ▁of ▁alt ▁and ▁c pk ▁ , ▁see ▁below ▁) ▁were ▁similar ▁between ▁place bo ▁and ▁la mi vu dine ▁treated ▁patients ▁ .
▁ad isc rete ▁no dul es ▁will ▁receive ▁an ▁initial ▁light ▁application ▁of ▁50 ▁j ▁/ ▁cm ▁( ▁using ▁short ▁diffuse r ▁) ▁before ▁the ▁ball oon ▁light ▁application ▁ .
▁fir da pse ▁should ▁not ▁be ▁used ▁during ▁pre gna ncy ▁ .
▁the ▁most ▁frequently ▁reported ▁advers e ▁reaction s ▁were ▁gastro inte stin al ▁disorder s ▁ , ▁infection s ▁and ▁in fest ations ▁ .
▁not ▁known ▁: ▁allergi c ▁reaction s ▁( ▁including ▁ana phy la ctic ▁reaction s ▁)
▁table ▁5 ▁summa rise s ▁key ▁ef fica cy ▁measure s ▁in ▁patients ▁previously ▁treated ▁or ▁na ï ve ▁to ▁treatment ▁with ▁i pili mum ab ▁ , ▁receiving ▁pe mbro liz um ab ▁at ▁the ▁recommended ▁dose ▁ .
▁4 ▁pens ▁of ▁3 ▁ml ▁5 ▁pens ▁of ▁3 ▁ml ▁6 ▁pens ▁of ▁3 ▁ml ▁9 ▁pens ▁of ▁3 ▁ml ▁10 ▁pens ▁of ▁3 ▁ml
▁therefore ▁xo terna ▁bre ezh a ler ▁should ▁not ▁be ▁given ▁together ▁with ▁beta - ad r energi c ▁block ers ▁( ▁including ▁eye ▁drop s ▁) ▁unless ▁there ▁are ▁comp e lling ▁reasons ▁for ▁their ▁use ▁ .
▁while ▁this ▁is ▁not ▁document ed ▁with ▁apro vel ▁ , ▁a ▁similar ▁effect ▁should ▁be ▁anticipat ed ▁with ▁ang io ten sin - ii ▁receptor ▁anta gon ists ▁ .
▁di so dium ▁ phos pha te ▁an hydro us ▁so dium ▁ phos pha te ▁di ba sic ▁hep ta hydrat e ▁di so dium ▁te tra bora te ▁de ca hydrat e ▁ed ta ▁te tras o dium
▁the ▁use ▁of ▁75 ▁mg ▁tablets ▁to ▁achieve ▁the ▁recommended ▁dose ▁is ▁appropriate ▁when ▁there ▁is ▁a ▁possibility ▁of ▁hyper sensitiv ity ▁to ▁specific ▁colour ing ▁agents ▁ , ▁or ▁difficult y ▁in ▁s w allowing ▁the ▁300 ▁mg ▁or ▁600 ▁mg ▁tablets ▁ .
▁pneu moc oc cal ▁poly s ac char ide ▁ser o type ▁5 ▁* ▁1 ▁1 ▁micro gram
▁if ▁necessary ▁ , ▁your ▁doctor ▁will ▁adjust ▁the ▁dose ▁during ▁treatment ▁ .
▁it ▁should ▁only ▁be ▁used ▁to ▁estima te ▁the ▁dos age ▁remain ing ▁in ▁the ▁cart ridge ▁ .
▁it ▁may ▁take ▁a ▁few ▁minutes ▁for ▁the ▁tablets ▁to ▁dis solve ▁ .
▁long - term ▁treatment ▁with ▁imati ni b ▁may ▁be ▁associated ▁with ▁a ▁clinic ally ▁significant ▁decline ▁in ▁renal ▁function ▁ .
▁un used ▁medicinal ▁product ▁should ▁be ▁returned ▁to ▁the ▁ pharma ci st ▁ .
▁very ▁common ▁: ▁na use a ▁ , ▁vom i ting
▁the ▁other ▁ingredients ▁are ▁man ni tol ▁ , ▁hydro ch lor ic ▁acid ▁and ▁so dium ▁hydro xi de ▁( ▁see ▁section ▁2 ▁) ▁ .
▁gi ▁tum our ▁sites ▁may ▁have ▁been ▁the ▁source ▁of ▁the ▁gi ▁ble ed s ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁it ▁is ▁not ▁known ▁ , ▁whether ▁el otu zum ab ▁passe s ▁into ▁breast ▁milk ▁or ▁if ▁there ▁is ▁any ▁risk ▁to ▁the ▁breast - fed ▁infant ▁ .
▁although ▁a ▁limited ▁number ▁of ▁children ▁have ▁been ▁studie d ▁ , ▁there ▁is ▁a ▁tende ncy ▁for ▁higher ▁fre que ncies ▁of ▁advers e ▁reaction s ▁in ▁children ▁a ged ▁7 -16 ▁years ▁as ▁compared ▁to ▁adults ▁ .
▁what ▁can ▁happen ▁if ▁a ▁blood ▁clo t ▁form s ▁in ▁an ▁arter y ▁?
▁de fera sir ox ▁induc ed ▁similar ▁response s ▁in ▁ir on - over load ed ▁patients ▁with ▁other ▁ana emia s ▁ .
▁the ▁safety ▁and ▁effective ness ▁of ▁lo ju xta ▁in ▁children ▁below ▁the ▁age ▁of ▁18 ▁have ▁not ▁been ▁established ▁;
▁one ▁sa chet ▁of ▁40 ▁g ▁is ▁ sufficient ▁for ▁a ▁total ▁of ▁1,000 ▁kg ▁of ▁tur key s ▁( ▁e . g ▁ .
▁in ▁this ▁case ▁you ▁could ▁also ▁have ▁a ▁higher ▁risk ▁of ▁having ▁a ▁heart ▁attack ▁or ▁stroke ▁;
▁problems ▁getting ▁an ▁er ection ▁ , ▁changes ▁in ▁e ja c ulation ▁;
▁the ▁use ▁of ▁single - agent ▁cri zo tin ib ▁in ▁the ▁treatment ▁of ▁ros 1- posi tive ▁advanced ▁n sc lc ▁was ▁investiga ted ▁in ▁multi center ▁ , ▁multi national ▁ , ▁single - arm ▁study ▁100 1 ▁ .
▁the ▁select ive ▁action ▁of ▁bis phos phon ates ▁on ▁bone ▁is ▁based ▁on ▁their ▁high ▁a ffin ity ▁for ▁mineral ised ▁bone ▁ , ▁but ▁the ▁precise ▁molecular ▁mechanism ▁leading ▁to ▁the ▁inhibi tion ▁of ▁osteo cla stic ▁activity ▁is ▁still ▁un clear ▁ .
▁in ▁a ▁population ▁ pharma cok ine tic ▁analysis ▁of ▁patients ▁with ▁primary ▁general ised ▁to nic - clo nic ▁se iz ures ▁receiving ▁per am panel ▁up ▁to ▁8 ▁mg ▁/ ▁day ▁in ▁a ▁place bo - control led ▁clinic al ▁study ▁ , ▁per am panel ▁clear ance ▁was ▁not ▁influence d ▁by ▁base line ▁creati nine ▁clear ance ▁ .
▁this ▁is ▁increased ▁to ▁one ▁tablet ▁once ▁a ▁day ▁( ▁1 x ▁10 ▁mg ▁) ▁in ▁the ▁second ▁week ▁and ▁to ▁1 ▁and ▁a ▁half ▁tablets ▁once ▁a ▁day ▁( ▁1 x ▁15 ▁mg ▁) ▁in ▁the ▁third ▁week ▁ .
▁you ▁may ▁experience ▁withdraw al ▁symptoms ▁similar ▁to ▁the ▁possible ▁side ▁effects ▁of ▁instan yl ▁when ▁dis continu ing ▁instan yl ▁ .
▁other ▁medicine s ▁and ▁tar ce va
▁age ▁of ▁6 ▁) ▁until ▁threat ▁is ▁resolve d ▁ .
▁as ▁for ▁other ▁medicinal ▁products ▁ac ting ▁on ▁the ▁re nin - angi oten sin ▁system ▁ , ▁cau tion ▁should ▁be ▁exercise d ▁when ▁ali ski ren ▁is ▁given ▁in ▁the ▁presence ▁of ▁conditions ▁pre - dis pos ing ▁to ▁ki dne y ▁dys function ▁such ▁as ▁hypo vola emia ▁( ▁e . g . ▁due ▁to ▁blood ▁loss ▁ , ▁severe ▁or ▁prolong ed ▁di ar r ho e a ▁ , ▁prolong ed ▁vom i ting ▁ , ▁etc ▁ . ▁) ▁ , ▁heart ▁disease ▁ , ▁ liver ▁disease ▁ , ▁diabetes ▁mell itus ▁or ▁ki dne y ▁disease ▁ .
▁the ▁side ▁effects ▁reported ▁with ▁cop alia ▁h ct ▁or ▁one ▁of ▁its ▁three ▁active ▁substance s ▁( ▁am lo di pine ▁ , ▁val sar tan ▁and ▁hydro ch lor o thi azi de ▁) ▁are ▁listed ▁below ▁and ▁may ▁occur ▁with ▁the ▁use ▁of ▁cop alia ▁h ct ▁ .
▁1 ▁pre fill ed ▁sy ringe ▁with ▁solve nt
▁tho rina ne ▁is ▁used ▁in ▁adults ▁to ▁:
▁it ▁may ▁also ▁present ▁itself ▁as ▁a ▁sud den ▁nu mb ▁or ▁we ak ▁feeling ▁in ▁the ▁face ▁ , ▁arms ▁ , ▁or ▁leg s ▁ .
▁a ▁single ▁oral ▁dose ▁of ▁40 ▁mg ▁osa tero ne ▁ac etate ▁in ▁human ▁male s ▁was ▁followed ▁by ▁a ▁spor a dic ▁decrease ▁of ▁sexual ▁hormone s ▁ , ▁rever sible ▁after ▁16 ▁days ▁ .
▁figure ▁1 ▁: ▁ka plan - me ier ▁cur ve ▁of ▁overall ▁survival ▁( ▁intent - to - tre at ▁population ▁)
▁animal ▁studies ▁have ▁shown ▁ex cre tion ▁of ▁bi mato prost ▁in ▁breast ▁milk ▁ .
▁there ▁is ▁limited ▁clinic al ▁data ▁( ▁n ▁= ▁2 ▁) ▁on ▁the ▁use ▁of ▁sir tur o ▁in ▁tubercul osis ▁patients ▁a ged ▁65 ▁years ▁and ▁older ▁ .
▁read ▁the ▁following ▁instructions ▁carefully ▁before ▁using ▁your ▁ flex pen ▁ .
▁your ▁doctor ▁will ▁usually ▁tell ▁you ▁your ▁dose ▁in ▁terms ▁of ▁the ▁number ▁of ▁full ▁vi als ▁that ▁supply ▁the ▁dose ▁most ▁suite d ▁to ▁you ▁ .
▁ad minister ▁two ▁dos es ▁of ▁2 ▁ml ▁sub cuta ne ously ▁with ▁a ▁3 ▁week ▁interval ▁ .
▁ inflammation ▁of ▁the ▁pan cre as ▁ , ▁severe ▁ra shes ▁which ▁may ▁be ▁associated ▁with ▁bli sters ▁in ▁the ▁mouth ▁ , ▁nos e ▁ , ▁eyes ▁and ▁other ▁mu co sal ▁membran es ▁( ▁er y thema ▁multi forme ▁ , ▁ste ven s ▁joh n son ▁syndrome ▁) ▁ , ▁ toxic ▁epi der mal ▁nec rol ysis ▁( ▁bli s tering ▁and ▁peeling ▁of ▁the ▁top ▁layer ▁of ▁skin ▁) ▁ .
▁film - co ating ▁: ▁la ctos e ▁mono hydrat e ▁hy pro mel lose ▁titan ium ▁ dioxid e ▁macro gol ▁3000 ▁ carna uba ▁wax ▁ .
▁these ▁occur red ▁more ▁frequently ▁at ▁higher ▁zid ovu dine ▁dos es ▁( ▁1200 - ▁1500 ▁mg ▁/ ▁day ▁) ▁and ▁in ▁patients ▁with ▁poor ▁bone ▁mar row ▁reserve ▁prior ▁to ▁treatment ▁ , ▁particularly ▁with ▁advanced ▁hi v ▁disease ▁ .
▁no ▁dos age ▁adjust ment ▁is ▁necessary ▁ .
▁a ▁dedicated ▁ pharma cok ine tic ▁study ▁in ▁patients ▁with ▁he pati c ▁im pair ment ▁has ▁not ▁been ▁conduct ed ▁ .
▁there ▁is ▁limited ▁experience ▁with ▁az ar ga ▁in ▁the ▁treatment ▁of ▁patients ▁with ▁pseudo ex folia tive ▁gla u com a ▁or ▁pigment ary ▁gla u com a ▁ .
▁ gile nya ▁has ▁not ▁been ▁studie d ▁in ▁multiple ▁sc ler osis ▁patients ▁with ▁con com i tant ▁diabetes ▁mell itus ▁ .
▁she lf ▁life ▁in ▁in fusion ▁bag ▁: ▁see ▁the ▁le a flet ▁ .
▁previous ▁ therapy ▁should ▁have ▁included ▁an ▁an thra cycli ne ▁ .
▁chronic ▁pan creati tis ▁ , ▁per i ton itis ▁ , ▁blood ▁am yla se ▁increased ▁ , ▁ile us ▁para ly tic ▁ , ▁gastro o eso - ▁pha ge al ▁ref lux ▁disease ▁ , ▁im pair ed ▁gas tric ▁empty ing
▁rif ampi cin ▁au c ▁ 1.00 ▁( ▁ 0.9 3-1 . 08 ▁) ▁ ↔
▁ ores ▁or ▁ul cer s ▁in ▁the ▁mouth ▁ , ▁di ar r ho e a ▁ , ▁stomach ▁pain ▁ , ▁heart burn ▁ , ▁difficult y ▁s w allowing ▁ , ▁dry ▁mouth
▁subject s ▁treated ▁with ▁pe gin tron ▁showed ▁mild ▁dose - related ▁eleva tions ▁in ▁body ▁temperature ▁ .
▁what ▁epi sal van ▁looks ▁like ▁and ▁content s ▁of ▁the ▁pack
▁a ▁risk ▁for ▁the ▁environment ▁due ▁to ▁use ▁of ▁ gile nya ▁by ▁patients ▁with ▁re laps ing ▁multiple ▁sc ler osis ▁is ▁not ▁expected ▁ .
▁incide nce s ▁of ▁ble ed ing ▁events ▁in ▁patients ▁receiving ▁the ▁recommended ▁regime n ▁in ▁the ▁treatment ▁of ▁d vt ▁or ▁pe ▁with ▁normal ▁renal ▁function ▁ , ▁mild ▁renal ▁im pair ment ▁ , ▁moderat e ▁renal ▁im pair ment ▁and ▁severe ▁renal ▁im pair ment ▁were ▁3.0 ▁% ▁( ▁34 ▁/ ▁1,1 32 ▁) ▁ , ▁4.4 ▁% ▁( ▁32 ▁/ ▁7 33 ▁) ▁ , ▁ 6.6 ▁% ▁( ▁21 ▁/ ▁3 18 ▁) ▁ , ▁and ▁14. 5 ▁% ▁( ▁8 ▁/ ▁55 ▁) ▁respective ly ▁ .
▁whenever ▁you ▁' ll ▁experience ▁vision ▁disturb ances ▁ , ▁eye ▁disco m fort ▁/ ▁pain ▁ , ▁eye ▁red ness ▁or ▁na use a ▁and ▁vom i ting ▁ , ▁immediately ▁refer ▁to ▁your ▁doctor ▁and ▁tell ▁about ▁your ▁symptoms ▁ .
▁different ▁strength s ▁of ▁vot ubi a ▁tablets ▁can ▁be ▁combine d ▁to ▁at tain ▁the ▁desire d ▁dose ▁ .
▁mean ▁absolute ▁bio ava il ability ▁after ▁a ▁single ▁sub lingu al ▁administration ▁of ▁zal vis o ▁relative ▁to ▁a ▁one - ▁minute ▁intra ven ous ▁su fen tan il ▁in fusion ▁of ▁15 ▁micro gram s ▁was ▁59 ▁% ▁ .
▁the ▁recommended ▁dose ▁is ▁one ▁75 ▁mg ▁tablet ▁of ▁clo pido gre l ▁tad ▁per ▁day ▁to ▁be ▁taken ▁oral ly ▁with ▁or ▁without ▁food ▁ , ▁and ▁at ▁the ▁same ▁time ▁each ▁day ▁ .
▁you ▁may ▁experience ▁withdraw al ▁symptoms ▁similar ▁to ▁the ▁possible ▁side ▁effects ▁of ▁pec fen t ▁when ▁dis continu ing ▁pec fen t ▁ .
▁therefore ▁ , ▁the ▁first ▁dose ▁may ▁be ▁given ▁using ▁versi can ▁plus ▁dh ppi ▁/ ▁l 4 ▁ .
▁in ▁patients ▁with ▁allergi c ▁r hin itis ▁ , ▁ne oc lari tyn ▁tablets ▁were ▁effective ▁in ▁reli e ving ▁symptoms ▁such ▁as ▁sne ez ing ▁ , ▁na sal ▁dis charge ▁and ▁it ching ▁ , ▁as ▁well ▁as ▁o cular ▁it ching ▁ , ▁te aring ▁and ▁red ness ▁ , ▁and ▁it ching ▁of ▁pala te ▁ .
▁kom bog ly ze ▁is ▁indicate d ▁as ▁an ▁ad jun ct ▁to ▁die t ▁and ▁exercise ▁to ▁improve ▁gly ca e mic ▁control ▁in ▁adult ▁patients ▁a ged ▁18 ▁years ▁and ▁older ▁with ▁type ▁2 ▁diabetes ▁mell itus ▁in adequa tely ▁control led ▁on ▁their ▁maximal ly ▁to ler ated ▁dose ▁of ▁met form in ▁alone ▁or ▁those ▁already ▁being ▁treated ▁with ▁the ▁combination ▁of ▁sax ag lip tin ▁and ▁met form in ▁as ▁separate ▁tablets ▁ .
▁2 ▁immun os up press ant ▁ therapy ▁could ▁only ▁be ▁dis continu ed ▁at ▁or ▁after ▁week ▁26 ▁at ▁the ▁investiga tor ▁' s ▁discret ion ▁if ▁the ▁subject ▁met ▁the ▁clinic al ▁response ▁criterio n
▁the ▁volume ▁or ▁salt ▁de ple tion ▁should ▁be ▁correct ed ▁prior ▁to ▁the ▁administration ▁of ▁rasi lam lo ▁ , ▁or ▁the ▁treatment ▁should ▁start ▁under ▁close ▁medical ▁super vision ▁ .
▁do ▁not ▁use ▁this ▁medicine ▁after ▁the ▁exp i ry ▁date ▁which ▁is ▁state d ▁on ▁the ▁vi al ▁label ▁and ▁carton ▁after ▁exp ▁ .
▁initiat ion ▁dose ▁must ▁be ▁used ▁under ▁medical ▁super vision ▁and ▁include ▁monitoring ▁of ▁lung ▁function ▁ .
▁t m z ▁is ▁spontane ously ▁hydro ly zed ▁at ▁physio logic ▁ph ▁primari ly ▁to ▁the ▁active ▁species ▁ ,
▁co bici stat ▁is ▁not ▁recommended ▁ .
▁if ▁you ▁vom it ▁less ▁than ▁1 ▁hour ▁after ▁taking ▁vite kta ▁ , ▁take ▁another ▁tablet ▁with ▁food ▁ .
▁ani se ▁aroma ▁water ▁ , ▁pur ified
▁therefore ▁ , ▁con com i tant ▁use ▁of ▁luma ca f tor ▁/ ▁i vac af tor ▁with ▁p - gp ▁substrat es ▁( ▁e . g . ▁ , ▁digo xin ▁) ▁may ▁alter ▁the ▁exposure ▁of ▁these ▁substrat es ▁ .
▁fa in ting ▁ , ▁sometimes ▁ac com pani ed ▁by ▁shak ing ▁or ▁sti ffen ing ▁ , ▁has ▁been ▁reported ▁ .
▁the ▁3 ▁year ▁d fs ▁rate ▁was ▁71 ▁% ▁for ▁xe lo x ▁versus ▁67 ▁% ▁for ▁5- fu ▁/ ▁ lv ▁ .
▁the ▁sign s ▁or ▁symptoms ▁of ▁ble ed ing ▁and ▁when ▁to ▁se ek ▁attention
▁these ▁results ▁should ▁be ▁interpret ed ▁with ▁cau tion ▁due ▁to ▁the ▁small ▁sample ▁size ▁within ▁the ▁sub group s ▁ .
▁your ▁doctor ▁will ▁continue ▁giving ▁you ▁yer voy ▁for ▁a ▁total ▁of ▁4 ▁dos es ▁ , ▁de pending ▁on ▁your ▁ tolerance ▁to ▁the ▁treatment ▁ .
▁table ▁2 ▁: ▁treatment ▁effects ▁of ▁rep atha ▁compared ▁with ▁place bo ▁in ▁patients ▁with ▁primary ▁hyper ch olesterol a emia ▁and ▁mix ed ▁dys li pida emia ▁- ▁mean ▁percent ▁change ▁from ▁base line ▁to ▁average ▁of ▁weeks ▁10 ▁and ▁12 ▁( ▁% ▁ , ▁ci ▁95 ▁% ▁)
▁renal ▁failure ▁a cute ▁ , ▁renal ▁failure ▁chronic ▁* ▁ , ▁urin ary ▁tract ▁infection ▁* ▁ , ▁urin ary ▁tract ▁sign s ▁and ▁symptoms ▁* ▁ , ▁ha e matu ria ▁* ▁ , ▁urin ary ▁re tention ▁ , ▁mic turi tion ▁disorder ▁* ▁ , ▁protein uria ▁ , ▁az ota emia ▁ , ▁oli guri a ▁* ▁ , ▁pol laki s uria
▁need ▁to ▁tell ▁treat ing ▁doctor ▁immediately ▁upon ▁su spicio n ▁of ▁pre gna ncy
▁each ▁hard ▁capsule ▁contain s ▁28. 5 ▁mg ▁of ▁la ctos e ▁( ▁as ▁mono hydrat e ▁) ▁ .
▁if ▁you ▁get ▁any ▁side ▁effects ▁ , ▁talk ▁to ▁your ▁doctor ▁ , ▁or ▁nurse ▁ .
▁the ▁european ▁medicine s ▁agency ▁has ▁de fer red ▁the ▁obliga tion ▁to ▁submit ▁the ▁results ▁of ▁studies ▁with ▁i del alis ib ▁in ▁one ▁or ▁more ▁sub set s ▁of ▁the ▁pa e dia tric ▁population ▁in ▁the ▁treatment ▁of ▁mature ▁b - cell ▁neo plas ms ▁( ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁) ▁ .
▁patients ▁previously ▁expose d ▁to ▁na tali zum ab ▁should ▁normal ly ▁wait ▁a ▁minimum ▁of ▁12 ▁weeks ▁prior ▁to ▁initiat ing ▁ therapy ▁with ▁en tyvi o ▁ , ▁unless ▁otherwise ▁indicate d ▁by ▁the ▁patient ▁' s ▁clinic al ▁condition ▁ .
▁patients ▁with ▁mild ▁ liver ▁disease ▁may ▁be ▁treated ▁with ▁their ▁normal ly ▁recommended ▁dose ▁of ▁efa vir enz ▁ .
▁transfer ▁of ▁the ▁breath ▁sample ▁through ▁the ▁ analytic al ▁system ▁must ▁be ▁accomplish ed ▁without ▁is oto pe ▁ fraction ation ▁ .
▁do ▁not ▁take ▁this ▁medicine ▁if ▁any ▁of ▁the ▁above ▁apply ▁to ▁you ▁ .
▁general ▁disorder s ▁and ▁administration ▁site ▁conditions
▁a ce tic ▁acid ▁ , ▁glaci al ▁( ▁for ▁ph ▁adjust ment ▁) ▁so dium ▁hydro xi de ▁( ▁for ▁ph ▁adjust ment ▁) ▁water ▁for ▁inject ions
▁hypo phos pha t asia ▁is ▁associated ▁with ▁multiple ▁bone ▁manifestation s ▁including ▁ri cket s ▁/ ▁osteo mala cia ▁ , ▁alter ed ▁calci um ▁and ▁ phos pha te ▁metabolism ▁ , ▁im pair ed ▁growth ▁and ▁mobil ity ▁ , ▁respirator y ▁compromis e ▁that ▁may ▁require ▁ventilation ▁ , ▁and ▁vitamin ▁b 6 - respons ive ▁se iz ures ▁ .
▁zal asta ▁15 ▁mg ▁oro dis per sible ▁tablets
▁the ▁frontal ▁lo bes ▁and ▁anterior ▁cin gulat e ▁( ▁f ▁ , ▁ac ▁ , ▁a xi al ▁review ▁)
▁the ▁risk ▁for ▁ana phy la ctic ▁reaction s ▁is ▁much ▁increased ▁in ▁patients ▁with ▁a ▁history ▁of ▁aller gy ▁to ▁red ▁me at ▁or ▁ti ck ▁bit es ▁or ▁positive ▁results ▁of ▁tests ▁for ▁ ige ▁anti bo dies ▁against ▁ce tu xim ab ▁( ▁α - 1-3 - gala ctos e ▁) ▁ .
▁each ▁e distri de ▁5 ▁mg ▁film - co ated ▁tablet ▁( ▁tablet ▁) ▁contain s ▁da pag lif lozi n ▁pro pane di ol ▁mono hydrat e ▁equivalent ▁to ▁5 ▁mg ▁da pag lif lozi n ▁ .
▁patients ▁continu ing ▁treatment ▁should ▁be ▁monitor ed ▁period ically ▁ .
▁in ▁healthy ▁non - pre gnant ▁subject s ▁receiving ▁at osi ban ▁in fusion s ▁( ▁10 ▁to ▁300 ▁micro gram s ▁/ ▁min ▁over ▁12 ▁hours ▁) ▁ , ▁the ▁stea dy ▁state ▁plasma ▁concentration s ▁increased ▁proportion ally ▁to ▁the ▁dose ▁ .
▁only ▁one ▁case ▁of ▁minor ▁ rash ▁was ▁observe d ▁ .
▁this ▁is ▁therefore ▁an ▁important ▁period ▁which ▁requires ▁close ▁monitoring ▁by ▁your ▁doctor ▁ .
▁more ▁severe ▁hypo gly ca emia ▁with ▁se iz ure ▁ , ▁loss ▁of ▁ conscious ness ▁or ▁coma ▁should ▁be ▁treated ▁with ▁intra ven ous ▁gluco se ▁ .
▁the ▁following ▁is ▁a ▁suitable ▁test ▁meal ▁:
▁however ▁ , ▁as ▁proven ge ▁is ▁an ▁auto logo us ▁product ▁ , ▁a ▁positive ▁test ▁does ▁not ▁pre clu de ▁the ▁manufacture ▁of ▁the ▁product ▁ .
▁if ▁your ▁doctor ▁in struct s ▁you ▁to ▁prolong ▁each ▁tit ration ▁step ▁longer ▁than ▁1 ▁week ▁ , ▁there ▁are ▁additional ▁di ary ▁pages ▁to ▁allow ▁you ▁to ▁track ▁this ▁ .
▁70 ▁mg ▁/ ▁5 , 600 ▁iu ▁tablets ▁are ▁available ▁in ▁pack s ▁contain ing ▁2 ▁ , ▁4 ▁or ▁12 ▁tablets ▁ .
▁f p ▁+ ▁h ▁n ▁= ▁29 4
▁difference s ▁for ▁both ▁end point s ▁were ▁maintain ed ▁through ▁week ▁48 ▁ .
▁due ▁to ▁can a gli flo zin ▁' s ▁mechanism ▁of ▁action ▁ , ▁patients ▁taking ▁vo kana met ▁will ▁test ▁positive ▁for ▁gluco se ▁in ▁their ▁urin e ▁ .
▁it ching ▁ , ▁dry ▁skin ▁ , ▁unusual ▁hair ▁loss ▁or ▁thi n ning ▁ , ▁ rash
▁patients ▁with ▁clinic ally ▁significant ▁response ▁( ▁% ▁)
▁ phy s ico - chem ical ▁data ▁suggest ▁ex cre tion ▁of ▁col is time tha te ▁so dium ▁in ▁human ▁milk ▁ .
▁film - co ated ▁tablets ▁100 ▁film - co ated ▁tablets
▁powder ▁: ▁suc rose ▁ , ▁gly cine ▁ , ▁glu ta mic ▁acid ▁ , ▁so dium ▁chlor ide ▁ , ▁so dium ▁hydro xi de ▁and ▁poly sor bate ▁80 ▁solve nt ▁: ▁water ▁for ▁inject ions
▁patients ▁should ▁be ▁informe d ▁of ▁the ▁first ▁sign s ▁of ▁gastro inte stin al ▁perfor ations ▁and ▁be ▁advise d ▁to ▁consult ▁rapid ly ▁in ▁case ▁of ▁occur r ence ▁ .
▁in ▁healthy ▁subject s ▁ , ▁the ▁au c ▁( ▁0 - t ▁) ▁and ▁c max ▁for ▁digo xin ▁( ▁p - gp ▁) ▁substrat e ▁) ▁were ▁increased ▁by ▁23 ▁% ▁and ▁29 ▁% ▁respective ly ▁ , ▁when ▁given ▁together ▁due ▁to ▁p - gp ▁inhibi tion ▁by ▁vand etan ib ▁ .
▁les inu rad ▁is ▁not ▁an ▁in ▁vi tro ▁inhibi tor ▁of ▁p - gly co prote in ▁ , ▁ bc rp ▁ , ▁o at p 1 b 3 ▁ , ▁m rp 2 ▁ , ▁m rp 4 ▁ , ▁o ct 2 ▁ , ▁mate 1 ▁and ▁mate 2- k ▁ .
▁1.2 ▁ml ▁of ▁solution ▁( ▁correspond ing ▁to ▁60 ▁mi u ▁) ▁is ▁contain ed ▁in ▁a ▁pen ▁made ▁of ▁a ▁cart ridge ▁( ▁type ▁i ▁glass ▁) ▁seal ed ▁at ▁one ▁end ▁with ▁a ▁cap ▁( ▁aluminium ▁) ▁contain ing ▁a ▁ liner ▁( ▁bro mo but yl ▁rub ber ▁) ▁and ▁at ▁the ▁other ▁end ▁by ▁a ▁plu nger ▁( ▁bro mo but yl ▁rub ber ▁) ▁ .
▁always ▁use ▁a ▁new ▁need le ▁for ▁activa tion ▁ .
▁nobili s ▁ ib ▁primo ▁q x ▁l yo phil isa te ▁and ▁solve nt ▁for ▁suspens ion ▁for ▁chicken s ▁nobili s ▁ ib ▁primo ▁q x ▁l yo phil isa te ▁for ▁suspens ion ▁for ▁chicken s
▁because ▁these ▁reaction s ▁are ▁reported ▁voluntari ly ▁from ▁a ▁population ▁of ▁un certa in ▁size ▁ , ▁it ▁is ▁not ▁always ▁possible ▁to ▁reli ably ▁estima te ▁their ▁fre que ncy ▁ .
▁ana phy la ctic ▁reaction ▁including ▁ang io ede ma ▁ , ▁skin ▁reaction s ▁ , ▁bron chos pas m ▁ , ▁respirator y ▁di stress ▁ , ▁hypo tension ▁and ▁loss ▁of ▁ conscious ness ▁have ▁been ▁observe d ▁in ▁patients ▁treated ▁with ▁de x raz ox ane ▁and ▁an thra cycli nes ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁low ▁level ▁of ▁ phos pha te ▁in ▁the ▁blood ▁( ▁seen ▁in ▁tests ▁) ▁ .
▁periodo n tal ▁( ▁affect ing ▁gum s ▁) ▁and ▁dental ▁disorder s ▁ , ▁alter ed ▁mental ▁status ▁ , ▁loss ▁of ▁ conscious ness ▁ , ▁a cute ▁hyper sensitiv ity ▁reaction s ▁including ▁ur tica ria ▁( ▁hi ves ▁) ▁ , ▁ang io ede ma ▁( ▁swe lling ▁of ▁the ▁hands ▁ , ▁feet ▁ , ▁an kle s ▁ , ▁face ▁ , ▁lips ▁ , ▁mouth ▁ , ▁or ▁ thro at ▁which ▁may ▁cause ▁difficult y ▁in ▁s w allowing ▁or ▁breath ing ▁) ▁ , ▁bron cho con stri ction ▁and ▁ana phy la xis ▁( ▁a ▁severe ▁ , ▁whole - body ▁allergi c ▁reaction ▁) ▁have ▁been ▁reported ▁ , ▁but ▁their ▁fre que ncy ▁is ▁un know n ▁ .
▁patients ▁with ▁rare ▁heredita ry ▁problems ▁of ▁gala ctos e ▁in tolerance ▁ , ▁the ▁la pp ▁lac tase ▁de fici en cy ▁or ▁gluco se - gala ctos e ▁mala b sor p tion ▁should ▁not ▁take ▁this ▁medicine ▁ .
▁the ▁maximum ▁recommended ▁dose ▁for ▁this ▁medicine ▁is ▁2 ▁vi als ▁( ▁2 g ▁) ▁since ▁its ▁effective ness ▁at ▁higher ▁dos es ▁has ▁not ▁been ▁established ▁ .
▁more ▁than ▁ 30,000 ▁patients ▁enter ed ▁into ▁clinic al ▁trial s ▁with ▁clo pido gre l ▁plus ▁asa ▁at ▁maintenance ▁dos es ▁lower ▁than ▁or ▁equal ▁to ▁325 ▁mg ▁ , ▁and ▁received ▁a ▁variety ▁of ▁con com i tant ▁medicinal ▁products ▁including ▁di ure tics ▁ , ▁beta ▁block ers ▁ , ▁a ce ▁inhibi tors ▁ , ▁calci um ▁anta gon ists ▁ , ▁cholesterol ▁lower ing ▁agents ▁ , ▁corona ry ▁vaso dila tors ▁ , ▁anti dia be tic ▁agents ▁( ▁including ▁insulin ▁) ▁ , ▁anti ep ile ptic ▁agents ▁and ▁g pi ib ▁/ ▁i i ia ▁anta gon ists ▁without ▁evidence ▁of ▁clinic ally ▁significant ▁advers e ▁interaction s ▁ .
▁dry ▁mouth ▁ , ▁increased ▁sal iva ▁ , ▁to oth ▁problems ▁ , ▁ha e mor r ho ids ▁ .
▁no ▁specific ▁dose ▁recommend ation ▁is ▁necessary ▁in ▁the ▁older ▁people ▁ .
▁( ▁ata zana vir ▁300 ▁mg ▁once ▁daily ▁with
▁ex cip ient s ▁with ▁known ▁effect ▁: ▁each ▁drop ▁contain s ▁4. 25 ▁mg ▁of ▁et han ol ▁ .
▁table ▁3 ▁: ▁ef fica cy ▁of ▁zosta va x ▁on ▁zo ster ▁incide nce ▁compared ▁with ▁place bo ▁in ▁the ▁sp s ▁in ▁subject s ▁60 ▁years ▁of ▁age ▁and ▁older ▁*
▁step ▁3 ▁- ▁3 ▁capsule s ▁( ▁120 ▁mg ▁)
▁common ▁( ▁may ▁affect ▁up ▁to ▁1 ▁in ▁10 ▁people ▁) ▁: ▁oral ▁infection s ▁ , ▁wo und ▁infection ▁ , ▁reduce d ▁number ▁of ▁blood ▁cell s ▁( ▁neutro p enia ▁ , ▁ thro mbo cy top enia ▁ , ▁lymph op enia ▁ , ▁leuk op enia ▁) ▁ , ▁increased ▁sugar ▁in ▁the ▁blood ▁ , ▁loss ▁of ▁weight ▁ , ▁change ▁in ▁mental ▁status ▁or ▁alert ness ▁ , ▁anxiety ▁/ ▁depression ▁ , ▁sleep ines s ▁ , ▁difficult y ▁speaking ▁ , ▁im pair ed ▁balance ▁ , ▁di zzi ness ▁ , ▁confusion ▁ , ▁forget ful ness ▁ , ▁difficult y ▁concentrat ing ▁ , ▁in ability ▁to ▁fall ▁a sleep ▁or ▁stay ▁a sleep ▁ , ▁ting ling ▁sensation ▁ , ▁bru ising ▁ , ▁shak ing ▁ , ▁ab normal ▁or ▁blu rry ▁vision ▁ , ▁double ▁vision ▁ , ▁hearing ▁im pair ment ▁ , ▁short ness ▁of ▁breath ▁ , ▁co ugh ▁ , ▁blood ▁clo t ▁in ▁the ▁leg s ▁ , ▁fluid ▁re tention ▁ , ▁swo llen ▁leg s ▁ , ▁di ar r ho e a ▁ , ▁stomach ▁or ▁abdominal ▁pain ▁ , ▁heart burn ▁ , ▁up set ▁stomach ▁ , ▁difficult y ▁s w allowing ▁ , ▁dry ▁mouth ▁ , ▁skin ▁irrita tion ▁or ▁red ness ▁ , ▁dry ▁skin ▁ , ▁it ching ▁ , ▁muscle ▁we ak ness ▁ , ▁pain ful ▁joint s ▁ , ▁muscle ▁a ches ▁and ▁pain s ▁ , ▁frequent ▁urin ation ▁ , ▁difficult y ▁with ▁holding ▁your ▁urin e ▁ , ▁allergi c ▁reaction ▁ , ▁fe ver ▁ , ▁radi ation ▁injury ▁ , ▁face ▁swe lling ▁ , ▁pain ▁ , ▁ab normal ▁taste ▁ , ▁ab normal ▁ liver ▁function ▁tests ▁ .
▁what ▁fa bly n ▁is ▁and ▁what ▁it ▁is ▁used ▁for
▁fent an yl ▁passe s ▁into ▁breast ▁milk ▁and ▁may ▁cause ▁sed ation ▁and ▁respirator y ▁depression ▁in ▁the ▁breast - fed ▁child ▁ .
▁allergi c ▁reaction s ▁related ▁to ▁bela ta cept ▁use ▁have ▁been ▁reported ▁in ▁the ▁clinic al ▁studies ▁ .
▁any ▁disease ▁other ▁than ▁multiple ▁sc ler osis ▁that ▁could ▁better ▁explain ▁sign s ▁and ▁symptoms ▁of ▁the ▁patient ▁had ▁to ▁be ▁exclu ded ▁ .
▁blu r red ▁vision ▁due ▁to ▁swe lling ▁( ▁or ▁fluid ▁) ▁at ▁the ▁back ▁of ▁the ▁eye ▁( ▁fre que ncy ▁not ▁known ▁) ▁has ▁also ▁been ▁reported ▁in ▁patients ▁taking ▁pi og lita zone ▁kr ka ▁ .
▁how ▁to ▁store ▁leve ti race tam ▁ratio ph arm
▁no ▁ pharma cok ine tic ▁interaction ▁was ▁observe d ▁between ▁oral ▁ri va stig mine ▁and ▁digo xin ▁ , ▁war far in ▁ , ▁dia zep am ▁or ▁flu o xe tine ▁in ▁studies ▁in ▁healthy ▁volunteer s ▁ .
▁v pri v ▁400 ▁unit s ▁powder ▁for ▁solution ▁for ▁in fusion ▁ve lag lu cera se ▁alfa
▁there ▁was ▁no ▁change ▁in ▁the ▁ki ne tics ▁of ▁imati ni b ▁on ▁repeat ed ▁dos ing ▁ , ▁and ▁accumula tion ▁was ▁1.5 - 2.5 - fold ▁at ▁stea dy ▁state ▁when ▁dos ed ▁once ▁daily ▁ .
▁eye ▁drop s ▁ , ▁solution ▁ , ▁in ▁single - dos e ▁container ▁ .
▁breast - feed ing ▁is ▁not ▁recommended ▁during ▁treatment ▁with ▁ar zer ra ▁and ▁for ▁12 ▁months ▁after ▁the ▁last ▁time ▁you ▁were ▁treated ▁with ▁ar zer ra ▁ .
▁store ▁in ▁accordance ▁with ▁local ▁regulations ▁for ▁radio active ▁substance s ▁ .
▁you ▁must ▁stop ▁taking ▁these ▁medicine s ▁for ▁at ▁least ▁14 ▁days ▁before ▁starting ▁my s imba ▁( ▁see ▁" ▁do ▁not ▁take ▁my s imba ▁" ▁) ▁ .
▁considering ▁all ▁reported ▁cases ▁ , ▁there ▁is ▁a ▁strong ▁causa li ty ▁relation ▁between ▁the ▁use ▁of ▁rano lazi ne ▁and ▁the ▁occur r ence ▁of ▁severe ▁hypo na trem ia ▁ .
▁4 ▁x ▁125 ▁dos es
▁if ▁you ▁are ▁a ▁poor ▁metabol iser ▁:
▁some ▁patients ▁taking ▁combination ▁anti ret rovi ral ▁medicine s ▁such ▁as ▁stri bild ▁may ▁develop ▁a ▁bone ▁disease ▁called ▁osteo ne cro sis ▁( ▁death ▁of ▁bone ▁tissu e ▁caused ▁by ▁loss ▁of ▁blood ▁supply ▁to ▁the ▁bone ▁) ▁ .
▁population ▁ pharma cok ine tic ▁analysis ▁indicate d ▁that ▁hepatitis ▁b ▁and ▁/ ▁or ▁c ▁virus ▁co - infect ion ▁had ▁no ▁clinic ally ▁relevant ▁effect ▁on ▁the ▁exposure ▁to ▁ri lp ivi rine ▁ .
▁a ▁calcula ted ▁as ▁( ▁c max ▁- ▁base line ▁factor ▁vii i ▁) ▁divide d ▁by ▁the ▁dose ▁in ▁iu ▁/ ▁kg ▁ , ▁where ▁c max ▁is ▁the ▁maximal ▁post - ▁in fusion ▁factor ▁vii i ▁measure ment ▁ .
▁without ▁a ▁load ing ▁dose ▁ , ▁it ▁is ▁estima ted ▁that ▁at tain ment ▁of ste ady - state ▁plasma ▁concentration s ▁would ▁require ▁nearly ▁two ▁months ▁of ▁dos ing ▁ .
▁use ▁the ▁oral ▁applica tor ▁suppli ed ▁with ▁the ▁pack ▁to ▁measure ▁your ▁dose ▁accurate ly ▁( ▁see ▁also ▁section ▁3 ▁) ▁ .
▁see ▁package ▁le a flet ▁for ▁information ▁ .
▁treatment ▁should ▁be ▁dis continu ed ▁after ▁14 ▁days ▁at ▁the ▁latest ▁if ▁no ▁clinic al ▁improvement ▁is ▁apparent ▁ .
▁following ▁treatment ▁with ▁the ▁dispersi ble ▁tablet ▁ , ▁exposure ▁to ▁bo sent an ▁was ▁lower ▁than ▁with ▁the ▁film - co ated ▁tablet ▁( ▁ratio ▁of ▁geometri c ▁means ▁for ▁au c 0 - ▁0 . 87 ▁[ ▁90 ▁% ▁ci ▁: ▁0 . 78 ▁ , ▁0 . 97 ▁] ▁) ▁ .
▁kin eret ▁was ▁common ly ▁associated ▁with ▁neutro p enia ▁( ▁an c ▁< ▁1.5 ▁x ▁109 ▁/ ▁l ▁) ▁in ▁place bo - control led ▁studies ▁in ▁ra ▁ .
▁the ▁dos age ▁should ▁be ▁determine d ▁by ▁the ▁physician ▁ , ▁according ▁to ▁the ▁patient ▁' s ▁requirements ▁ .
▁the ▁quanti ty ▁of ▁so dium ▁in ▁the ▁maximum ▁daily ▁dose ▁may ▁exceed ▁200 ▁mg ▁ .
▁disc ard ▁any ▁un used ▁medium ▁after ▁each ▁investigation ▁ .
▁in ▁patients ▁previously ▁treated ▁with ▁che mo therapy ▁ , ▁the ▁initial ▁dose ▁is ▁150 ▁mg ▁/ ▁m ▁2 ▁once ▁daily ▁ , ▁to ▁be ▁increased ▁in ▁the ▁second ▁cycle ▁to ▁200 ▁mg ▁/ ▁m ▁2 ▁once ▁daily ▁ , ▁for ▁5 ▁days ▁if ▁there ▁is ▁no ▁ha e mat ological ▁ toxic ity ▁( ▁see ▁section ▁4.4 ▁) ▁ .
▁dose ▁adjust ment ▁is ▁not ▁required ▁in ▁patients ▁with ▁mild ▁to ▁moderat e ▁ liver ▁im pair ment ▁ .
▁the ▁patient ▁should ▁be ▁monitor ed ▁for ▁one ▁hour ▁following ▁in fusion ▁ .
▁patient ▁a ges ▁range d ▁from ▁22 ▁to ▁89 ▁years ▁with ▁a ▁mean ▁of ▁64 ▁years ▁ .
▁very ▁rare ▁cases ▁of ▁ana phy la xis ▁ , ▁ana phy la ctic ▁/ ▁ana phy lac to id ▁reaction s ▁and ▁shock ▁have ▁been ▁reported ▁from ▁the ▁post - marketing ▁use ▁of ▁intra ven ous ▁palo nos et ron ▁ .
▁ata zana vir ▁was ▁negative ▁in ▁an ▁am es ▁rever se - mu tation ▁as say ▁but ▁did ▁induc e ▁chr om oso mal ▁aber ration s ▁in ▁vi tro ▁in ▁both ▁the ▁ absence ▁and ▁presence ▁of ▁metabol ic ▁activa tion ▁ .
▁the ▁mechanism ▁of ▁interaction ▁is ▁decrease d ▁solu bility ▁of ▁ata zana vir ▁as ▁intra - gas tric ▁ph ▁increase s ▁with ▁h 2 ▁block ers ▁ .
▁how ▁to ▁use ▁doce ta xel ▁teva ▁ pharma
▁fre que ncies ▁are ▁define d ▁as ▁very ▁common ▁( ▁> ▁1 ▁/ ▁10 ▁) ▁ , ▁common ▁( ▁> ▁1 ▁/ ▁100 ▁to ▁< ▁1 ▁/ ▁10 ▁) ▁ , ▁un com mon ▁( ▁> ▁1 ▁/ ▁1000 ▁to ▁< ▁1 ▁/ ▁100 ▁) ▁ , ▁rare ▁( ▁> ▁1 ▁/ ▁10,000 ▁to ▁< ▁1 ▁/ ▁1000 ▁) ▁ , ▁very ▁rare ▁( ▁< ▁1 ▁/ ▁10,000 ▁) ▁ .
▁al pro lix ▁( ▁ef tren ona co g ▁alfa ▁) ▁is ▁a ▁long - ac ting ▁ , ▁fully ▁reco mbin ant ▁ , ▁fusion ▁protein ▁compris ing ▁human ▁coa g ulation ▁factor ▁ ix ▁co valent ly ▁link ed ▁to ▁the ▁ fc ▁domain ▁of ▁human ▁immun o glob ulin ▁g 1 ▁ , ▁and ▁produced ▁by ▁reco mbin ant ▁d na ▁technology ▁ .
▁if ▁you ▁stop ▁taking ▁rap am une
▁for ▁the ▁other ▁parameter s ▁the ▁improvement s ▁seen ▁for ▁the ▁combination ▁were ▁for ▁overall ▁response ▁( ▁16. 5 ▁% ▁versus ▁ 6.7 ▁% ▁) ▁; ▁clinic al ▁benefit ▁rate ▁( ▁42 . 7 ▁% ▁versus ▁27. 9 ▁% ▁) ▁; ▁time ▁to ▁progression ▁( ▁4. 8 ▁months ▁versus ▁2.4 ▁months ▁) ▁ .
▁week -14 ▁responder s ▁( ▁195 ▁/ ▁28 2 ▁) ▁were ▁anal y zed ▁for ▁the ▁primary ▁end point ▁ , ▁which ▁was ▁time ▁from ▁random isation ▁to ▁loss ▁of ▁response ▁( ▁see ▁table ▁7 ▁) ▁ .
▁keep ▁in ▁out er ▁carton ▁in ▁order ▁to ▁protect ▁from ▁light ▁ .
▁if ▁not ▁used ▁immediately ▁ , ▁in - use ▁storage ▁times ▁and ▁conditions ▁prior ▁to ▁use ▁are ▁in ▁the ▁responsibility ▁of ▁the ▁user ▁ .
▁you ▁may ▁have ▁to ▁perform ▁the ▁safety ▁test ▁several ▁times ▁before ▁insulin ▁is ▁seen ▁ .
▁1 ▁bottle ▁contain s ▁5 ▁mg ▁zo le dro nic ▁acid ▁( ▁as ▁mono hydrat e ▁) ▁ .
▁rasa gi line ▁did ▁not ▁present ▁geno toxic ▁potential ▁in ▁vivo ▁and ▁in ▁several ▁in ▁vi tro ▁systems ▁using ▁bacteria ▁or ▁he pato cy tes ▁ .
▁therefore ▁ , ▁you ▁should ▁discuss ▁the ▁benefits ▁of ▁sila po ▁with ▁your ▁doctor ▁ , ▁particularly ▁if ▁you ▁are ▁obes e ▁or ▁have ▁a ▁history ▁of ▁blood ▁clo ts ▁/ ▁blood ▁clo tting ▁disorder s ▁ .
▁physician s ▁and ▁patients ▁should ▁be ▁vigila nt ▁for ▁pro drom al ▁sign s ▁or ▁finding s ▁of ▁hepatitis ▁ , ▁such ▁as ▁ano re xia ▁ , ▁na use a ▁ , ▁ja undi ce ▁ , ▁bilir u bin uria ▁ , ▁acho lic ▁sto ol s ▁ , ▁he pato mega ly ▁or ▁ liver ▁tender ness ▁ .
▁for ▁p net ▁ , ▁the ▁recommended ▁dose ▁of ▁su tent ▁is ▁3 7.5 ▁mg ▁taken ▁oral ly ▁once ▁daily ▁without ▁a ▁schedule d ▁rest ▁period ▁ .
▁do ▁not ▁expose ▁the ▁vi als ▁to ▁direct ▁heat ▁ .
▁table ▁below ▁shows ▁that ▁the ▁incide nce ▁of ▁grade ▁4 ▁neutro p enia ▁ , ▁febr ile ▁neutro p enia ▁and ▁neutro pen ic ▁infection ▁was ▁decrease d ▁in ▁patients ▁who ▁received ▁primary ▁g - cs f ▁pro phy la xis ▁after ▁it ▁was ▁made ▁mandato ry ▁in ▁the ▁tac ▁arm - ge ica m ▁study ▁ .
▁apply ▁imi qui mod ▁cream ▁for ▁6 ▁weeks ▁ , ▁5 ▁times ▁per ▁week ▁( ▁example ▁: ▁monda y ▁to ▁fri day ▁) ▁prior ▁to ▁normal ▁sleeping ▁hours ▁ , ▁and ▁leave ▁on ▁the ▁skin ▁for ▁approximately ▁8 ▁hours ▁ .
▁for ▁a baca vir ▁there ▁was ▁a ▁decrease ▁in ▁c max ▁with ▁23 ▁% ▁and ▁au c ▁was ▁un change d ▁ .
▁one ▁control led ▁clinic al ▁trial ▁with ▁ex ta via ▁was ▁perform ed ▁in ▁patients ▁with ▁a ▁single ▁clinic al ▁event ▁and ▁magnetic ▁res on ance ▁imagin g ▁( ▁m ri ▁) ▁features ▁suggest ive ▁of ▁multiple ▁sc ler osis ▁( ▁at ▁least ▁two ▁clinic ally ▁silent ▁les ions ▁on ▁the ▁t 2- weight ed ▁m ri ▁) ▁ .
▁this ▁includes ▁the ▁gaba ▁receptor ▁complex ▁ , ▁the ▁ binding ▁site ▁for ▁seda tive ▁hypno tics ▁ , ▁and ▁receptor s ▁that ▁bind ▁neuro pe pti des ▁ , ▁cy tok ines ▁ , ▁serotonin ▁ , ▁no rad rena line ▁ , ▁a ce tyl cho line ▁ , ▁and ▁op iate s ▁ .
▁strange ▁taste ▁in ▁the ▁mouth
▁the ▁plastic ▁need le ▁cover ▁will ▁" ▁pop ▁" ▁off ▁ .
▁sun set ▁yellow ▁( ▁e 110 ▁) ▁and ▁all ura ▁red ▁( ▁e 129 ▁) ▁: ▁may ▁cause ▁allergi c ▁reaction s ▁ .
▁carton s ▁of ▁10 ▁ , ▁50 ▁or ▁100 ▁sy ring es
▁in ▁the ▁phase ▁i i ▁study ▁d 220 1 ▁( ▁resolve ▁) ▁ , ▁151 ▁patients ▁were ▁treated ▁with ▁ rani biz um ab ▁( ▁6 ▁mg ▁/ ▁ml ▁ , ▁n ▁= ▁51 ▁ , ▁10 ▁mg ▁/ ▁ml ▁ , ▁n ▁= ▁51 ▁) ▁or ▁sham ▁( ▁n ▁= ▁49 ▁) ▁by ▁monthly ▁intra vit real ▁inject ions ▁ .
▁if ▁you ▁have ▁cancer ▁of ▁ova ries ▁ , ▁u terus ▁or ▁breast ▁ .
▁ pharma co therapeut ic ▁group ▁: ▁immun os up press ants ▁ , ▁inter le u kin ▁inhibi tors ▁ , ▁at c ▁code ▁: ▁l 04 ac 05 ▁ .
▁r hab dom yol ysis ▁and ▁blood ▁creati ne ▁ phos pho kina se ▁increased ▁*
▁there ▁was ▁no ▁effect ▁on ▁se rum ▁corti sol ▁in ▁subject s ▁with ▁severe ▁he pati c ▁im pair ment ▁( ▁flu ticas one ▁fur o ate ▁/ ▁vil ante rol ▁100 ▁/ ▁12. 5 ▁micro gram s ▁) ▁ .
▁the ▁dose ▁is ▁2. 125 ▁mg ▁ tyl valo sin ▁per ▁kg ▁body weight ▁per ▁day ▁in - feed ▁for ▁7 ▁consecutiv e ▁days ▁ .
▁cael y x ▁concentrat e ▁for ▁solution ▁for ▁in fusion ▁: ▁vi als ▁which ▁provide ▁10 ▁ml ▁( ▁20 ▁mg ▁) ▁or ▁25 ▁ml ▁( ▁50 ▁mg ▁) ▁ .
▁single ▁dose ▁intra ven ous ▁studies ▁in ▁human ▁pre gna ncy ▁show ▁that ▁col is time tha te ▁so dium ▁cross es ▁the ▁place nta ▁and ▁consequent ly ▁there ▁is ▁potential ▁for ▁fo e tal ▁ toxic ity ▁if ▁ad minister ed ▁during ▁pre gna ncy ▁ .
▁table ▁1 ▁advers e ▁reaction s ▁in ▁studies ▁investiga ting ▁o selt ami vir ▁for ▁treatment ▁and ▁pre vention ▁of ▁influenza ▁in ▁adults ▁and ▁adolescents ▁or ▁through ▁post - marketing ▁sur ve illa nce
▁if ▁so dium ▁correct ion ▁exceed s ▁6 ▁mm ol ▁/ ▁l ▁during ▁the ▁first ▁6 ▁hours ▁of ▁administration ▁or ▁8 ▁mm ol ▁/ ▁l ▁during ▁the ▁first ▁6 -12 ▁hours ▁ , ▁respective ly ▁ , ▁the ▁possibility ▁that ▁se rum ▁so dium ▁correct ion ▁may ▁be ▁over ly ▁rapid ▁should ▁be ▁considered ▁ .
▁detailed ▁information ▁on ▁this ▁product ▁is ▁available ▁on ▁the ▁website ▁of ▁the ▁european ▁medicine s ▁agency ▁http ▁: ▁/ ▁/ ▁www . ema . europa . eu
▁one ▁rhe um ato id ▁ar thri tis ▁patient ▁mistake n ly ▁self - ad minister ed ▁62 ▁mg ▁en bre l ▁sub cuta ne ously ▁twice ▁week ly ▁for ▁3 ▁weeks ▁without ▁experi en cing ▁unde sir able ▁effects ▁ .
▁allow ▁yourself ▁enough ▁time ▁to ▁inject ▁the ▁whole ▁of ▁the ▁solution ▁until ▁the ▁sy ringe ▁is ▁empty ▁ .
▁no ▁information ▁is ▁available ▁on ▁the ▁use ▁of ▁the ▁vaccin e ▁in ▁ser o posi tive ▁animals ▁including ▁those ▁with ▁matern ally - der i ved ▁anti bo dies ▁ .
▁ca ▁was ▁define d ▁as ▁the ▁proportion ▁of ▁all ▁subject s ▁treated ▁who ▁did ▁not ▁smo ke ▁( ▁not ▁even ▁a ▁puff ▁of ▁a ▁cigarette ▁) ▁from ▁week ▁9 ▁through ▁week ▁52 ▁and ▁did ▁not ▁have ▁an ▁ex hal ed ▁co ▁measure ment ▁of ▁> ▁10 ▁pp m ▁ .
▁hyper tension ▁has ▁been ▁observe d ▁with ▁cabo zan tin ib ▁ .
▁what ▁you ▁need ▁to ▁know ▁before ▁you ▁use ▁ma ci ▁do ▁not ▁use ▁ma ci ▁if ▁you ▁: ▁are ▁allergi c ▁to ▁any ▁of ▁the ▁ingredients ▁of ▁ma ci ▁( ▁listed ▁in ▁section ▁6 ▁) ▁ , ▁or ▁por cine ▁products ▁( ▁deri ved ▁from ▁pig s ▁) ▁ , ▁bo vine ▁se rum ▁( ▁a ▁protein ▁deri ved ▁from ▁co ws ▁) ▁or ▁gent ami cin ▁( ▁an ▁antibiotic ▁)
▁non - clin ical ▁data ▁reveal ▁no ▁special ▁hazard s ▁for ▁humans ▁based ▁on ▁convention al ▁studies ▁of ▁safety ▁ pharma c ology ▁or ▁repeat - dos e ▁ toxic ity ▁ .
▁other ▁medicine s ▁and ▁insu man ▁implant able
▁the ▁safety ▁of ▁the ▁product ▁in ▁male ▁dog s ▁and ▁male ▁cat s ▁used ▁for ▁breed ing ▁has ▁not ▁been ▁determine d ▁ .
▁if ▁viagra ▁does ▁not ▁help ▁you ▁to ▁get ▁an ▁er ection ▁ , ▁or ▁if ▁your ▁er ection ▁does ▁not ▁last ▁long ▁enough ▁for ▁you ▁to ▁complete ▁sexual ▁inter cours e ▁you ▁should ▁tell ▁your ▁doctor ▁ .
▁some ▁people ▁will ▁get ▁this ▁infection ▁whilst ▁very ▁young ▁but ▁for ▁others ▁it ▁will ▁be ▁much ▁later ▁ .
▁1 ▁ml ▁sy ringe ▁) ▁and ▁inject ion ▁need le ▁( ▁e . g ▁ .
▁rough ▁handling ▁or ▁mis use ▁may ▁cause ▁in ac cura te ▁dos ing ▁ , ▁which ▁can ▁lead ▁to ▁too ▁high ▁or ▁too ▁low ▁blood ▁sugar ▁level ▁ .
▁treatment - em er gent ▁persist ent ▁ isolation ▁( ▁define d ▁as ▁absent ▁at ▁screening ▁/ ▁base line ▁then ▁present ▁at ▁3 ▁or ▁more ▁subsequent ▁consecutiv e ▁visit s ▁) ▁of ▁m ssa ▁occur red ▁in ▁6 ▁% ▁of ▁azt re on am - tre ated ▁patients ▁compared ▁to ▁3 ▁% ▁of ▁t ns - tre ated ▁patients ▁ .
▁do ▁not ▁take ▁any ▁medicine ▁to ▁treat ▁di ar r ho e a ▁without ▁first ▁checking ▁with ▁your ▁doctor ▁ .
▁ul ti bro ▁bre ezh a ler ▁increased ▁post - dos e ▁tro ugh ▁fe v 1 ▁by ▁200 ▁ml ▁compared ▁to ▁place bo ▁at ▁the ▁26- week ▁primary ▁end point ▁( ▁p ▁< ▁0.0 01 ▁) ▁and ▁showed ▁statistic ally ▁significant ▁increase s ▁compared ▁to ▁each ▁mono therapy ▁component ▁treatment ▁arm ▁( ▁in da cate rol ▁and ▁gly copy rro nium ▁) ▁as ▁well ▁as ▁the ▁tio tropi um ▁treatment ▁arm ▁ , ▁as ▁shown ▁in ▁the ▁below ▁table ▁ .
▁watch ▁the ▁status ▁light ▁during ▁the ▁inject ion ▁process ▁ .
▁your ▁doctor ▁may ▁do ▁regular ▁blood ▁tests ▁while ▁you ▁are ▁receiving ▁iba ndro nic ▁acid ▁accord ▁ .
▁z yp adh era ▁210 ▁mg ▁: ▁each ▁vi al ▁contain s ▁olan za pine ▁pamo ate ▁mono hydrat e ▁equivalent ▁to ▁210 ▁mg ▁olan za pine ▁ .
▁no ▁dose ▁adjust ment ▁is ▁necessary ▁in ▁patients ▁above ▁the ▁age ▁of ▁65 ▁years ▁( ▁see ▁section ▁5.2 ▁) ▁ .
▁the ▁required ▁quanti ty ▁of ▁product ▁is ▁thorough ly ▁mix ed ▁with ▁a ▁feed ▁ingredient ▁of ▁similar ▁physical ▁nature ▁( ▁e . g . ▁w heat ▁mid d lings ▁) ▁in ▁the ▁proportion ▁: ▁1 ▁part ▁eco nor ▁10 ▁% ▁premi x ▁to ▁10 ▁parts ▁feed ▁ingredient ▁ .
▁ assemble ▁the ▁suppli es ▁you ▁will ▁need ▁for ▁your ▁inject ion ▁ .
▁the ▁european ▁medicine s ▁agency ▁has ▁wa i ved ▁the ▁obliga tion ▁to ▁submit ▁the ▁results ▁of ▁studies ▁with ▁troba lt ▁in ▁pa e dia tric ▁patients ▁a ged ▁0 ▁to ▁below ▁2 ▁years ▁with ▁len no x ▁ga sta ut ▁syndrome ▁( ▁see ▁section ▁4.2 ▁for ▁information ▁on ▁pa e dia tric ▁use ▁) ▁ .
▁eight een ▁percent ▁of ▁patients ▁achieve d ▁ , ▁or ▁had ▁an ▁improve d ▁response ▁[ ▁mr ▁( ▁11 ▁% ▁) ▁or ▁pr ▁( ▁7 ▁% ▁) ▁] ▁with ▁combination ▁treatment ▁ .
▁if ▁a ▁bit ▁of ▁alcohol ▁is ▁left ▁on ▁the ▁skin ▁ , ▁you ▁may ▁get ▁a ▁sting ing ▁sensation ▁ .
▁if ▁you ▁are ▁taking ▁any ▁medicine s ▁to ▁prevent ▁blood ▁clo ts ▁( ▁e . g . ▁war far in ▁ , ▁ac eno cou mar ol ▁)
▁no ▁case ▁of ▁over dos e ▁has ▁been ▁reported ▁ .
▁the ▁daily ▁dose ▁of ▁bri vara ce tam ▁range d ▁from ▁5 ▁to ▁200 ▁mg ▁/ ▁day ▁across ▁these ▁studies ▁ .
▁recently ▁treated ▁animals ▁should ▁not ▁be ▁handle d ▁until ▁the ▁application ▁site ▁is ▁dry
▁therefore ▁ , ▁the ▁progression - free ▁survival ▁advantage ▁primari ly ▁reflect s ▁the ▁population ▁with ▁disease ▁stabil isation ▁( ▁correspond ing ▁to ▁67 ▁% ▁of ▁the ▁afin itor ▁treatment ▁group ▁) ▁ .
▁pack ▁size s ▁of ▁1 ▁ , ▁10 ▁or ▁25 ▁vi als ▁ .
▁repeat ▁step ▁6 ▁ , ▁if ▁more ▁than ▁one ▁vi al ▁of ▁reco mbin ant ▁human ▁hy alu ron idas e ▁is ▁needed ▁for ▁your ▁dose ▁ .
▁do ▁not ▁try ▁to ▁remove ▁this ▁air ▁bu bble ▁before ▁making ▁the ▁inject ion ▁- ▁you ▁may ▁los e ▁some ▁of ▁the ▁medicine ▁if ▁you ▁do ▁ .
▁each ▁bottle ▁contain s ▁either ▁30 ▁tablets ▁or ▁350 ▁tablets ▁ .
▁special ▁population s ▁el der ly ▁patients ▁:
▁mye lo dys plast ic ▁syndrome ▁/ ▁a cute ▁mye lo id ▁leuk a emia
▁this ▁indicate s ▁a ▁low ▁like li hood ▁for ▁interaction s ▁with ▁other ▁medicinal ▁products ▁through ▁plasma ▁protein ▁ binding ▁dis place ment ▁ .
▁pro phy la ctic ▁anti py re tic ▁medication ▁is ▁recommended ▁: ▁for ▁all ▁children ▁receiving ▁ preven ar ▁simultan e ously ▁with ▁vaccin es ▁contain ing ▁whole ▁cell ▁per tus sis ▁because ▁of ▁higher ▁rate ▁of ▁febr ile ▁reaction s ▁( ▁see ▁section ▁4. 8 ▁) ▁ . ▁for ▁children ▁with ▁se iz ure ▁disorder s ▁or ▁with ▁a ▁prior ▁history ▁of ▁febr ile ▁se iz ures ▁ .
▁teva ▁ pharma ▁b . v . ▁ , ▁s wens weg ▁5 ▁ , ▁20 31 ga ▁haar lem ▁ , ▁the ▁ne ther lands
▁it ▁is ▁used ▁as ▁a ▁consolida tion ▁ therapy ▁to ▁improve ▁the ▁re duction ▁in ▁the ▁number ▁of ▁lymph oma ▁cell s ▁( ▁re mission ▁) ▁achieve d ▁with ▁the ▁initial ▁che mo therapy ▁regime n ▁ .
▁clinic al ▁trial s ▁in vol ving ▁6 987 ▁subject s ▁who ▁received ▁pro quad ▁demonstrat ed ▁detect able ▁immun e ▁response s ▁to ▁me as les ▁ , ▁mum ps ▁ , ▁rub ella ▁ , ▁and ▁vari cella ▁in ▁a ▁high ▁proportion ▁of ▁individuals ▁ .
▁pain ▁in ▁the ▁ab dom en ▁( ▁stomach ▁) ▁ , ▁caused ▁by ▁ inflammation ▁of ▁the ▁pan cre as
▁bli ster ▁pack ▁of ▁28 ▁x ▁1 ▁mg ▁varen ic line ▁film - co ated ▁tablets ▁ , ▁heat ▁seal ed ▁card
▁treatment ▁initiat ion ▁with ▁re vas c ▁should ▁be ▁under tak en ▁only ▁in ▁a ▁setting ▁where ▁medical ▁assistance ▁is ▁read ily ▁available ▁and ▁where ▁there ▁is ▁access ▁to ▁treatment ▁for ▁ana phy la ctic ▁reaction s ▁ .
▁en var sus ▁ therapy ▁should ▁commence ▁at ▁a ▁dose ▁of ▁0.1 1 ▁- ▁0.1 3 ▁mg ▁/ ▁kg ▁/ ▁day ▁ad minister ed ▁once ▁daily ▁in ▁the ▁morning ▁ .
▁in ▁healthy ▁volunteer s ▁ , ▁no ▁significant ▁interaction ▁was ▁observe d ▁when ▁my co phen ola te ▁mo fe til ▁was ▁con com i tant ly ▁ad minister ed ▁with ▁nor flo xa cin ▁or ▁metro ni da zole ▁separate ly ▁ .
▁+ ▁species ▁with ▁> ▁50 ▁% ▁acquire d ▁resist ance ▁in ▁one ▁or ▁more ▁member ▁state
▁in ▁smoking ▁subject s ▁with ▁mild ▁he pati c ▁dys function ▁ , ▁mean ▁elimina tion ▁half - life ▁( ▁39 . 3 ▁hr ▁) ▁was ▁prolong ed ▁and ▁clear ance ▁( ▁18. 0 ▁l ▁/ ▁hr ▁) ▁was ▁reduce d ▁analog ous ▁to ▁non - smo king ▁healthy ▁subject s ▁( ▁4 8.8 ▁hr ▁and
▁the ▁con com i tant ▁administration ▁with ▁fus i dic ▁acid ▁is ▁contra indica ted ▁in ▁dermatolog ical ▁infection s ▁ . ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁this ▁medicinal ▁product ▁must ▁not ▁be ▁mix ed ▁with ▁other ▁medicinal ▁products ▁ .
▁this ▁will ▁help ▁you ▁get ▁the ▁best ▁results ▁and ▁lower ▁the ▁risk ▁of ▁side ▁effects ▁ .
▁the ▁race ▁distribution ▁of ▁subject s ▁was ▁as ▁follow s ▁: ▁77 ▁% ▁white ▁ , ▁19 ▁% ▁black ▁ , ▁and ▁4 ▁% ▁others ▁ .
▁zu ram pic ▁causes ▁an ▁increase ▁in ▁renal ▁u ric ▁acid ▁ex cre tion ▁ , ▁which ▁may ▁lead ▁to ▁trans ient ▁increase s ▁in ▁se rum ▁creati nine ▁ , ▁renal - related ▁advers e ▁reaction s ▁and ▁ki dne y ▁sto nes ▁ .
▁plasma ▁concentration s ▁were ▁higher ▁in ▁female s ▁than ▁in ▁male s ▁ , ▁without ▁relevant ▁influence ▁on ▁ef fica cy ▁ .
▁this ▁as say ▁is ▁limited ▁in ▁that ▁it ▁is ▁sensitive ▁for ▁inter fer on ▁but ▁la cks ▁specific ity ▁for ▁inter fer on ▁beta ▁ .
▁patients ▁were ▁followed ▁for ▁a ▁media n ▁of ▁71 ▁weeks ▁and ▁87 ▁weeks ▁ , ▁respective ly ▁ .
▁the ▁phase ▁of ▁the ▁poly - t ▁variant ▁identified ▁with ▁the ▁r 117 h ▁mutation ▁should ▁be ▁determine d ▁in ▁accordance ▁with ▁local ▁clinic al ▁recommendations ▁ .
▁therefore ▁ , ▁care ▁should ▁be ▁taken ▁if ▁cell cept ▁1 ▁g ▁/ ▁5 ▁ml ▁powder ▁for ▁oral ▁suspens ion ▁is ▁ad minister ed ▁to ▁patients ▁with ▁ phen y lke ton uria ▁( ▁see ▁section ▁6.1 ▁)
▁the ▁maximum ▁dose ▁ad minister ed ▁to ▁human ▁subject s ▁in ▁clinic al ▁studies ▁was ▁200 ▁mg ▁as ▁a ▁single ▁dose ▁; ▁there ▁were ▁no ▁advers e ▁reaction s ▁ .
▁have ▁you ▁recently ▁become ▁ill ▁?
▁de laman id ▁is ▁not ▁recommended ▁in ▁patients ▁with ▁moderat e ▁to ▁severe ▁he pati c ▁im pair ment ▁( ▁see ▁section s ▁4.4 ▁and ▁5.2 ▁) ▁ .
▁however ▁ , ▁la cta ting ▁mother s ▁should ▁be ▁advise d ▁to ▁avoid ▁breast ▁feed ing ▁or ▁alternative ▁medicinal ▁products ▁used ▁ .
▁your ▁doctor ▁will ▁ask ▁you ▁to ▁have ▁blood ▁tests ▁period ically ▁during ▁treatment ▁with ▁gli di pion ▁ .
▁to ▁prevent ▁cat s ▁from ▁being ▁accident ally ▁expose d ▁to ▁the ▁product ▁ , ▁keep ▁treated ▁dog s ▁away ▁from ▁cat s ▁until ▁the ▁application ▁site ▁is ▁dry ▁ .
▁a cute ▁lymph obla stic ▁leuk a emia ▁is ▁a ▁form ▁of ▁leuk a emia ▁in ▁which ▁certain ▁ab normal ▁white ▁cell s ▁( ▁na med ▁lymph obla st s ▁) ▁start ▁growing ▁out ▁of ▁control ▁ .
▁co - administration ▁may ▁cause ▁significant ▁decrease s ▁in ▁the ▁plasma ▁concentration s ▁of ▁ri lp ivi rine ▁( ▁in duction ▁of ▁cy p 3 a ▁) ▁and ▁te no fo vir ▁ala fen ami de ▁( ▁in duction ▁of ▁p - gp ▁) ▁ .
▁your ▁child ▁will ▁first ▁be ▁given ▁other ▁medicine s ▁ .
▁gen vo ya ▁should ▁not ▁be ▁initiat ed ▁in ▁patients ▁with ▁estima ted ▁cr cl ▁< ▁30 ▁ml ▁/ ▁min ▁as ▁there ▁are ▁limited ▁data ▁available ▁regarding ▁the ▁use ▁of ▁gen vo ya ▁in ▁this ▁population ▁( ▁see ▁section s ▁5.1 ▁and ▁5.2 ▁) ▁ .
▁flu - like ▁symptoms ▁may ▁also ▁be ▁reduce d ▁by ▁administration ▁of ▁non - steroid al ▁anti - in flam ma tory ▁medicinal ▁products ▁ .
▁10 ▁ml ▁twice ▁daily
▁the ▁rate ▁of ▁t kv ▁increase ▁over ▁3 ▁years ▁was ▁significantly ▁less ▁for ▁to lv ap tan - tre ated ▁subject s ▁than ▁for ▁subject s ▁receiving ▁place bo ▁: ▁2. 80 ▁% ▁per ▁year ▁vs ▁5. 51 ▁% ▁per ▁year ▁ , ▁respective ly ▁( ▁ratio ▁of ▁geometri c ▁mean ▁ 0.9 74 ▁; ▁95 ▁% ▁ci ▁0 . 969 ▁to ▁0 . 980 ▁; ▁p ▁< ▁0.0 001 ▁) ▁ .
▁how ▁to ▁store ▁bene pali
▁though ▁ef fica cy ▁may ▁not ▁be ▁complete ▁ , ▁ime pito in ▁is ▁considered ▁to ▁be ▁a ▁suitable ▁treatment ▁option ▁in ▁some ▁dog s ▁because ▁of ▁its ▁safety ▁profile ▁ .
▁if ▁this ▁occur s ▁ , ▁they ▁should ▁be ▁evaluat ed ▁fully ▁ , ▁and ▁appropriate ▁intervention ▁considered ▁on ▁an ▁individual ▁basis ▁ .
▁tel zir ▁tablet ▁can ▁be ▁taken ▁with ▁or ▁without ▁food ▁ .
▁re - administration ▁for ▁an ky los ing ▁ spon dy liti s
▁your ▁heart ▁might ▁beat ▁very ▁slowly ▁or ▁you ▁may ▁feel ▁di zzy ▁ .
▁zo meta ▁4 ▁mg ▁/ ▁100 ▁ml ▁solution ▁for ▁in fusion
▁stale vo ▁75 ▁mg ▁/ ▁18. 75 ▁mg ▁/ ▁200 ▁mg ▁tablet ▁comes ▁in ▁five ▁different ▁pack ▁size s ▁( ▁10 ▁ , ▁30 ▁ , ▁100 ▁ , ▁130 ▁or ▁175 ▁tablets ▁) ▁ .
▁may ▁cause ▁stomach ▁up set ▁and ▁di ar r ho e a ▁ .
▁after ▁the ▁cap ▁is ▁removed ▁ , ▁if ▁the ▁tam per ▁evident ▁snap ▁col lar ▁is ▁loo se ▁ , ▁remove ▁before ▁using ▁product ▁ .
▁when ▁remo ving ▁the ▁need le ▁ , ▁withdraw ▁it ▁from ▁the ▁les ion ▁slowly ▁to ▁avoid ▁le ak age ▁or ▁s plash ▁back ▁of ▁im lyg ic ▁at ▁the ▁ insertion ▁point ▁ .
▁interaction ▁studies ▁with ▁i trac ona zole ▁and ▁keto con a zole ▁ , ▁two ▁cy p 3 a 4 ▁inhibi tors ▁ , ▁showed ▁that ▁maximum ▁plasma ▁concentration s ▁of ▁te li thro my cin ▁were ▁increased ▁respective ly ▁by ▁1. 22 ▁and ▁1. 51 ▁ fold ▁and ▁au c ▁by ▁respective ly ▁1. 54 ▁ fold ▁and ▁2.0 ▁ fold ▁ .
▁patients ▁should ▁be ▁instru cted ▁to ▁inform ▁their ▁physician s ▁upon ▁the ▁occur r ence ▁of ▁any ▁skin ▁changes ▁ .
▁please ▁inform ▁your ▁doctor ▁immediately ▁if ▁you ▁experience ▁che st ▁disco m fort ▁ .
▁ 0.4 ▁ml ▁of ▁solution ▁in ▁a ▁clear ▁ , ▁colour less ▁type ▁i ▁neutral ▁glass ▁sy ringe ▁barre l ▁with ▁fixed ▁need le ▁and ▁need le ▁ shield ▁closed ▁by ▁chlor o but yl ▁rub ber ▁stopper ▁and ▁a ▁yellow ▁poly propyl ene ▁plu nger ▁rod ▁ .
▁your ▁doctor ▁may ▁need ▁to ▁change ▁your ▁dose ▁ , ▁or ▁stop ▁your ▁treatment ▁temporar ily ▁or ▁permanent ly ▁ .
▁over dos e ▁( ▁symptoms ▁ , ▁emergency ▁procedure s ▁ , ▁anti do tes ▁)
▁ara - c ▁2 x ▁2 ▁g ▁/ ▁m 2 ▁i . v . ▁( ▁3 ▁h ▁ , ▁q ▁12 ▁h ▁) ▁ , ▁day ▁5
▁however ▁ , ▁c max ▁and ▁t max ▁of ▁ro flu mi last ▁n - oxid e ▁are ▁una ffe cted ▁ .
▁drink ▁it ▁straight ▁away ▁ .
▁levo do pa ▁/ ▁car bido pa ▁/ ▁en ta ca pone ▁or ion ▁175 ▁/ ▁43 . 75 ▁/ ▁200 ▁mg
▁patient ▁dose ▁( ▁mg ▁) ▁divide d ▁by ▁1 ▁( ▁mg ▁/ ▁ml ▁concentrat e ▁of ▁vi mizi m ▁) ▁= ▁total ▁number ▁of ▁ml ▁of ▁vi mizi m
▁ir besar tan ▁had ▁no ▁effect ▁upon ▁fertil ity ▁of ▁treated ▁rat s ▁and ▁their ▁off spring ▁up ▁to ▁the ▁dose ▁levels ▁induc ing ▁the ▁first ▁sign s ▁of ▁parent al ▁ toxic ity ▁( ▁see ▁section ▁5.3 ▁) ▁ .
▁at ▁the ▁end ▁of ▁your ▁patch ▁cycle ▁( ▁week ▁4 ▁) ▁:
▁the ▁need ▁for ▁effective ▁contra ception ▁ , ▁without ▁interrupt ion ▁ , ▁4 ▁weeks ▁before ▁starting ▁treatment ▁ , ▁throughout ▁the ▁entire ▁du ration ▁of ▁treatment ▁ , ▁and ▁4 ▁weeks ▁after ▁the ▁end ▁of ▁treatment
▁in ▁the ▁rien so ▁and ▁oral ▁ir on ▁groups ▁ , ▁42 ▁% ▁and ▁44 ▁% ▁of ▁patients ▁ , ▁respective ly ▁ , ▁were ▁receiving ▁er y thro po ies is ▁stimula ting ▁agents ▁( ▁esas ▁) ▁at ▁base line ▁ .
▁for ▁patients ▁switch ing ▁from ▁separate ▁tablets ▁of ▁a log lip tin ▁and ▁met form in ▁( ▁as ▁dual ▁ therapy ▁or ▁as ▁part ▁of ▁triple ▁ therapy ▁with ▁insulin ▁) ▁ , ▁both ▁a log lip tin ▁and ▁met form in ▁should ▁be ▁dos ed ▁at ▁the ▁total ▁daily ▁dose ▁already ▁being ▁taken ▁; ▁the ▁individual ▁dose ▁of ▁a log lip tin ▁should ▁be ▁halv ed ▁as ▁it ▁will ▁be ▁taken ▁twice ▁daily ▁whilst ▁the ▁dos ing ▁of ▁met form in ▁should ▁remain ▁un change d ▁ .
▁anti body ▁fragment s ▁are ▁known ▁to ▁be ▁elimina ted ▁main ly ▁by ▁prote oly tic ▁cata bol ism ▁in ▁the ▁ki dne y ▁ .
▁you ▁must ▁throw ▁away ▁the ▁bottle ▁4 ▁weeks ▁after ▁you ▁first ▁opened ▁it ▁ , ▁to ▁prevent ▁infection s ▁ , ▁and ▁use ▁a ▁new ▁bottle ▁ .
▁this ▁is ▁to ▁make ▁sure ▁that ▁your ▁medicine ▁is ▁fully ▁effective ▁ , ▁and ▁to ▁reduce ▁the ▁risk ▁of ▁developing ▁resist ance ▁to ▁the ▁treatment ▁ .
▁drink ing ▁alcohol ▁may ▁affect ▁your ▁ability ▁to ▁get ▁an ▁er ection ▁ .
▁sug amma dex ▁can ▁be ▁used ▁to ▁rever se ▁different ▁levels ▁of ▁ roc uro nium ▁or ▁vec uro nium ▁induc ed ▁neuro mus cular ▁block ade ▁:
▁no ▁dose ▁adjust ment ▁of ▁in cre syn c ▁for ▁patients ▁with ▁mild ▁renal ▁im pair ment ▁is ▁necessary ▁( ▁see ▁section ▁4.2 ▁) ▁ .
▁each ▁vi al ▁contain s ▁80 ▁micro gram s ▁of ▁pe g inter fer on ▁alfa -2 b ▁measure d ▁on ▁a ▁protein ▁basis ▁ .
▁calcula ted ▁creati nine ▁clear ance ▁ ≥ ▁30 ▁ml ▁/ ▁mina
▁therefore ▁ , ▁an ▁alternative ▁ , ▁effective ▁ , ▁safe ▁method ▁of ▁contra ception ▁should ▁be ▁used ▁during ▁treatment ▁( ▁see ▁section ▁4.5 ▁) ▁ .
▁live nsa ▁is ▁not ▁for ▁use ▁in ▁children ▁and ▁adolescents ▁ .
▁tell ▁your ▁doctor ▁immediately ▁if ▁you ▁are ▁having ▁any ▁thoughts ▁or ▁feeling s ▁about ▁hur ting ▁yourself ▁ .
▁the ▁decline ▁from ▁pe ak ▁plasma ▁concentration ▁of ▁asi ii ▁occur s ▁in ▁a ▁bi pha sic ▁manner ▁and ▁is ▁character ized ▁by ▁an ▁initial ▁rapid ▁distribution ▁phase ▁followed ▁by ▁a ▁slow er ▁terminal ▁elimina tion ▁phase ▁ .
▁patients ▁with ▁substance ▁use ▁/ ▁abuse
▁fe ver ▁ ≥ ▁38 ▁○ ▁c ▁and ▁an c
▁the ▁princip le ▁route ▁of ▁ex cre tion ▁in ▁dog s ▁is ▁via ▁the ▁bile ▁( ▁> ▁80 ▁% ▁) ▁with ▁the ▁remain der ▁via ▁the ▁urin e ▁ .
▁colour less ▁type ▁i ▁glass ▁vi als ▁of ▁10 ▁ml ▁ , ▁20 ▁ml ▁or ▁100 ▁ml ▁ , ▁closed ▁with ▁a ▁rub ber ▁stopper ▁and ▁seal ed ▁with ▁an ▁aluminium ▁cap ▁ .
▁se rum ▁electro ly tes ▁should ▁be ▁monitor ed ▁in ▁chronic ▁renal ▁failure ▁patients ▁ .
▁although ▁in ▁the ▁majority ▁of ▁cases ▁the ▁information ▁was ▁too ▁limited ▁to ▁allow ▁a ▁causa li ty ▁assessment ▁ , ▁con found ing ▁factors ▁such ▁as ▁pre - exist ing ▁lup us ▁ , ▁including ▁potential ▁in cip ient ▁s le ▁ , ▁were ▁present ▁in ▁many ▁of ▁the ▁remain ing ▁cases ▁and ▁the ▁path ogen es is ▁of ▁s le ▁/ ▁drug - indu ced ▁lup us ▁is ▁still ▁poor ly ▁understood ▁and ▁probably ▁multi factor ial ▁ , ▁it ▁does ▁not ▁appear ▁un rea son able ▁that ▁xo la ir ▁ , ▁a ▁drug ▁that ▁form s ▁immun e ▁complexe s ▁with ▁ ige ▁with ▁the ▁potential ▁to ▁induc e ▁immun e ▁complex ▁injury ▁and ▁for ▁which ▁events ▁such ▁as ▁se rum ▁sick ness ▁have ▁been ▁rare ly ▁reported ▁ , ▁could ▁play ▁a ▁role ▁in ▁the ▁path ogen es is ▁of ▁s le ▁/ ▁drug - indu ced ▁lup us ▁ .
▁manufacture r ▁responsible ▁for ▁bat ch ▁release
▁aza thi op rine ▁is ▁a ▁medicine ▁that ▁sup press es ▁your ▁immun e ▁system ▁ , ▁using ▁this ▁medicine ▁in ▁combination ▁with ▁riba vir in ▁may ▁increase ▁your ▁risk ▁of ▁developing ▁severe ▁blood ▁disorder s . ▁anti - human ▁immun o de fici en cy ▁virus ▁( ▁hi v ▁) ▁medicine s ▁- ▁[ ▁nucleo side ▁rever se ▁tran script ase ▁inhibi tor ▁( ▁nr ti ▁) ▁ , ▁and ▁/ ▁or ▁combine d ▁anti - ret rovi ral ▁ therapy ▁( ▁cart ▁) ▁] ▁:
▁prepare ▁the ▁required ▁number ▁of ▁vi als ▁( ▁2 ▁vi als ▁for ▁the ▁300 ▁mg ▁dose ▁) ▁ .
▁the ▁active ▁substance ▁is ▁bo ce pre vir ▁ .
▁the ▁administration ▁system ▁is ▁intended ▁for ▁use ▁in ▁the ▁electro magnet ic ▁environment ▁specifi ed ▁below ▁ .
▁table ▁6 ▁: ▁das atin ib ▁patients ▁with ▁b cr - a bl ▁10 ▁% ▁and ▁> ▁10 ▁% ▁at ▁3 ▁months
▁safety ▁and ▁ef fica cy ▁data ▁are ▁available ▁which ▁demonstrat e ▁that ▁this ▁vaccin e ▁can ▁be ▁mix ed ▁and ▁ad minister ed ▁with ▁meri al ▁non - ad ju vante d ▁vaccin e ▁against ▁fel ine ▁leuk a emia ▁and ▁/ ▁or ▁ad minister ed ▁the ▁same ▁day ▁but ▁not ▁mix ed ▁with ▁meri al ▁ad ju vante d ▁vaccin e ▁against ▁rabi es ▁ .
▁mean ▁du ration ▁of ▁treatment ▁with ▁bas al ▁insulin ▁at ▁base line ▁( ▁years ▁)
▁these ▁patients ▁should ▁be ▁treated ▁with ▁cau tion ▁when ▁re - ad minister ing ▁a gal sida se ▁beta ▁( ▁see ▁section ▁4. 8 ▁) ▁ .
▁vor ico na zole ▁is ▁indicate d ▁for ▁pa e dia tric ▁patients ▁a ged ▁two ▁years ▁or ▁older ▁ .
▁the ▁lo west ▁effective ▁dose ▁of ▁flu ticas one ▁propi onate ▁needed ▁to ▁maintain ▁adequat e ▁as th ma ▁control ▁should ▁be ▁used ▁in ▁the ▁treatment ▁of ▁pregnant ▁women ▁ .
▁these ▁reaction s ▁can ▁usually ▁be ▁managed ▁by ▁with hold ing ▁imati ni b ▁temporar ily ▁and ▁with ▁di ure tics ▁and ▁other ▁appropriate ▁support ive ▁care ▁measure s ▁ .
▁what ▁im bru vica ▁looks ▁like ▁and ▁content s ▁of ▁the ▁pack
▁in ▁vi tro ▁studies ▁show ▁that ▁the ▁metabolism ▁of ▁brin zola mi de ▁main ly ▁involve s ▁cy p 3 a 4 ▁as ▁well ▁as ▁at ▁least ▁four ▁other ▁iso zy mes ▁( ▁cy p 2 a 6 ▁ , ▁cy p 2 b 6 ▁ , ▁cy p 2 c 8 ▁and ▁cy p 2 c 9 ▁) ▁ .
▁what ▁je t rea ▁looks ▁like ▁and ▁content s ▁of ▁the ▁pack
▁the ▁requirements ▁for ▁sub mission ▁of ▁periodic ▁safety ▁update ▁reports ▁for ▁this ▁medicinal ▁product ▁are ▁set ▁out ▁in ▁the ▁list ▁of ▁union ▁reference ▁dates ▁( ▁eur d ▁list ▁) ▁provided ▁for ▁under ▁article ▁107 c ▁( ▁7 ▁) ▁of ▁direct ive ▁2001 ▁/ ▁83 ▁/ ▁ec ▁and ▁any ▁subsequent ▁updates ▁published ▁on ▁the ▁european ▁medicine s ▁web - portal ▁ .
▁clinic al ▁ef fica cy ▁and ▁safety ▁of ▁tac rol imus ▁ad minister ed ▁twice ▁daily ▁in ▁other ▁primary ▁organ ▁transplant ation
▁the ▁most ▁common ly ▁( ▁ ≥ ▁5 ▁% ▁) ▁reported ▁advers e ▁drug ▁reaction s ▁in ▁patients ▁with ▁another ▁indica tion ▁treated ▁with ▁pra mi pe xo le ▁were ▁na use a ▁ , ▁head ache ▁ , ▁di zzi ness ▁and ▁fatigue ▁ .
▁an ▁investigation ▁into ▁the ▁consequ ence ▁of ▁ser o con version ▁showed ▁that ▁the ▁presence ▁of ▁anti bo dies ▁was ▁not ▁synonym ous ▁with ▁a ▁loss ▁of ▁clinic al ▁response ▁ , ▁and ▁did ▁not ▁have ▁an ▁impact ▁on ▁the ▁overall ▁safety ▁profile ▁ .
▁based ▁on ▁interaction ▁studies ▁with ▁tol but ami de ▁and ▁oral ▁contra cep tives ▁ , ▁total ▁exposure ▁of ▁con com i tant ly ▁ad minister ed ▁active ▁substance s ▁metabol ised ▁by ▁cy p 2 c 9 ▁or ▁cy p 3 a 4 ▁may ▁be ▁reduce d ▁up ▁to ▁15 -30 ▁% ▁ .
▁specific ▁studies ▁have ▁not ▁been ▁conduct ed ▁in ▁older ▁people ▁( ▁see ▁fl are ▁treatment ▁section ▁above ▁) ▁ .
▁instructions ▁for ▁prepar ing ▁and ▁inject ing ▁re vesti ve
▁no ▁clinic ally ▁relevant ▁interaction ▁of ▁be va ci zum ab ▁was ▁observe d ▁on ▁the ▁ pharma cok ine tics ▁of ▁co - ▁ad minister ed ▁inter fer on ▁al pha ▁2 a ▁ , ▁er lo tin ib ▁( ▁and ▁its ▁active ▁metabol ite ▁os i - 420 ▁) ▁ , ▁or ▁the ▁che mo therapie s ▁i rino te can ▁( ▁and ▁its ▁active ▁metabol ite ▁s n 38 ▁) ▁ , ▁cap e cita bine ▁ , ▁o xa li plat in ▁( ▁as ▁determine d ▁by ▁measure ment ▁of ▁free ▁and ▁total ▁platin um ▁) ▁ , ▁and ▁ci s plat in ▁ .
▁however ▁ , ▁a ▁signal ▁towards ▁a ▁higher ▁rate ▁of ▁decrease d ▁appetit e ▁and ▁/ ▁or ▁food ▁in take ▁was ▁observe d ▁in ▁the ▁ade fo vir ▁arm ▁as ▁compared ▁to ▁the ▁place bo ▁arm ▁ .
▁b sa ▁= ▁1. 90 ▁- ▁2. 09 ▁m 2
▁patient ▁weight ▁( ▁kg ▁) ▁multipli ed ▁by ▁2 ▁( ▁mg ▁/ ▁kg ▁) ▁= ▁patient ▁dose ▁( ▁mg ▁)
▁les ions ▁clinic ally ▁a typ ical ▁for ▁ak ▁or ▁su spicio us ▁for ▁malign an cy ▁should ▁be ▁bio psi ed ▁to ▁determine ▁appropriate ▁treatment ▁ .
▁oed ema ▁per i pher al ▁ , ▁as th enia ▁ , ▁face ▁oed ema ▁ , ▁oed ema
▁geno toxic ▁and ▁car cino ge nic ▁potential ▁are ▁not ▁expected ▁ .
▁this ▁protein ▁is ▁involved ▁in ▁infla mma tory ▁process es ▁of ▁the ▁body ▁ , ▁and ▁block ing ▁it ▁can ▁reduce ▁the ▁ inflammation ▁in ▁your ▁body ▁ .
▁non - clin ical ▁data ▁reveal ▁no ▁special ▁hazard ▁for ▁humans ▁based ▁on ▁convention al ▁studies ▁of ▁safety ▁ pharma c ology ▁ , ▁repeat ed ▁dose ▁ toxic ity ▁ , ▁as ▁well ▁as ▁reproduc tive ▁and ▁development ▁ toxic ology ▁studies ▁ .
